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Abstract 
Structural protein VP22 is a major component of the virus tegument of herpes simplex virus-
1 (HSV-1). VP22 is not essential for the structure of the virus but has been associated with 
several functions, including the regulation of the virion host shut off (vhs) endoribonuclease 
activity and the promotion of optimal late protein synthesis. Many of its activities are 
believed to function through its interaction with a second tegument protein, VP16, which is 
known to help downregulate vhs activity during infection. It has been proposed that when 
the VP22-encoding gene is deleted, HSV-1 acquires spontaneous secondary mutations within 
vhs rendering it inactive. Here we show that a wild-type vhs is not inherently lethal for virus 
replication in the absence of VP22, as we generated a replication-competent Δ22 virus by 
homologous recombination which maintains a wild-type vhs gene and has no other gross 
mutations. By contrast, replication-competent Δ22 viruses recovered from a bacterial 
artificial chromosome contain multiple amino acid changes within a conserved region of vhs. 
Hence, we conclude that the mode of virus rescue influences the acquisition of secondary 
mutations. Nonetheless, we demonstrate that wild-type vhs is poorly expressed in the 
absence of VP22 in infection, a defect that is attributed to poor translation rather 
transcription. While VP22 has been shown to bind to vhs only in the presence of VP16, it is 
shown here that this VP22-VP16 complex is neither sufficient nor required for the efficient 
translation of vhs. Moreover, using primary human fibroblasts as a physiologically relevant 
model system, VP22 is shown to enhance the translation of additional virus proteins, 
revealing a general role in infected cell translation.  Finally, and unlike the situation in 
permissive Vero cells, the Δ22 virus fails to form plaque in primary human fibroblasts, 
indicating that VP22 is essential for virus replication in this highly relevant cell type.  
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1.1 HERPES SIMPLEX VIRUSES 
Herpes simplex viruses are large enveloped double-stranded DNA viruses belonging to the 
Herpesviridae family that cause disease in animals including humans. The Herpesviridae family is 
classified into three subfamilies, the Alphaherpesvirinae, the Betaherpesvirinae and the 
Gammaherpesvirinae which all have four basic characteristics in common: a large number of viral 
genes encoding enzymes involved in DNA replication, protein synthesis and posttranslational 
modification; genome replication and capsid assembly occur in the nucleus with virion maturation 
taking place in the cytoplasm; infection results in the complete destruction of the cell; and the virus 
is able to establish life-long latency within the host [184, 312]. The main characteristic features that 
distinguish the three subfamilies are the length of the replication cycle, and the range of host cells 
the virus is able to infect [184, 312].  
Alphaherpesviruses are neurotropic with a relatively short replication cycle and rapid cell-to-cell 
spread leading to cell destruction [184, 312], whereas members of the Betaherpesvirinae and 
Gammaherpesvirinae have a long replicative life cycle with a slow progression of infection [184, 
312]. The Alphaherpesvirinae which include Herpes Simplex virus 1 and 2, and Varicella Zoster virus 
replicate in a wide variety of host tissues. They characteristically infect and establish latent infection 
in sensory nerve ganglia [184, 312]. In contrast, Betaherpesvirinae which include the 
Cytomegalovirus (HHV-5), Human herpesvirus 6A and 6B and Human herpesvirus-7 have a restricted 
host range and establish latency in secretory glands, lymphocytes and kidney cells, while 
Gammaherpesvirinae which include the well characterised Kaposi sarcoma-associated herpes virus 
(HHV-8) and Epstein–Barr virus (HHV-4) have a highly limited host range as they are restricted to 
lymphoid cells such as B- and T-cells [184, 235, 312]. Infection with alphaherpesvirus, 
betaherpesvirus and gammaherpesvirus is mainly non-symptomatic within the immunocompetent 
host. However, in immunocompromised hosts, such as AIDS patients and transplant patients, 
infection can lead to serious disease with potential mortality such as Kaposi's sarcoma caused by 
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HHV-8, Burkitt's lymphoma and Hodgkin's lymphoma caused by HHV-4, gastric cancer caused by 
HHV-4/HHV-5 or encephalitis [184].  
 
Herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), members of the 
Alphaherpesvirinae, share a similar genome structure and an 83% amino acid homology [416].  
Herpes simplex type 1 (HSV-1) is the prototypic member of the Alphaherpesvirinae and will be the 
focus of this thesis. 
 
1.1.1 TRANSMISSION AND DISEASE 
HSV-1 and HSV-2 infect humans of all ages and ethnicity worldwide. Their infection causes a variety 
of diseases ranging from mild mucous membrane infections to fatal diseases in newborns and adults 
[416]. Their epidemiology and clinical pathology is similar and it is estimated that at least 50% of the 
adult population in the UK are seropositive for HSV-1 [290, 406]. 
Herpes simplex viruses establish life-long infections which can be asymptomatic or result in 
recurrent lesions. HSV-1 and HSV-2 infection is usually acquired through physical contact and occurs 
through the epidermis where it causes blisters and lesions in the skin or mucous membranes of the 
mouth, lips or genitals [416]. After initial infection with herpes simplex virus, the virus establishes 
latency in ganglionic nerve cells and causes sporadic viral outbreaks [328]. Recurrences are mainly 
spontaneous but can also be caused by emotional or physical stress, immunosuppression or 
concurrent infection [318]. 
HSV-1 has mainly been associated with oral lesions, commonly known as cold sores of the mouth or 
lips, whereas HSV-2 is almost entirely associated with genital disease.  Frequent reactivation of the 
lesions can lead to greatly reduced quality of life for the sufferer. Recent studies indicate that HSV-1 
is increasingly prevalent in genital herpes [17, 19, 197]. In contrast to HSV-2, genital infection with 
HSV-1 results in milder disease and fewer symptomatic recurrences which decrease over time [197, 
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242, 315].  Genital HSV-1 infection however, does not prevent any risks of genital HSV-2 acquisition 
[24, 216], whereas HSV-2 provides partial protection against HSV-1 [26]. 
HSV-2 infection affects more than 500 million people worldwide [217] with approximately 22% of 
adults affected in the USA, 15% in Europe and 50% in some developing countries in sub-Saharan 
Africa [220]. Genital herpes causes morbidity and even mortality [368]. However, the majority of 
infected people are asymptomatic and unaware of their recurrences which ultimately results in the 
spread of HSV-2 infection [116, 241]. HSV infection becomes of real concern in patients with 
HIV/AIDS and other immunocompromising conditions as it can lead to sporadic fatal encephalitis, 
especially in newborns and immunocompromised patients, or corneal blindness [184]. Ocular 
infection with HSV-1 is the leading cause of corneal blindness worldwide as viral reactivation causes 
potentially blinding recurrent corneal herpetic disease which ranges from blepharitis and 
conjunctivitis to dendritic keratitis [39]. 
In addition, HSV-1 and HSV-2 have been proven to increase the risk of HIV acquisition and 
transmission [64, 122, 133, 232, 300, 307, 335] whilst HIV infection increases HSV-2 recurrences and 
shedding [2, 19, 37, 122, 231, 326, 375, 420]. The hypothesis is that HSV-1/HSV-2 infection 
stimulates higher levels of circulating CD4+ T cells, which are the target cells for HIV infection [12]. 
Furthermore, epithelial damage and inflammation caused by HSV infection produces a susceptible 
environment for HIV infection. Therefore, pre-existing infection with HSV at mucosal surfaces is a 
major risk factor for HIV transmission [157]. 
Neonatal herpes is one of the most devastating complications of herpes infection which has a high 
morbidity and mortality of up to 80%. Transmission to the neonate is at the highest risk in woman 
who acquire primary HSV infection in the third trimester and who shed the virus at term [27, 186, 
201]. 
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1.1.2 TREATMENTS AND VACCINES 
HSV-1 and HSV-2 infection and the associated symptoms are currently treated with antiviral drugs 
such as acyclovir and valaciclovir [289]. These antivirals alleviate the severity of the disease, by 
reducing the frequency, duration and severity of outbreaks, and prevent complications; however, 
they do not eradicate latent virus infection which persists for life [89, 180, 240, 250, 289, 410]. 
Acyclovir, a nucleoside analogue of guanosine, was introduced in the early 1980s and can be 
administered either topically [50, 249] or orally [58, 270]. It has a high specificity in infected cells as 
it must be phosphorylated first by the viral thymidine kinase [89]. It functions by inhibiting the viral 
DNA polymerase and subsequently leads to viral DNA chain termination. Since it blocks DNA 
replication, acyclovir is only effective against actively replicating viruses and does not affect viruses 
in persistent or latent states. Mutation in the enzyme is thought to confer resistance during therapy 
which presents a major problem in the treatment of immunocompromised patients [30, 55, 179, 
347, 394]. 
Attempts to develop HSV-1 and HSV-2 vaccines have been carried out since the 1920s, but to this 
date no successful licensed vaccine is available because the immune evasion mechanisms of both 
viruses are very complex [51, 138, 166, 187].  The only licensed human herpes virus vaccines 
available are the live attenuated Oka varicella vaccine to prevent chickenpox and shingles, which 
was prepared from cells isolated from a healthy Japanese child with varicella and attenuated by 
serial passage in cell culture [7, 338]. 
When developing live attenuated vaccines, safety issues are of high importance as the virus can 
establish latent infection [78]. Attempts into developing vaccines have included attenuated live 
virus, whole inactivated virion preparations, recombinant subunit vaccines, gene-delivery vehicles 
expressing structural or non-structural HSV antigens, and DNA plasmid expressing HSV antigens 
[reviewed in references 46, 202]. Only a small number of developed vaccines tested in animals have 
shown to establish resistance to infection in animal models, but failed in subsequent clinical trials. 
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This could be due to sequence changes of viral proteins and the expression of immune evasion 
genes [78]. Additionally, animal models such as mice and guinea pigs are not considered good 
models to study reactivation since mice do not suffer recurrent episodes [39].  
Vaccines using recombinant glycoprotein have been the most successful and are of interest as 
glycoproteins are involved in virus entry and are sequence-conserved between strains and relatively 
conserved between HSV-2 and HSV-1 [44, 158, 176]. It is thought that any vaccine development 
would be relevant as it may generate potential cross-reactive protection where a HSV-2 vaccine may 
also target HSV-1 [10, 25, 42, 160]. Protective immunity is thought to involve the persistent 
infiltration of CD4+ and CD8+ T cells directed towards HSV present in the mucosa and at nerve 
endings [166, 430].  
Recent studies using a HSV-2 glycoprotein D–based subunit (gD-2) vaccine strongly induced both 
neutralizing antibody and CD4+ immune responses in HSV1/ HSV-2 seronegative persons [17, 18, 49, 
200, 369]. Unfortunately, the vaccine did not confer HSV-1 or HSV-2 resistance in HSV-1 and HSV-2 
seronegative women who received the vaccine. However, it reduced HSV-1 genital disease by 58% 
and HSV-1 infection by up to 35% [17]; but it did not prevent HSV-2 disease or infection [17, 19, 
197]. The reason for failure to protect against HSV-2 is not fully understood. A possible reason 
considered for the better protection against genital HSV-1 is the mode of transmission (oral-genital 
sex), which might have a lower inoculum concentration; and the genital tract might be less 
hospitable for HSV-1 replication than HSV-2 [17]. 
The most extensive human trial with attenuated live HSV vaccine was with strain R7020, which was 
originated from HSV-1 strain F and had a deletion covering ICP27 through the promoter region of 
ICP4 [187]. Unfortunately, patients treated with this attenuated virus developed local reactions and 
systemic side effects during a dose increase study [187].  
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1.2 THE HERPES VIRUS PARTICLE 
The HSV-1 particle is approximately 200nm in diameter and consists of a host cell-derived lipid 
membrane envelope composed of a mixed population of virally encoded glycoprotein and cellular 
proteins [184, 219]. Underneath the envelope lies a complex proteinaceous structure known as the 
tegument layer [184, 219] which holds the icosahedral capsid encasing the large double stranded 
linear 152kb DNA genome (Figure 1.1). The protein capsid consists of 162 capsomeres composed of 
150 hexons and 12 pentons that lie on a T=16 icosahedral lattice. The proteins comprising the capsid 
are five conserved viral proteins: VP5, which is the major capsid protein; VP23 and VP19c, which are 
proteins that form triplexes and interact and help stabilise adjacent capsids; VP26, which covers all 
hexons, and UL26, which forms the portal through which the viral genome is injected into the 
nucleus [246]. 
 The large HSV-1 genome consist of one unique long (UL) and one unique short (US) segment each 
flanked by inverted repeats, and encodes approximately 80 open reading frames (ORFs) [177, 184, 
407]. The gene products of HSV-1 are either named according to their genomic location on the open 
reading frame (e.g.UL49), their relative size on a polyacrylamide gel (e.g. Virion Protein 22), or 
according to their position on a polyacrylamide gel (e.g. ICP0) of infected cell lysate. Viral 
glycoproteins are defined by letters (e.g. gD) [184]. 
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Figure 1.1: HSV-1 particle (adapted from Fields Virology  [117])  
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1.3 VIRAL GLYCOPROTEINS  
Herpes simplex virus 1 (HSV-1) encodes 12 known glycoproteins which play a role at various stages 
of virus infection including virus entry, virus spread and immune evasion [120]. Some members of 
the glycoproteins are conserved among the herpes viruses, with glycoprotein gB being the most 
conserved among the herpesviruses [148]. Other glycoproteins, such as gD and gC, are restricted to 
the herpes simplex viruses [346]. These glycoproteins are involved in various aspects of the virus life 
cycle, including spread, entry, acquisition of the final envelope and egress.  
HSV-1 glycoprotein gK has been shown to exist in a functional complex with membrane-associated 
UL20 viral protein to facilitate virion entry and cytoplasmic virion envelopment [118, 119]. For viral 
entry both proteins interact with glycoprotein gB as well as with the membrane fusion regulator 
glycoprotein gH, which leads to the fusion of the viral envelope with cellular membranes [43, 120]. 
The gK-UL20 complex has been shown to be essential for virion envelopment as in the absence of it 
capsids accumulate in the cytoplasm without progressing for further envelopment [119, 120]. 
Viral glycoproteins gB, gD, gH and gL are important for virus entry as deletion of any one of these 
leads to impaired virus entry [365, 366]. Glycoprotein gD together with gB and complex formation 
gH-gL facilitate virus entry via interaction with cellular components, while gC performs an accessory 
role [33, 192, 365]. It has also been proposed that viral glycoproteins are involved in secondary 
envelopment by forming an association of the capsid with the cellular membrane via their 
interaction with the outer tegument proteins, such as gD and VP22, gE and VP22 and gH and VP16 
[28, 41, 107, 125, 134, 244, 246, 276], although none of these interactions are essential for virus 
assembly.  Glycoprotein gM and complex gE-gI are required for efficient cell-to-cell spread in vitro 
and in vivo [69–71], while gE-gI is also involved in evading immune response by blocking off 
immunoglobulin G though their binding to the Fc domain of IgG [79, 121, 162, 261]; and gE and gM 
are demonstrated to take part in recruiting ICP0 into the virion [225].  
  
Chapter 1                                                                                                             General Introduction 
30 
 
HSV-1 lacking gE and gM resulted in defective secondary envelopment with unwrapped capsids 
accumulating in the cytoplasm and a reduction in virus yield [225, 377]. Double deletion gD and gE 
resulted in a striking defect in particle assembly [106].  
A number of protein-protein interactions between glycoproteins and VP22 have been described that 
may provide useful insight into the assembly process. VP22, as an outer tegument protein, has been 
shown to interact with glycoproteins gE and gM during infection [107, 276, 377]. This association is 
thought to be involved in recruiting VP22 to the virus particle via the interaction of the cytoplasmic  
tails of both gE and gM with VP22 [377]. Hafezi et al. (2005) reported that the C-terminal half of 
VP22 is absolutely required for packaging of VP22 into the virus particle [136]. Since then it has been 
shown that the gE-binding domain of VP22 is located at the C-terminus of VP22 and seems sufficient 
to facilitate VP22 packaging into the virion particle [276, 377]. A 14-residue deletion within the gE-
binding domain in VP22 abolishes VP22 interaction with gE and gM and results in reduced VP22 
content in the virus particle. Furthermore, VP22 lacking gE -binding appears diffuse in the cytoplasm, 
whilst full-length VP22 colocalises with gE in the Golgi region of the cell [377]. Recently, Maringer et 
al. (2012) have shown that a ΔgE virus and a ΔgM virus package VP22 to Wild-type levels into the 
virion, whereas a double mutant, containing the deletion of gE and gM, is unable to package VP22 
into assembling virus particles, indicating that both glycoproteins are involved in recruiting VP22 to 
the virus particle [225]. This is also reported for PRV [125]. Interaction of glycoprotein gD and VP22 
has also been described [107]. Whilst HSV-1 UL49-Null mutants have been shown to contain reduced 
amounts of gD in the virus particle [81, 94], others have been unable to detect VP22 binding to gD 
[377]. 
 
1.4 HSV-1 LIFE CYCLE 
Infection with HSV-1 occurs through damaged epithelial cells via fusion of the cell membrane and 
virus envelope [128, 184]. Following lytic infection of keratinocytes the virus is delivered to the 
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dorsal root ganglia via retrograde transport where it becomes latent in the nucleus of the sensory 
neurons and causes sporadic viral outbreaks [128, 184, 325]. Once the latent virus is reactivated it 
travels to the axonal termini via anterograde transport resulting in a secondary infection at the 
primary site of infection. Lytic reactivation of the virus occurs intermittently throughout the lifetime 
of the host and can be brought on by stress, UV light exposure, anxiety and malnutrition [314, 408]. 
Lytic reactivation of the virus can result in recurrent mucocutaneous lesions as well as asymptomatic 
infection leading to transmission of the progeny virus to a new host [184, 314, 408].  
 
1.4.1 ATTACHMENT AND ENTRY 
Virus entry to the cell occurs via fusion of the viral envelope with the cellular membrane mediated 
by viral glycoproteins [5].  Of the identified HSV-1 glycoproteins gB, gC, gD, gH, and gL have been 
shown to contribute to viral entry with only gC not being essential as its absence results in reduced 
binding only [4, 25, 26, 260, 277].  
To date, three classes of HSV-1 cell surface entry receptors have been identified. The first entry 
receptor to be reported was HVEM (Herpesvirus entry mediator), a member of the tumour necrosis 
factor (TNF) receptor family [252], which is expressed in a variety of cell types, including 
lymphocytes, epithelial cells, and fibroblasts. Since the discovery of HVEM, nectin1 and nectin-2, two 
members of a small subfamily of the immunoglobulin superfamily, have been identified; as well as 
specific sites in heparan sulfate generated by certain isoforms of 3-O-sulfotransferases [364, 366]. 
Nectin-1 and nectin-2 are also expressed in a variety of cell types, including epithelial cells, 
fibroblasts, and neurons [364, 366]. 3-O sulphated heparan sulphate is a non-protein receptor 
shown to facilitate entry of HSV-1, but not HSV-2 [346, 364].  
Entry of HSV-1 is facilitated by interactions of viral proteins with at least two, perhaps more, cell 
surface receptors. The initial binding of the virus is facilitated by the interaction of gC and/or gB with 
glycosaminoglycan (GAG) chains of heparan sulphate on the plasma membrane [149, 340]. Heparan 
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sulfate binding may not necessarily be essential for attachment as it is reversible, but it is thought to 
greatly increase the efficiency of viral entry by concentrating the virus on the cell surface [366]. 
After binding to heparan sulphate gC and/or gB is stabilised once glycoprotein gD binds to one of its 
cell surface receptors, nectins-1/-2, herpesvirus entry mediator (HVEM) or 3-O sulphated heparan 
sulphate [5, 192, 252, 345, 346, 365]. Following binding to its receptor, glycoprotein D acts then 
together with three other glycoproteins gB, gH and gL to induce fusion of the virus envelope with 
the cell membrane which is followed by entry of the capsid and release of tegument proteins into 
the cytoplasm of the cell [5, 8, 35, 47, 142]. Additionally to gD, entry receptors for gB have been 
identified with paired immunoglobulin-like receptor alpha and non-muscle myosin heavy chain IIA 
facilitating virus entry [6, 324]. Successful entry of the virus particle is also contributed to by actin 
microfilaments and phosphorylation of host proteins as well as tegument proteins by viral and 
cellular kinases [128, 253, 298].  
While entry of HSV-1 into the cell is thought to occur via fusion of the viral envelope with the 
membrane,  other studies have reported low pH-dependent entry via endocytosis [266, 267]. HSV-1 
has been shown to enter most cells via the pH-independent route. However, it is thought that the 
route of entry may vary depending upon the cell type [267]. In commonly used Vero cells HSV has 
been shown to penetrate the plasma membrane via fusion and delivers its capsid directly into the 
cytosol [360, 364]. In other common continuous cell lines, such as CHO and HeLa cells, HSV is 
suggested to enter the cell via endocytosis [266]. CHO cell, however do not contain any specific 
entry receptors and therefore require modification to express HSV entry receptors such as HVEM, 
nectin-1 or nectin-2 in order to be infected [266, 267].  
 
1.4.2 TRANSLOCATION TO THE NUCLEUS 
Following entry into the cell the viral capsid is translocated to the nucleus by utilising host processes 
[361]. Research suggest that upon entry tegument proteins VP13/14 and VP22, are phosphorylated 
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by casein kinase II and protein kinase UL13, respectively which leads to the disassociation of the 
tegument proteins from the capsid [229, 253]; whereas VP1/2 and VP16 remain capsid-associated 
and recruit the cellular microtubule motor dynein and its cofactor dynactin in order to deliver the 
capsid into the cytosol and transport it along the microtubules towards the nucleus [75, 223, 224, 
299, 360, 419]. However, it was also reported that VP16 was transported to the nucleus 
independently to the capsid [16]. 
Tegument protein VP1/2 and capsid protein UL25 have been demonstrated to interact with host 
nuclear import factor importin β, as well as the NPC proteins Nup358/RanBP2 and Nup214/CAN, 
respectively and are involved in targeting the capsid towards the nucleus as well as binding it to the 
nuclear pore complex [48, 278, 310, 311]. The precise process of capsid transport via the cellular 
microtubule network involving tegument proteins is unclear.  
Tegument proteins VP1/2, UL37 and US3 are thought to remain associated with the capsid after 
penetration into the cytoplasm, whereas UL11, UL46, VP13/14, VP16 and VP22 are lost after 
penetration [132], indicating that a portion of the tegument remains attached to the membrane 
after the virus entered the cell [229]. 
The successful docking to the nuclear pore is followed by injection of the viral DNA into the nucleus 
[48, 278, 422]. Within the nucleus, transcription and replication of viral the DNA and viral genes 
occurs.  
 
1.4.3 GENE EXPRESSION, GENOME REPLICATION AND CAPSID ASSEMBLY 
Following nuclear entry of the viral DNA, viral gene expression is temporally regulated in a three-
stage cascade of immediate-early genes, early genes and late genes (Figure 1.2) in order to facilitate 
efficient virus replication. Immediate-early genes, which encode proteins that regulate the 
expression of early and late genes, are the first to be expressed. Transcription of immediate-early 
genes occurs in the absence of prior viral protein synthesis and is initiated by the major viral  
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Figure 1.2 Illustration of Herpes simplex temporal gene expression 
Viral gene expression of HSV-1 is temporally regulated into immediate-early (IE), early (E) and late (L) 
genes. Transcription of IE genes is initiated by viral transactivator protein VP16 present in the 
infecting virion. Expressed IE proteins (ICP0, ICP4, ICP27, etc.) are required for early gene 
transcription, which products (ICP8, gD, gI, etc.) are involved in viral DNA replication and efficient 
transcription of viral late genes. The proteins of late gene expression (VP16, VP22, gC, etc.) are 
mostly structural and required for virion assembly. IE – Immediate-Early, E – Early, L – Late.  
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transactivator protein VP16 present in the infecting virion [143]. VP16 is transported into the 
nucleus independently of the capsid [16, 297] where it forms a complex with the cellular cofactors 
HCF and Oct-1 and activates immediate-early gene expression [36, 129, 297, 370]. While early gene 
expression is required for efficient viral DNA replication and the production of certain envelope 
glycoproteins (i.e. gD, gE, gI, gG, etc.) (Figure 1.2) [184], late gene expression results in the 
translation of viral proteins (gC, gB, UL26, etc.) that form the virion particle  and are involved in virus 
assembly, maturation, and egress [184] and contribute to immune evasion [378] (Figure 1.2). ICP4 is 
the major transcriptional activator of early and late gene expression and is essential for viral growth. 
It stabilises transcription initiation complexes on viral promoters via its DNA binding activity [321, 
409]. ICP27 also plays an essential regulatory role in virus replication [316, 356] and it is thought to 
facilitate the expression of several early and late genes by directly interacting with viral mRNA 
enhancing their stability and mediating their export from the nucleus to the cytoplasm [322]. 
Additionally, ICP27 is proposed to recruit cellular translation initiation factors and thereby 
promoting translation of viral mRNAs [202]. In contrast to ICP4 and ICP27, immediate-early protein 
ICP0 is considered a promiscuous transactivator as it transactivates a wide range of cellular 
promoters without binding DNA or recruiting transcriptional factors [31, 32, 135, 169, 170, 196]. 
ICP4, ICP27 and ICP0 have been shown to functionally interact with each other [129, 404, 273, 318, 
319] which is thought to facilitate cooperative activation of gene expression [424]. ICP22 plays a role 
in transcriptional regulation, however, it is not clearly established yet if ICP22 represses early genes 
or enhances transcription of late genes [23, 295, 308]. 
Additionally to regulating viral gene transcription, some of the immediate-early proteins contribute 
to evading host cell immune responses in order to ensure efficient virus replication [378]. While ICP0 
has been shown to target host defensive molecules for ubiquitin-mediated proteasomal 
degradation, which reduces host defenses and facilitates viral gene expression [22, 85, 144, 199, 
256, 359], ICP27, ICP22 and ICP47 have been shown to counteract antiviral host responses by 
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downregulating the JAK/STAT pathway [165], reducing the effect of interferon-β [280] and blocking 
the major histocompatibility complex class I antigen presentation pathway, respectively [399]. 
The way by which the viral DNA is replicated is not yet clear. It is commonly accepted that upon 
infection or reactivation from latency, linear viral DNA is circularized and then replicated in two 
phases: an initial phase of theta replication, followed by a rolling-circle replication. The latter process 
is facilitated by viral and host factors generating concatemers of the viral genome within nuclear 
domains [reviewed in 238], [15, 159]. Those domains enlarge and cause cellular chromatin to 
condense and marginalise to the nuclear periphery [348][reviewed in 20]. The viral DNA 
concatemers are cleaved and subsequently packaged into autocatalytic formed capsids with the aid 
of viral scaffolding proteins [15, 21, 264, 390, 393][reviewed in 58, 99]. The viral genome-containing 
capsid acquires a primary envelope via budding through the inner nuclear membrane involving 
membrane proteins UL31 and UL34 which form a complex with Us3 [244, 304, 305][reviewed in 94, 
95]. The viral kinase protein Us3 regulates the localisation of the UL31/UL34 complex within the 
inner nuclear membrane [173, 181, 306]. 
 
1.4.4 LATENCY 
Herpes simplex virus 1 establishes latent infection in sensory neurons at the oral or genital mucosa 
as it is transported via retrograde microtubule-associated transport to the nerve cell body. During 
latent infection circularized viral DNA becomes associated with heterochromatin which results in the 
repression of lytic gene expression, while the virus genome is stably retained within sensory 
neurones. Reactivation into lytic infection is initiated when the chromatin is extensively reorganized 
and repressive histone modifications are reversed resulting in the production of infectious virus 
[[184][reviewed in 160, 241]. 
Reactivation occurs periodically in response to various stimuli such as emotional stress, fever, UV 
exposure, hormonal changes, dental surgery and cranial trauma [68, 268, 418]. Following 
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reactivation the virus travels anterograde back to the periphery where it infects the epithelial cell 
resulting in virus transmission. Latency ensures long-term persistence and spread to new host cells, 
however, how the switch from lytic to latent infection is decided is unclear.  
It is thought that inefficient axonal transport of viral lytic initiator protein VP16 is promoting latency 
as its complex formation with its partners HCF-1 and Oct-1 is affected [191, 313]. Furthermore, 
latency-associated transcripts (LATs) are believed to play a key role during HSV-1 latency [207, 294, 
392] by downregulating genes required for lytic replication such as ICP0 and ICP4; however their 
mechanism of action remains to be determined [412]. They are the only transcripts active during 
latency [408] and it is the accumulation of LATs and their encoded miRNAs that is thought to 
facilitate the establishment of latency [367][reviewed in 44, 120].  
 
1.4.5 VIRUS ASSEMBLY AND EGRESS  
Assembly of the virus particle is initiated in the nucleus where the viral DNA is packaged into the 
assembling capsid [reviewed in 58]. A number of potential mechanisms for subsequent steps leading 
to a mature virion have been suggested [reviewed in 96]. Initially it was proposed that the 
nucleocapsids exit the nucleus via budding at the inner nuclear membrane (INM) and mature to 
infectious virus particles via the secretory pathway by transiting through the endoplasmic reticulum 
(ER) and Golgi apparatus [59, 330]. Another pathway that has been proposed is the egress of the 
capsids from the nucleus via enlarged nuclear pores [209, 417]; however this remains contested 
[152]. In this model addition of the tegument and envelopment of the capsids is thought to occur at 
the outer nuclear membrane or within the secretory pathway [209]. The more widely accepted 
model of virion assembly and egress is the envelopment-deenvelopment-reenvelopment pathway 
(Figure 1.3) where it is suggested that capsids are shuttled from the nucleus to the cytoplasm via a 
budding-fusion event that occurs across the inner and outer membranes of the nucleus, in which  
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Figure 1.3: Illustration of the Envelopment-deenvelopment-reenvelopment model of herpesvirus 
assembly. Nucleocapsids acquire their primary envelope by budding through the inner nuclear 
membrane (INM). Deenvelopment of the capsids occurs upon fusion with the outer nuclear 
membrane (ONM) resulting in free capsids in the cytosol. After tegument acquisition reenvelopment 
occurs by budding via glycoprotein-containing membranes of the recycling endocytic network. 
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they lose their initial envelope [349][reviewed in 65]. This model is supported by a wide range of 
biochemical, genetic and ultra-structural studies. 
Final tegument assembly and re-envelopment of the free capsid is thought to occur at a site in the 
cytoplasm that remains a point of contention [134, 243, 262]. The trans-Golgi network (TGN) is 
commonly cited as the site of final envelopment as viral glycoproteins have been reported to localise 
at its compartments [reviewed in 67, 102][402].  
Research from our lab by Hollinshead et al. (2012) and Johns et al. (2014) however, provided 
evidence that secondary envelopment of the capsids occurs at glycoprotein-containing membranes 
of the recycling endocytic network and not the TGN or other membranes from the secretory 
pathway (Figure 1.3). Viral envelope proteins are hypothesized to be transported through the 
Golgi/TGN to the plasma membrane ahead of capsid release from the nucleus and recycled into the 
endocytic pathway.  This conclusion was made as depletion of Rab5, a cellular protein that regulates 
endocytosis, resulted in the retention of envelope glycoproteins at the cell surface and inhibition of 
capsid wrapping; this indicates that Rab5 is required to retrieve viral glycoproteins from the cell 
surface [161]. These observations were made by making use of fluid phase marker horseradish 
peroxidase (HRP) in which the cells were incubated and transmission electron microscopy. After only  
2 min of incubation in HRP, capsids appeared to be wrapped in HRP-positive membranes, reaching 
nearly 90% of all capsids being wrapped within 30min. As the HRP-positive wrapping membranes 
had to undergo endocytosis and encounter a capsid to enwrap in that very short timescale, it was 
concluded that the capsids are wrapped by tubules derived from the plasma membrane. Further 
screening of human Rabs identified RAB6 as a major factor for production of infectious virus. RAB6 is 
Golgi-associated and its depletion resulted in the inability of the HSV-1 envelope proteins to reach 
the cell surface. Instead they were retained in the Golgi/TGN during infection which resulted in the 
subsequent accumulation of naked capsids which were not associated with infectivity as virus yield 
was reduced to 1%. This suggests that Rab6 is involved in trafficking envelope proteins from the  
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Golgi/TGN to the cell surface and that glycoprotein exocytosis is a prerequisite for morphogenesis 
[153]. Furthermore, it was noted that in infection, tubulation and redistribution of Rab6 positive 
membranes from the Golgi/TGN to peripheral membranes was initiated which delivered large 
amounts of envelope constituents to the PM that requires the Rab6 effector ERC1 for optimal 
efficiency. This observation indicates that HSV-1 activates a Rab6-specific exocytic pathway required 
to transport virus glycoproteins from the Golgi/TGN to the PM to provide membrane subsequently 
used for virus wrapping [153]. A number of studies have helped to understand the process of 
tegumentation that occurs during the egress pathway. Several tegument proteins are highly 
conserved across the herpesvirus family and therefore are considered to be involved in critical 
interactions required in the process of secondary envelopment during the course of herpes virus 
assembly [204].  
 
1.5 THE TEGUMENT 
The tegument is a layer of densely-packaged protein molecules between the capsid and the 
envelope of the virus particle. The HSV-1 tegument is one of the largest virion compartments as 
determined by mass spectrometry of purified HSV-1 particles, containing 54% of all identified 
peptides within the virion; with up to 23 viral tegument constituents identified to date [219, 363]. 
Seven of the identified proteins (UL7, UL11, UL16, UL21, VP1/2, ICP32 and UL51) are conserved in all 
three herpesvirus subfamilies, while four are unique to the alphaherpesviruses (VP11/12, VP13/14, 
VP16, VP22) [175, 219, 284].  The packaged tegument proteins vary in size and abundance, with 
tegument protein VP1/2 documented as the largest to date (330kDa). The tegument proteins exhibit 
different functions and roles during infections [219, 243]  
VP1/2, UL37 and VP16 are considered essential structural proteins for HSV-1 [67, 205, 415], as 
deletion of VP1/2 leads to un-enveloped capsids [66, 205]; deletion of VP16 strongly impairs 
secondary envelopment [255]; and deletion of UL37 inhibits secondary envelopment [67]. A number 
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of studies have demonstrated though, that significant changes in the composition of the tegument 
did not disrupt virus assembly and viable virus was produced [52, 296, 428]. 
VP1/2 has a relatively low abundance of between 60 and 120 copies per [147, 238] compared to 
major tegument proteins VP22 and VP13/14 which are the most abundent tegument proteins with 
600 to 2,000 molecules each, representing 5 - 10% and over 10% of the total virion protein content, 
respectively [219, 284]. Additionally to viral proteins, the tegument holds an array of cellular host 
proteins including cytoskeletal, heat-shock and Rab proteins which are involved in trafficking and 
exocytosis [219]. The tegument also contains cellular and selected viral mRNAs [332]. Even though 
the tegument is frequently described as amorphous, it has been shown that it is a self-supporting 
structure due to numerous protein-protein interactions, and it does not require the capsid or 
envelope to maintain its integrity [175, 236]. The tegument structure can be designated as an inner 
or outer layer of proteins which is based on the preferential association of the tegument proteins 
with either the capsid or viral membranes during entry and egress [175, 247, 299, 419]. The inner 
tegument layer has a partial icosahedral order due to its close association with the capsid via VP1/2 
[265, 429], while the outer tegument layer is less ordered [45, 236].   
VP1/2 is considered as an inner tegument protein due to its association with the capsid and 
participation in its transport to the nucleus by the microtubule/dynein motor system [360]. 
Furthermore, VP1/2 is required for nuclear targeting of capsids to nuclear pores and for the release 
of the viral genome into the nucleus for transcription and replication [1, 16, 48, 310].  
VP1/2 has been shown to interact with essential tegument protein UL37 [174, 403]. UL37 is 
conserved among  the herpesvirus family and thought to play a key role in the early stages of virion 
maturation, as in its absence naked capsids, unable to progress for envelopment, are found in the 
cytoplasm [67]. Recruitment of UL37 to HSV-1 capsids is dependent on VP1/2 [29] and it is proposed 
that their complex formation acts as a scaffold for tegumentation and secondary envelopment [284]. 
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Another tegument protein VP1/2 has been shown to interact with is VP16. It is proposed that this 
interaction recruits VP16 into the virion [185, 381]. However, it is not an essential interaction for 
VP16 recruitment as in the absence of VP1/2-VP16 binding VP16 is packaged into the virion by an 
additional route [381]. VP16 has also been demonstrated to interact with conserved tegument 
protein VP13/14 [76, 377], however its role in virus infection has not been established yet. 
Publications by our group and others on tegument-tegument and tegument-glycoprotein 
interactions suggest that the tegument proteins facilitate tegument assembly and association of the 
viral capsid to the envelope, which occurs predominantly in the cytoplasm [41, 90, 107, 134, 204, 
225, 226, 284, 377, 403].  
 Besides giving structural support to the tegument, the proteins perform an array of other functions. 
Tegument proteins function within the cell immediately after entry and prior to the de novo 
synthesis of viral proteins; as well as during and after de novo protein synthesis of viral proteins. 
Proteins functioning during and after de novo protein synthesis of viral proteins focus on targeting 
virion components to and from the nucleus during entry and egress; recruitment of cellular 
molecular motors during entry and egress; regulation of viral and host cell gene and protein 
expression; and assembly of virions during egress [175, 299, 310]. 
Proteins functioning within the cell immediately after entry and prior to the de novo synthesis of 
viral proteins facilitate efficient viral replication, such as VP16 and vhs. VP16 functions in activating 
transcription of viral immediate early genes [36, 129, 297, 370, 421], while vhs degrades host mRNA 
during the early stages of infection [353, 354] in order to facilitate efficient temporal gene 
expression. 
There are numerous functions of different essential and non–essential tegument proteins that could 
be mentioned; however those proteins most relevant to this thesis are addressed in more detail 
below. 
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1.6 TEGUMENT PROTEIN VP22  
The HSV-1 structural protein VP22 is a major component of the virus tegument with an average of 
2,000 copies present in each virion [147]. VP22 is encoded by the UL49 gene, which is highly 
conserved throughout the alphaherpesvirus family [93]. The structural protein contains 301 amino 
acids with a predicted molecular weight of 32kDa and an observed weight of 38kDa [233]. Apart 
from being a major structural component of the virion tegument, VP22 has also been associated 
with several other functions. Nonetheless, the precise role of VP22 in the virus replication cycle is 
unclear.  
Characterisation of VP22 and its role in virus infection has been carried out by creating VP22 
knockout mutants (∆22 virus) and different results about the requirement of VP22 have been 
published. Deletion of VP22 homologues in other alphaherpesviruses resulted in different 
phenotypes. The first VP22-null mutant was constructed in bovine herpesvirus (BHV-1). The deletion 
of the entire VP22 open reading frame demonstrated that BHV-1 VP22 is dispensable for virus 
growth in cell culture. However, the absence of VP22 resulted in significantly reduced growth of the 
virus [213].  Subsequent animal studies demonstrated slow replication and reduced virulence [214]. 
In pseudorabies virus (PRV) VP22 is also dispensable for virus growth in either culture or animal [65], 
as no apparent differences in phenotypes were observed compared to the wild-type. Testing the 
absence of VP22 in the rodent model revealed that VP22 had no effect on virulence or 
neuroinvasiveness of the brain, as all symptoms were indistinguishable from the WT virus.  In 
contrast, Marek’s disease virus (MDV) and Varicella Zoster virus (VZV) VP22 is absolutely essential 
for virus replication [38, 77].  Marek’s Disease Virus was the first alphaherpesvirus to exhibit the 
requirement of VP22 for virus growth and cell-to-cell spread. Deletion of the VP22 gene in MDV and 
VZV resulted in viruses unable to grow in cell culture. The inability to replicate and produce 
infectious virus was confirmed to be due specifically to the lack of the VP22 protein being expressed, 
as the repair of the VP22 deletion was able to rescue virus growth in cultured cells. 
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The first HSV-1 recombinant VP22 deletion virus was generated in our lab [94], by replacing the 
entire VP22 reading frame with green fluorescent protein (GFP). This ∆22 virus replicated to wild-
type levels in Vero cells and its release from cells was not impaired in comparison to the WT virus 
demonstrating that VP22 is not essential for virus replication in Vero cells. Additionally, it was found 
that the absence of VP22 had little effect on the virion content of major structural proteins. In 
contrast, the ∆22 virus displayed a cell specific replication defect in epithelial MDBK cells compared 
to the WT virus. The replication defect was due specifically to the absence of VP22 expression as a 
revertant virus rescued viral replication. This difference in virus growth in the presence of VP22 in 
various cell lines may indicate a differential requirement for VP22 in HSV-1 replication [94]. Duffy et 
al. reported a reduced virus yield in the absence of VP22 compared to the wild-type virus as well as a 
reduced plaque size for ∆22 virus grown in Vero cells. It was determined by multi-step growth 
analysis that the reduced plaque size was largely due to decreased viral release, suggesting a 
requirement of VP22 for efficient viral spread in Vero cells [81, 333].  Additionally to a possible 
requirement for cell-to-cell spread in cell culture, a role for VP22 in HSV-1 viral spread animal models 
was confirmed as Duffy et al. reported that viral spread of the ∆22 virus in the mouse cornea was 
significantly reduced compared to wild-type-virus [81]. More recently, VP22 has been reported to be 
required for replication and spread of in the brains of mice following intracerebral inoculation, as a 
mutant with amino acid substitutions at residue 251 and 252 resulted in impaired virus growth 
[389]. The data in animal models points to VP22 playing a role in virulence.  
Additionally to a reduced plaque size, Duffy reported reduced viral protein accumulation for ICP0, gE 
and gD at late times in infection; and reduced accumulation for viral mRNA at early times in 
infection, of at least gE, gD, and vhs [82, 230]. As no significant effect on ICP0 mRNA was observed at 
any time in infection, VP22 was suggested to have separate roles in both protein and mRNA 
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accumulation [82]. The defect in protein accumulation for gE and gD was confirmed to occur at the 
translation level independent of mRNA abundance late in infection [230]. 
 
Defining an exact role for VP22 has been complicated by the observation that other VP22-deletion 
viruses carry secondary mutations in the vhs gene encoding the virion host shutoff protein (vhs) 
[230, 333]. Studies of VP22 knockout mutants of strain F generated in a bacterial artificial 
chromosome (BAC) system showed that Δ22 viruses were only viable after obtaining spontaneous 
secondary mutations in the vhs gene, indicating an important relationship between these two 
proteins [230, 333]. Sciortino and colleagues concluded that expression of the vhs protein in the 
absence of VP22 protein is lethal [333]. In light of Sciortino’s observations our lab sequenced the vhs 
gene of the previously described VP22 deletion virus (Δ22) [94] and found it to be of wild-type 
sequence. 
Duffy et al. also sequenced the vhs of their VP22 deletion virus generated using BAC recombination 
and reported that the documented observations of the VP22 deletion virus and its defect in protein 
translation were obtained in the presence of a wild-type vhs [82]. However, it was also reported that 
the defect in protein translation in the absence of VP22 was able to be compensated by mutations 
within vhs abolishing its nuclease activity, pointing towards a role of VP22 in modulating vhs activity 
[230]. Caution, therefore, may be needed when interpreting the impact of VP22 deletion as 
characteristics of the observed phenotypes may actually be influenced from changes in vhs activity. 
 
To date all known VP22 functions map to the C-terminal half of the protein, although N-terminal 
sequences contribute to VP22 multimerisation (Figure 1.4A) [136, 228, 258]. A conserved region in 
VP22 among homologous HSV-1, BHV-1, EHV-1, VZV and MDV is essential and sufficient for VP22 
incorporation into the virion [136, 258, 276]. The same region has been shown to interact with VP16 
and gE using VP22 truncation mutants in immunoprecipitation- and GST-pull down assays  
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Figure 1.4: Schematic overview of HSV-1 tegument proteins VP22, VP16 and vhs.  
A) VP22 protein consisting of 301 amino acids with a conserved region spanning aa 174-256 (grey 
shaded box). VP16-binding domain of VP22 spanning aa 160-267 (blue shaded box). B) VP16 protein 
consisting of 490 amino acids. VP22 binding domain of VP16 spanning aa 452-490 (yellow shaded 
box). C) Vhs protein consisting of 489 amino acids with four conserved domains (I-IV) (grey shaded 
boxes) separated by low conserved sequences. VP16-binding domain of vhs is spanning aa 310-330 
(black shaded box). 
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[136, 276, 277]. While it was suggested that VP16 and/or gE might therefore recruit VP22 into the 
virion [90, 136, 276], it has since been shown that neither protein individually, or jointly, were 
required for VP22 assembly using VP22-binding mutants deficient in their interaction with VP16 and 
gE [275, 277]; suggesting that additional determinants may contribute to the virion incorporation of 
VP22. Recently, Maringer et al. [225] have shown that a ΔgE virus and a ΔgM virus package VP22 to 
wild-type levels into the virion, whereas a double mutant, containing the deletion of gE and gM, is 
unable to package VP22 into assembling virus particles, indicating that both glycoproteins are 
involved in recruiting VP22 to the virus particle [225]. VP22 has been demonstrated to associate with 
the immediate-early (IE) protein ICP0, a general transactivator of gene expression. This association is 
thought to be essential for the recruitment of ICP0 to the tegument compartment of the virus 
particle, as Δ22 virions contain no detectable levels of ICP0 [94, 226].  Maringer et al. [226] have 
shown that ICP0 packaging correlates directly with the ability of ICP0 to complex with VP22 via its 
RING finger domain in infected cells [226].  
 
1.7 TEGUMENT PROTEIN VP16 
The HSV-1 protein VP16 is an abundant 490 amino acid virion phosphoprotein with an observed 
molecular weight of 65-kDa. It is encoded by the UL48 gene and is present in 500 to 1,000 copies in 
the tegument per virion [36, 90, 147, 208, 227].  
VP16 is a transactivator of viral immediate-early gene transcription also designated α-transinducing 
factor (αTIF) or Vmw65 [36, 57, 147, 292, 363] and acts early during infection. It is synthesised late in 
infection and subsequently packaged into the tegument of virions [255, 262]. It is transported to the 
nucleus independently of the capsid where it associates with host transcription factors HCF-1 and 
Oct-1 in order to stimulate the transcription of viral immediate early (IE) genes which facilitates the 
onset of lytical gene expression [16, 129, 272, 273, 297, 370, 400, 401, 421]. 
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The transcription of IE genes is regulated in an organised and sequential cascade fashion [156, 423] 
by VP16 whose C-terminal domain is a potent transcriptional activation domain that targets the 
TAATGARATTC consensus sequence found in IE promoters with high affinity through the interaction 
with the host factors Oct-1 and HCF [57, 150, 274, 292, 400, 401]. The gene transcription activation 
function of VP16, however, is not essential for virus replication in vitro as complete transactivation-
deficient mutants can be propagated in tissue culture, although with reduced infectivity and 
diminished IE gene expression [3, 53, 352, 379, 388, 400]. In contrast, in animal models a 
transactivation-deficient mutant was unable to replicate or establish a latent infection in 
the peripheral and central nervous systems of immunocompetent mice, indicating that the 
transcriptional activation domain in VP16 is a neurovirulence determinant [388]. 
Additionally, VP16 is a structural tegument protein which appears to be important for secondary 
envelopment via its interaction with many viral tegument proteins, including tegument protein 
VP1/2 and VP22 [90, 185], as well as glycoproteins, such as gH [124, 134, 171, 255, 403, 405]. The 
direct interaction of VP16 with VP1/2 is thought to be important for viral assembly as it is required 
to recruit VP16 to virion capsids and to efficiently link the inner tegument with the outer tegument 
during assembly [381, 403]. A HSV-1 VP16 null mutant exhibits a severe defect in virus assembly and 
virion maturation during infection as packaging of viral DNA into capsids is reduced and no 
extracellular enveloped virions are observed [255, 415].  
Another binding partner identified of VP16 is tegument protein VP22 [90]. Although initially 
assumed to be involved in virus assembly, it has since been demonstrated that this interaction is not 
required for either protein to be assembled into the virion[277]. Using truncated VP16 protein 
constructs, it was shown that the cellular interaction of VP16 and VP22 is dependent on the C-
terminal activation domain of VP16 (Figure 1.4B). Mutations within the transcriptional activation 
domain affected the transactivation function of VP16 as well as VP22-binding, which implies this 
readily-detected complex has a different role to play in virus infection [90]. 
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In addition to its transcriptional activation function and role in virion assembly/maturation, VP16 has 
been shown to interact with the virion-associated virion host shutoff protein (vhs) via direct binding 
[182, 329, 350, 384]. Knez and colleagues have demonstrated that amino acid residues 1-345 of 
VP16 are involved in binding vhs [182]. The direct binding of vhs is thought to facilitate the 
downregulation of vhs activity, which is important for efficient virus replication in cell culture [255, 
329, 350, 384] and animal models [198, 371].  
 
1.8 VIRION HOST SHUTOFF PROTEIN 
The virion host shutoff (vhs) protein of HSV-1 is encoded by the UL41 gene and present in the 
tegument as a minor structural component with an average of 200 copies in each virion. It is a 
phosphoprotein consisting of 489 amino acids with an observed molecular weight of 58kDa [147, 
193, 234, 302]. Sequence homologues of the HSV-1 vhs gene have been found in a number of 
alphaherpesviruses, including HSV-2, varicella-zoster virus, pseudorabies virus, bovine herpesvirus, 
equine herpesvirus 1 herpesviruses [20, 63, 101, 110, 215]. The conservation of vhs in 
alphaherpesviruses and observed absence in beta- and gammaherpesviruses indicates a possible 
fundamental role of vhs in the infection of alphaherpesviruses [reviewed in 199]. Sequence 
comparison between all amino acid sequences from vhs homologues indicates the presence of 
several conserved domains, separated by low conserved sequences. [20]. The herpes simplex virus 
type 1 virion host shutoff protein contains four domains (domain I-IV) (Figure 1.4C) whose 
sequences are conserved among neurotropic herpesviruses. Mutational analysis of domain III and 
domain IV has demonstrated them to be functionally important in host cell shutoff and virulence 
[372].  
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Vhs is an endoribonuclease that shares some amino acid sequence similarity to the fen-1 family of 
nucleases and substrate specificity with RNase A as it degrades single stranded RNA species in the 
absence of other cellular or viral proteins [74, 105, 383, 385]. 
Upon virus infection vhs is deposited in the cytoplasm of the cell where it functions in degrading 
both cellular and viral mRNAs resulting in translational arrest of host cell proteins. By degrading viral 
mRNAs belonging to all three temporal classes vhs facilitates virus replication to occur more 
efficiently as it improves the sequential expression of the immediate early  genes, early genes and 
late genes [62, 105, 112, 115, 193, 195, 281, 282, 344, 383, 385].  
First evidence that mRNA degradation was carried out by an RNase was provided by Frenkel and 
associates [193, 194, 301, 376]. In the beginning it was assumed that vhs did not discriminate 
between host and viral mRNAs and degraded mRNA until its activity was regulated by VP16 late in 
infection [105, 172, 198, 293, 383]. It was the consensus that vhs mostly targeted actively translating 
cellular mRNA whilst sparing rRNA and, tRNAs during infection [96, 97, 189, 190, 193, 281, 282, 362, 
376, 426]. This specificity was thought to stem from common features to most mRNAs, such as the 
3’polyA tail and the 5’cap. The interaction of vhs with eukaryotic translation initiation factors 
including elF4H, eIF4AI, and eIF4AII, elF4B, elF4F has contributed to the concept as vhs seems to 
target 5’-methylguanylate caps of stable host mRNA [73, 108, 109, 285, 323, 341] and rapidly 
degrade from 5′ to 3′ [87, 108, 293]. eIF4H is suggested to be essential for vhs activity as mutations 
in vhs affecting its interaction with eIF4H also result in the inability of vhs to degrade mRNA [323, 
341] despite retaining its RNase activity [221]. While it was suggested that vhs cuts at preferred sites 
of the mRNA such as the 3’polyA tail and the 5’cap [172, 426], it has since been disputed,  as RNA 
degradation is not affected by the presence of a 5′ cap or 3′ poly(A) tail, and can occur in the 
absence of ribosomes [87, 172, 426] indicating that obvious structural features usually distinguishing 
most mRNAs from other cellular transcripts are not conferring substrate specificity. Instead vhs cuts 
target RNAs at many sites [105, 383, 426] and is not dependent on the recognition of a specific 
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nucleotide sequence, as the inactivation of vhs leads to the stabilization of cellular [114, 301, 327, 
376] as well as viral mRNA [193, 195, 281, 282, 376]. Nevertheless, vhs seems to exhibit a preference 
for certain cutting sites in some of the mRNAs analyzed. Those cutting sites lie in regions of 
translation initiation [87, 88, 96, 172, 341, 382]. 
A real insight into the selective mRNA targeting of vhs has been provided by Roizman and 
colleagues. They have shown that vhs targets short-lived stress response mRNAs which are 
characterized by the presence of AU-rich elements in their 3′ untranslated regions (3′ UTR). These 
elements are shown to be targeted by tristetraprolin to exosomes or P bodies for degradation in 
uninfected cells [96]. In infected cells vhs is able to bind tristetraprolin at the AU-rich elements and 
starts cleaving the mRNA at the 5’end towards the AU-rich element [385]. Furthermore it has been 
shown that vhs shuttles between the cytoplasm and nucleus, and it is suggested that stable mRNAs 
are degraded in the cytoplasm, whereas the AU-rich mRNAs may be degraded in the cytoplasm as 
well as the nucleus [342]. 
The rapid degradation of cellular mRNA creates the optimum environment for viral replication as 
viral mRNA gains access to the translation machinery [reviewed in 240]. Vhs is thought to prevent an 
over-accumulation of mRNA during infection as excess amounts of mRNA would lead to reduced 
translation of true-late gene mRNA due to available ribozymes having become limited [61, 62]. 
Recent studies have demonstrated that once vhs has entered the cell it degrades mRNA that had 
been made prior to infection such as cellular mRNA, but it spares mRNA made after infection 
essentially sparing β (early) and γ (late) viral mRNAs from degradation  [386]. This selectivity 
exhibited by vhs has been shown to be due to its interaction with VP13/14 [344]. However, this 
interaction does not inhibit the degradation of AU-rich mRNAs.  
In addition, recent studies have suggested that the rate and overall extent of vhs-mediated mRNA 
degradation may depend upon the cell type that is infected. Dauber et al. have demonstrated that 
infection with vhs deletion mutant resulted in reduced virus yield and decreased levels of true late 
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gene products in Hela cells but, not Vero cells. This observation was shown to be due to reduced 
translational activity [61]. Dauber et al. have suggested that vhs enhances translation of viral late 
mRNAs by preventing mRNA overload. Therefore in the absence of vhs, viral mRNAs accumulate to 
levels that overwhelm the capacity of the host translational machinery which subsequently leads to 
functional exclusion of the last mRNAs that are made during infection [62]. 
 
Investigation into the activity of the virion host shutoff protein has revealed that the efficiency of 
overall host protein destabilization of the various alphaherpesviruses varies [101], reviewed in [354]. 
The vhs protein of HSV-2 is approximately 50-fold more active that the vhs protein of HSV-1 [103, 
111, 113], while the vhs homologues of pseudorabies and varicella-zoster virus are significantly less 
active compared to HSV-1 [64, reviewed in 243]. The vhs protein of equine herpesvirus 1 (EHV-1) 
seems to be impaired in host cell shutoff activity as inhibition of host protein synthesis is barely 
detectable compared to strain F by protein labelling assay [110] reviewed in [354].  
The vhs homologues of HSV-1 and HSV-2 have been the most extensively studied and have provided 
evidence of type-specific host shutoff function [101, 111, 113]. Fenwick and Everett have carried out 
sequence analysis of the vhs gene of HSV-1 (S17) and HSV-2 (G) which revealed 87% sequence 
identity, but they were unable to determine any coding changes that might contribute to the 
different phenotypes, with HSV-2 quickly eliminating host protein synthesis compared to HSV-1 
[101]. Further analysis of vhs activity using recombinant viruses with exchanged vhs coding regions 
confirmed that vhs determines the phenotype of host protein shutoff [113]. This observation was 
supported by Everly and colleagues who compared the degradation activity of vhs alleles from HSV-1 
(KOS) and HSV-2 (strain 333) using transient expression assays with a cotransfected reporter gene, 
and showed that HSV-2 contains a significantly more active vhs protein compared to KOS in the 
absence of other viral gene products. The enhanced vhs activity of HSV-2 (strain 333) is attributed to 
several type specific amino acids which were identified using site-directed mutagenesis [103, 104]. 
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Comparison of HSV-1 strains 17 and KOS by Vojvodova and colleagues indicates that S17 is 4 to 5 
times less active in early shutoff function. Subsequent sequence analysis found a mutation in KOS 
resulting in an amino acid change at 317 which could attribute to the increased shutoff activity of 
strain KOS [404]. 
 
The contribution of vhs to herpes simplex virus infection has been demonstrated in cell culture and 
animal models using vhs deletion viruses. It has been shown that the virion host shutoff function is 
not essential to virus growth in cell culture. Nevertheless, inactivation of vhs leads to a reduced 
plaque size and a slight reduction in virus replication [301, 351]. Mixed infections of virus deficient in 
vhs activity and wild-type virus confirm that the function of vhs is advantageous to virus growth as 
the wild-type virus rapidly outgrows the mutant [195]. 
In contrast to cell culture experiments, animal studies have shown that the absence of vhs severely 
affects virus replication, virulence and pathogenesis in mouse models [259, 357, 358, 372, 373]. This 
indicates that the RNAse activity of vhs contributes to HSV pathogenicity and neurovirulence. It is 
suggested that vhs might be involved in evading host immunity, as vhs-deﬁcient viruses showed a 
signiﬁcantly reduced ability to cause clinical disease, as well as reduced ability to establish latency 
and to reactivate [206, 357, 373, 374]. Evidence suggests that vhs evades host defences of the 
innate and adaptive immune system by supressing cytokine and chemokine production [380], 
inhibiting dendritic cell apoptosis [13], inhibiting dendritic cell activation [167, 320], and reducing 
interferon-alpha and –beta activity [80, 188, 259, 288, 380][reviewed in 218].  
Vhs has been shown to interfere with IFNα/-activity by inhibiting JAK/STAT signalling, [239] as 
replication of a vhs deletion virus in STAT1 knockout mice was partially restored. Vhs has also been 
suggested to interfere with IFN-γ activity [212, 287]. Liang and Roizman reported that expression of 
IFN-gamma-dependent genes is blocked by the degradation of IFN-gamma-dependent gene 
transcripts [212]. Shen et al. reported that HSV-1 infection abolished viperin expression, a gamma 
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interferon (IFN-γ)-inducible protein; and that ectopic expression of viperin could not restrict the 
replication of HSV-1. They have shown that vhs degraded viperin mRNA, thereby inhibiting its 
accumulation [339].  
In addition to viperin, vhs has also been suggested to block the expression of tetherin, an interferon 
(IFN)-inducible membrane glycoprotein that has been shown to have potent antiviral activity by 
inhibiting the release of many enveloped viruses. Tetherin levels were depleted in HSV-1 wild-type 
infection compared to vhs deletion virus; and removal of tetherin compensated for defects in 
replication and release of a vhs deletion virus  [427]. Recently, it has been demonstrated that vhs 
blocks the activation of protein kinase R (PKR) which is a major activator of innate immune defense 
mechanisms early in infection. It blocks PKR activation in cooperation with MEK (mitogen-activated 
protein kinase kinase) by degrading RNAs that potentially trigger PKR [288, 331] 
 
1.9 REGULATION OF VHS FUNCTION 
The regulation of vhs activity is important for efficient viral replication as it is thought to facilitate 
temporal viral gene expression and protein synthesis [198, 350, 384]. 
The virion host shutoff protein and its nuclease activity is thought to be regulated at various stages 
of the HSV-1 life cycle by several viral proteins (VP16, ICP27, VP13/14, VP22) [198, 344, 384, 387]  
(Figure 1.5) and at least one host protein (tristetraprolin) [98, 343]. While UL47 and ICP27 are 
thought to initiate regulation of vhs activity early in infection [344, 387], VP16 and VP22 are thought 
to function late in infection [198, 384].  
The first viral protein shown to regulate vhs activity was tegument protein VP16.  Lam et al. were the 
first to show that during infection VP16 is required for the regulation of vhs activity as infection with 
a VP16 deletion virus resulted in a severe decline of viral protein synthesis and mRNA levels at 
intermediate times after infection, leading to almost complete arrest of viral protein synthesis at late 
times in infection [198]. The severe decline in viral protein synthesis and viral mRNA levels was not  
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Figure 1.5: Illustration of virion host shut off activity regulation.  
Tegument-associated vhs is deposited in the cytoplasm, while the capsid is trafficked to the nucleus 
along microtubules to release the viral genome. During infection vhs degrades viral as well as host 
mRNA resulting in host cell protein shutoff. Vhs activity is regulated by viral proteins VP16, VP13/14, 
ICP27, and possibly VP22. 
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observed during infection with a virus expressing a transactivation-defective VP16 protein which 
retained its vhs binding activity [198]. Further evidence for VP16-medited vhs regulation was 
provided by Mossman et al. who demonstrated that the translational arrest and virus replication can 
be rescued by second site mutations in the vhs gene [255].  
Smibert et al. have shown that VP16 directly interacts with vhs [350]. Residues 238 to 344 of vhs 
were identified to be sufficient for the direct interaction with VP16, and that the VP16 
transcriptional activation domain was not required [350]. Further deletion analysis of vhs by 
Schmelter et al. narrowed the VP16-binding domain down to a 20-amino-acid-long domain spanning 
residues 310 to 330 (Figure 1.4C) [329]. Site-directed mutagenesis of this region identified 
tryptophan 321 as a crucial determinant for interaction with VP16. It was concluded that vhs 
residues 310 to 330 (Figure 1.4C) constitute an independent and modular binding interface that is 
recognized by VP16 [329]. In contrast, Strand et al. reported that the VP16-binding domain had no 
effect on the RNA degradation activity of the vhs protein in transient transfections, or the complex 
formation of vhs with VP16 [371]. Interestingly though, their VP16-binding domain mutant exhibited 
reduced pathogenesis in the mouse model, indicating the importance of the tegument-derived vhs 
activity [371]. Knez and colleagues also provided evidence for VP16-mediated regulation of vhs, as 
complementation assays with a VP16 deletion mutant and a VP16/vhs double deletion mutant 
revealed that the direct interaction of VP16 and vhs is necessary to downregulate the nuclease 
activity of vhs. The recombinant mutant lacking vhs-V16 complex formation was able to assist the 
growth of the double deletion mutant but not the VP16 deletion mutant [182].  
 
The first evidence of VP22 to be involved in the regulation of vhs activity was provided by Sciortino 
et al. who reported that three independently derived VP22 deletion  viruses generated by bacterial 
artificial chromosome system were unable to replicate unless the vhs gene acquired gross 
mutations, which rendered it inactive [333]. Further analysis revealed that the independently 
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derived VP22 deletion viruses expressed either a truncated or non-functional vhs protein, as the 
clones either lacked a 162bp segment close to the N-terminus or contained a deletion of only 2 
nucleotides towards the 3’-prime end, respectively. The mutations were acquired spontaneously 
during transfection, as the UL49-revertant virus accumulated a functional vhs protein. Additionally, 
the bacterial artificial chromosome (BAC)-HSV-1 DNA, utilised to generate the VP22 deletion viruses, 
contained the correct vhs open reading frame, capable of expressing a functional vhs protein. The 
authors interpreted these results to mean that a small amount of vhs is lethal in the absence of VP22 
[333]. Furthermore, another independently generated VP22 deletion virus, also constructed using a 
BAC system has recently been shown to have acquired a spontaneous secondary mutation within its 
vhs gene, resulting in a frameshift at codon 248 that yielded a non-functional vhs protein.  
The suggestion that VP22 was involved in the regulation of vhs was further supported by Taddeo et 
al. who reported that VP22 binds to vhs only in the presence of VP16; and that the accumulation of 
vhs protein required the expression of VP16 and VP22 in transfected cells [384]. Additionally, a 
cotransfected reporter gene with vhs was not expressed in the absence of VP22 and VP16, and 
expression was only restored when both VP22 and VP16 were coexpressed. When examining 
accumulating vhs mRNA levels during expression of vhs alone to coexpression with VP22 and VP16, 
no significant differences were observed. Combining the interaction results with the observed 
expression results Taddeo proposed a model where, vhs sequesters mRNAs in compartments 
inaccessible to the translational machinery and VP22 and VP16 counteract this effect by enabling 
mRNA translation rather than inhibiting vhs degradation via their interaction with vhs. 
Since then, it has also been reported by Duffy et al. [230] that VP22 deletion resulted in a protein 
translation defect, which was rescued by a secondary compensatory frameshift mutation in vhs, 
therefore supporting a role for VP22 in modulating vhs activity. Protein levels late in infection were 
reduced in the absence of VP22, but found to be independent of mRNA abundance, suggesting a 
defect in translation [230].  
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Infected-cell-protein ICP27 has been shown to directly interact with vhs in transfection and infection 
[387]. It is suggested to be involved in vhs regulation as upon infection ICP27 deletion mutant 
brought a vhs protein in to the cell that was reduced in potency at time of infection relative to the 
wild-type. Furthermore, it was reported that vhs did not accumulate to wild-type levels in cells 
infected with ICP27 deletion mutant [387].  
 
The most recent viral protein identified to be involved in vhs activity regulation is tegument protein 
VP13/14 [344]. Vhs has been shown to directly interact with VP13/14 via GST-pulldowns [344]. 
VP13/14 is brought into the cell together with vhs at infection and it is thought that VP13/14 
interaction with vhs result in the regulation of vhs activity early, as well as late in infection. Shue and 
colleagues have reported that VP13/14 downregulates the destabilization of host and viral 
immediate early mRNA activity, and blocks the degradation of viral - and γ-mRNAs [344]. It is 
suggested that VP13/14 attenuates vhs activity along with ICP27 by binding to vhs and colocalising at 
the cap structure of viral mRNA through their interaction with enzymes in polyribosomes [344, 386]. 
 
  
Chapter 1                                                                                                             General Introduction 
63 
 
1.10 HYPOTHESIS AND AIMS 
Independent publications of VP22 knockout mutants of strain F constructed in a bacterial artificial 
chromosome (BAC) system investigating the role of VP22 in the virus life cycle have reported that 
∆22 viruses were only viable after acquiring spontaneous secondary mutations in the vhs gene 
rendering it inactive [82, 333]. This indicates a role for VP22 in the regulation of vhs. The aim of the 
present study is to provide a better understanding of the relationship of VP22 and vhs in the virus 
replication cycle; and provide significant contribution to the role of tegument protein VP22 in the 
HSV-1 life cycle.  
It is hypothesized that VP22 knockout mutants are able to replicate with a functional vhs and that 
the role of VP22 extends past the regulation of vhs. 
 
1.10.1 AIMS 
1. Construct a range of new ∆VP22 viruses in strain 17, using Two-step Red-mediated 
recombination utilising bacterial artificial chromosome (BAC). 
2. Determine the integrity and expression of vhs in VP22 knockout viruses made by different 
methods. 
3. Characterise the VP22/VP16/vhs relationship during infection. 
4. Analyse the phenotype of viruses lacking VP22 or vhs in physiologically relevant cell lines 
HFFF (human foetal foreskin fibroblast)  
Chapter 2                                                                                                                        
Materials & Methods 
 
64 
 
 
 
CHAPTER 2 
 
MATERIALS & METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2                                                                                                Materials & Methods 
65 
 
2.1 CELLS AND TISSUE CULTURE 
Unless otherwise stated the solvent used for all buffers and solutions was deionised 18.2 MΩ water. 
If not specified here, standard buffers and solutions are detailed in Appendix 1, and where 
appropriate solutions were autoclaved prior use. 
 
2.1.1 CELL TYPES 
Vero (African green monkey-derived kidney fibroblast-like cell line), HeLa (human epithelial 
carcinoma cell line), BHK-21 (baby hamster kidney cell line) and HFFF2 (primary human foetal 
foreskin fibroblast) cells were obtained from the European Collection of Cell Cultures (ECACC) 
(Health Protection Agency, Porton Down, UK). The human primary immortalised keratinocyte cell 
line HaCaT (Human adult low Calcium Temperature) was a kind gift from Professor Judith Breuer 
(University College London, UK).  All cells used were adherent cell types and used below passage 20, 
or passage 13 for HFFF2. 
 
2.1.2 CELL CULTURE MAINTENANCE 
Tissue culture was performed in BioMAT2 class II microbiological safety cabinets (Medical Air 
Technology, Oldham, UK) and in a LabGard ES 425 Class II, Type A2 Biological Safety Cabinet (NuAire 
Inc.). All cells were maintained in supplemented Gibco® Dulbecco’s modified eagle medium (DMEM; 
Invitrogen) (Appendix 1). Vero, HeLa and BHK-21 cells were grown in DMEM supplemented with 10 
% v/v newborn calf serum (NCS; Invitrogen), 100 U/ml Penicillin and 100 μg/ml Streptomycin 
(1%Pen-Strep) (Sigma-Aldrich). HaCaT and HFFF2 cells were grown in DMEM media supplemented 
with the same amount of Penicillin and Streptomycin, but substituting NCS with 10% v/v foetal calf 
serum (FCS; Invitrogen). All cell lines were routinely cultured in 225cm2 plastic tissue culture flasks 
and incubated at 37°C in a Heraeus® HERAcell 240 incubator (Thermo Fisher Scientific Inc.) with a 
humidified 10% carbon dioxide atmosphere. Vero and BHK-21 cells were also cultured in 850 cm2 
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CELLSTAR® tissue culture treated roller bottles with standard caps (Greiner Bio One) for extracellular 
virus purification (section 2.2.5). To establish the required CO2 environment for the cells, the cell 
culture media in the roller bottles was CO2 enriched by gently bubbling CO2 through it for 
approximately 3-5 seconds. Roller bottles were incubated in a Wheaton standard incubator (Thermo 
Fisher Scientific Inc.). Cells were routinely sub cultured in tissue culture flasks twice a week with 
Vero, HeLa and BHK-21 cells split at 1:10 and HFFF-2 cells split at 1:3 when grown to a monolayer. 
For this, the culture medium was removed and cells were washed twice briefly with a small amount 
of 0.5 g/L trypsin- ethylenediaminetetraacetic acid (EDTA) solution (Invitrogen) (Appendix 1) before 
being incubated at 37°C in 1ml of this solution for approximately 3 mins to detach the cells. Once the 
cells detached, they were re-suspended in 10ml fresh culture media and diluted into a new tissue 
culture flask containing the appropriate growth media. For experiments, cells were seeded at the 
appropriate density in 1 ml (12-well plate), 2 ml (6-well plate) or 5 ml (60 mm dish) medium per well 
or dish. All reagents required for tissue culture were warmed to 37°C before use. All tissue culture 
plastic ware was from VWR unless otherwise stated. 
New cells stocks were revived from frozen aliquots of low passage cells when necessary. To revive, 
cells were rapidly thawed at 37°C in a water bath and diluted in 10ml of fresh, pre-warmed culture 
media. The cells were pelleted at 1300rpm for 5min at 4°C in a TX-750 swinging bucket rotor for the 
Heraeus® Megafuge 40R centrifuge (Thermo Fisher Scientific Inc.). The pellet was resuspended in 
10ml of culture medium and added to a 25 cm2 or a 75 cm2 tissue culture flask and grown to 100% 
confluency before further passaging. Low passage cells were periodically frozen into aliquots and 
stored in liquid nitrogen. Briefly, trypsinised cells were counted and pelleted by centrifugation for 
5min at 3,000rpm at 4°C in a TX-750 swinging bucket rotor for the Heraeus® Megafuge 40R 
centrifuge (Thermo Fisher Scientific Inc.). The cell pellet was re-suspended in Gibco® Recovery™ cell 
culture freezing medium (Invitrogen) at a density of 3 x 106 cells/ml and 1ml aliquots were frozen at -
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80°C using a 5100 Cryo 1°C freezing container (Thermo Fisher Scientific Inc.) before being transferred 
to liquid nitrogen. 
 
2.1.3 CELL COUNTING AND SEEDING 
For experiments using various sized culture plates, cells were counted and seeded at specific cell 
densities. A suspension of trypsinised cells was diluted in culture media by a known dilution factor 
and transferred to the chamber of a haemocytometer (Fisher Scientific Inc.). The cells were counted 
in 4 sets of 16 squares under an Olympus CKX31 light microscope (Olympus) using a 10x objective. 
The average cell number was used to calculate the number of cells per ml of the cell suspension 
used for seeding after an adjustment of the dilution factor. Cells were seeded into 96/24/12/ or 6-
well CELLSTAR® culture plates (Greiner Bio One) at a volume of 100µl/ 500µl/ 1ml or 2ml, 
respectively, at the densities listed in Table 2.1 to achieve 100% confluency 24hours post seeding. 
For transfections studies cells were seeded at 75% of the density shown in Table 2.1 to achieve 70-
80% sub-confluent monolayers at 24 hours post seeding.  
 
2.2 VIRUS TECHNIQUES 
All virus work was performed in BioMAT2 class II microbiological safety cabinets (Medical Air 
Technology) and later on in a LabGard ES 425 Class II, Type A2 Biological Safety Cabinet (NuAire Inc.). 
All cells used for virus work were cultured in Heraeus® HERAcell 150 incubators (Thermo Fisher 
Scientific Inc.) at 37°C in a humidified, 5% CO2 atmosphere. All virus stocks and samples were 
collected and stored in 2ml screw-top microtubes (Sarstedt) at -80°C. Virus stock was not used for 
experiments past two freeze-thaw cycles unless otherwise stated. All reagents required for 
infections were pre-warmed to 37°C before use in a SUBAqua 12 Plus water bath (Grant 
Instruments) unless otherwise indicated. 
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Table 2.1: Cell numbers required to be seeded 
Cell numbers required to be seeded in various sized tissue culture plates in order to be 100% 
confluent 24 hours post-seeding 
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Table 2.1 
 
 Number of cells seeded per well in cell culture plate 
Cell Type 96 24 12 6 
Vero 2 x 104 1x 105 3.0 x 105 6.0 x 105 
HeLa 3 x 104 2x 105 4.0 x 105 8.0x105 
HFFF2   4.0 x 105 8.0 x 105 
HaCaT   1.0 x 106 2.0 x 106 
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2.2.1 VIRUSES 
Viruses that were used in this study are listed in the table below (Table 2.2).  
Wild-type HSV-1 strain 17 (S17) was originally isolated in Glasgow (Hay ‘76). Wild-type strain Sc16 
was kindly donated by Helena Browne (University of Cambridge, UK) (Hill ’75); wild-type strains KOS 
and HFEM [155, 183] were kindly donated by Peter O’Hare (Imperial College London, UK) whilst wild-
type strain F [291] was a kind donation from Konstantin Gus Kousoulas (Louisiana State University, 
US).  Viruses expressing a recombinant form of VP22 were derived from our lab strain 17. Virus 
encoding green fluorescent protein (GFP)-tagged full length VP22 (GFP22v)[91, 92], GFP in place of 
VP22 (∆22v)[94] or its revertant (Δ22vR) were constructed by Prof. Gill Elliott.  Recombinant viruses 
expressing GFP-tagged residues 108 to 301 (GFP22v:108-301), 160 to 301 (GFP22v:160-301), 1 to 
165 (GFP22v:1-165) or 1 to 212 (GFP22v:1-212) of VP22 were constructed by Wali Hafezi when he 
was a member of the lab [136]. Strain 17-derived vhs deletion virus (∆vhs) was kindly provided by 
Roger Everett (University of Glasgow, UK) [111]. Strain Sc16-derived mutants lacking gE (∆gE)[11], 
gM (∆gM)[28], gE and gM (∆gEgM)[28] were kindly donated by Helena Browne (University of 
Cambridge, UK) and Colin Crump (University of Cambridge, UK). Strain KOS-derived mutant lacking 
the C-terminal 38 residues (452-490aa) of the activation domain of VP16 (∆ct) as well as its revertant 
were kindly provided by Steven Triezenberg (Van Andel Research Institute, US) [388].  
 
2.2.2 PRODUCTION OF VIRUS WORKING STOCKS 
New virus working stock was prepared from Master- or Sub-Master stock of virus grown on either 
confluent BHK-21 or Vero cells in five 225cm2 tissue culture flasks (CORNING®Inc.). The culture media 
was removed and cells were infected at a multiplicity of infection (MOI) of 0.02–0.05 virus infectious 
unit per cell in 50ml infection media consisting of DMEM with 2% v/v newborn calf serum and 
1%Pen-Strep. The cells were incubated at 37°C until extensive cytopathic effect was visible; yellow  
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Table 2.2: Viruses used in this study. 
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Table 2.2: 
Virus Referred as Description Ref. 
s17 s17 Wild-type HSV-1 strain17 Hay ’76[146] 
Sc16 Sc16 Wild-type HSV-1 strain SC16 Hill’75[151]
4 
HFEM HFEM Wild-type HSV-1 strain HFEM Knipe ‘81[183]
1 
KOS KOS Wild-type HSV-1 strain KOS Honess ‘84[155]
1 
F F Wild-type HSV-1 strain F Pellett ’85 [291]
3 
166v GFP22v s17 expressing GFP fused to VP22 (GFP-VP22) Elliott ‘99[91] 
169v Δ22v s17 expressing GFP in place of VP22 Elliott ‘05[94] 
187v GFP22v: 108-301 s17 expressing GFP fused to VP22 residues 108-301 Hafezi ‘05[136] 
193v GFP22v:1-212 s17 expressing GFP fused to VP22 residues 1-212 Hafezi ‘05[136] 
195v GFP22v: 160-301 s17 expressing GFP fused to VP22 residues 160-301 Hafezi ‘05[136] 
WH1v GFP22v:1-165 s17 expressing GFP fused to VP22 residues 1-165 Hafezi ‘05[136] 
∆vhs ∆vhs S17 containing deletion of vhs Fenwick ‘90 [111]
2 
∆gE ∆gE SC16 containing deletion of gE Balan ‘94[11] 
∆gM ∆gM SC16 containing deletion of gM Browne ‘04[28] 
∆gEgM ∆gEgM SC16 containing deletion of gE and gM Browne ‘04[28] 
RP3v ∆ct KOS strain expressing VP16 with deleted 452-490 aa Tal-Singer ‘99[388] 
RP3Rv ∆ctR KOS strain, revertant of RP3v Tal-Singer ‘99[388] 
WH3Rv Δ22vR s17, revertant of 169v Elliott ‘05[94]
 
DLWT S17  DLWT s17 BAC–ve 
Gierasch ‘06[130] 
/Hay ‘76[146] 
1 Peter O’Hare, Imperial College London, UK  
2 Roger Everett, University of Glasgow, UK 
3 Gus Kousoulas, Louisiana State University, US 
4 Helena Browne, University of Cambridge, UK 
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colour of media and rounded up cells which became non-adherent when the flask was tapped. The 
infected cells were harvested into the media and pelleted in a 500ml centrifuge tube (CORNING®Inc.) 
which was spun at 3,000 rpm for 30 min at 4˚C in an airtight swinging bucket rotor (7500 6445) for 
the Sorvall® Legend RT centrifuge (both Thermo Fisher Scientific Inc.). The supernatant was discarded 
and the cell pellet was re-suspended in 2ml of sterile phosphate buffered saline (PBS; VWR) 
(Appendix 1). The re-suspension was subjected to three cycles of freeze/thaw to disrupt the cell and 
release intracellular virus using dry ice (BOC Group PLC)/ethanol (VWR) and a 37°C SUBaqua 12 Plus 
water bath (Grant Scientific). Cell debris was pelleted at 3,000rpm for 5min at 4°C in a Sorvall® 
Legend RT centrifuge using an airtight swinging bucket rotor (7500 6445) and the cleared 
supernatant was aliquoted and stored at -80°C. Before experiments were conducted, virus stocks 
were titrated onto Vero cells to determine the titre (pfu/ml). 
 
2.2.3 TITRATIONS 
All titrations were performed in duplicate on Vero cells seeded to a monolayer in 6-well plates 
unless otherwise stated. Virus samples or virus stock were diluted in a 10-fold titration series using 
DMEM with 2% v/v newborn calf serum and 1%Pen-Strep. The culture media was removed from 
one-day old confluent monolayers and replaced with 800 µl of virus dilution per well. After one hour 
of incubation at 37°C, 5%CO2 the inoculum was removed and replaced with 2ml per well of cell 
culture media containing 2% v/v newborn calf serum, 1%Pen-Strep and 1% human serum (HS, Sera 
Laboratories Ltd.). The cells were further incubated at 37°C, 5%CO2 until plaques visible to the eye 
appeared. In order to count the plaques, the cells were fixed with 2ml of 2x formal saline solution 
added directly to the well (Appendix 1) for 20min at room temperature, before being stained with 
0.5ml of 0.1% crystal violet (Appendix 1). 
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2.2.4 EXPERIMENTAL VIRUS INFECTION 
For experimental virus infection, cells from a spare well were trypsinised and counted as described 
in section 2.1.3 to determine the volume of virus stock needed for infection at the desired MOI. The 
cell culture medium was removed from one-day old confluent cell monolayers and the prepared 
virus inoculum was added as 400 µl (12-well plate), 800 µl (6-well plate or 10cm2 dishes) or 2 ml (60 
mm dish) accordingly. After one hour of incubation at 37°, 5% CO2 the inoculum was removed and 
cells were returned to 37°C, 5% CO2 in fresh infection media. Infection was allowed to progress until 
time point of interest or until all cells were rounded up and ready for harvest. 
For subsequent protein expression analysis, cells were washed once in ice-cold PBS and lysed in 100 
µl (12-well plate) or 200 µl (6-well plate) 2X SDS-PAGE sample buffer (Appendix 1) unless otherwise 
stated. When measuring the effect of virus infection on the induction of interferon stimulated genes, 
cells were treated with 500IU/ml interferon beta (IFN-) (Merck Millipore) and incubated alongside 
the infected wells as a positive control. 
 
2.2.5 PURIFICATION OF EXTRACELLULAR VIRUS PARTICLES 
BHK-21 or Vero cells grown to 100% confluency in 225cm2 flasks were infected as described in 
section 2.2.2. The cells were collected along with the infected media in 500ml centrifuge tubes 
(CORNING® Inc.) once extensive cytopathology was detected. Cell debris was removed via 
centrifugation at 3,000 rpm for 30 min at 4°C in an airtight swinging bucket rotor (7500 6445) for the 
Sorvall® Legend RT centrifuge. The cleared supernatant was collected in a SLA-3000 centrifuge tube 
and infectious virus particle was pelleted by centrifugation at 9,000 rpm for 90 min at 4°C in a SLA-
3000 Super-Lite rotor for the Sorvall® RC5C centrifuge (both Thermo Fisher Scientific Inc.). The virion 
pellet was re-suspended in 1ml of sterile PBS and layered onto a ml 5% to 15% w/v Ficoll (Sigma-
Aldrich) gradient which was prepared beforehand in a 13.2ml thin-walled polyallomer 
ultracentrifuge tube (Beckman Coulter) using a single channel peristaltic pump P-1 and gradient 
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maker (GE Healthcare). The gradient was centrifuged at 12,000 rpm for two hours at 4°C in a SW41 
Ti swinging bucket rotor (Beckman Coulter) for the Sorvall® DiscoveryTM SE centrifuge (Thermo Fisher 
Scientific Inc.). The purified virions were visible as a slight opaque band and were harvested through 
the side of the tube using a 19-gauge BD MicrolanceTM hypodermic needle (Becton Dickinson). The 
virions were re-suspended in 10ml sterile PBS and pelleted at 25,000 rpm for one hour at 4°C in a 
SW41 Ti swinging bucket rotor (Beckman Coulter) for the Sorvall® DiscoveryTM SE centrifuge (Thermo 
Fisher Scientific Inc.). The virion pellet was re-suspended in 200 µl sterile PBS ready for use or stored 
at -80°C. Purified virions were analysed by Coomassie blue-stained SDS-PAGE gel (sections 2.8.1 and 
2.8.3) prior to further use. 
 
2.3 BACTERIOLOGICAL TECHNIQUES 
All plasmids were prepared from Escherichia coli strain HB101 (ECACC) apart from recombinants of 
bacterial artificial chromosome (BAC) containing full-length, infectious DNA of HSV-1 strain 17 (BAC-
HSV-1S17) which were prepared from E.coli strain GS1783. Competent bacteria of E.coli strain 
GS1783 carrying bacterial artificial chromosome (BAC) containing full-length, infectious DNA of HSV-
1 strain 17 (BAC-HSV-1S17) used for Red recombination was provided by David Leib (Dartmouth 
Medical School, US). The original E.coli strain GS1783 was kindly provided by Greg Smith 
(Northwestern University, Chicago, US). Bacteria work was performed with sterile reagents and tools 
under a blue flame on the bench. Waste was disposed of in compliance with Cambridge University, 
Imperial College London and University of Surrey health and safety policy. 
 
2.3.1 BACTERIAL CULTURE 
Bacteria were isolated by plating on Luria-Bertani (LB) agar plates containing appropriate antibiotics 
(reagents from Sigma-Aldrich; Appendix 1) and incubated at 37°C in a Heraeus® T 5042 E gravity 
convection oven D 6450 Hanau (Thermo Fisher Scientific Inc.). A starter culture was prepared by 
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inoculating 2ml of LB media containing appropriate antibiotics (reagents from Sigma-Aldrich; 
Appendix 1) with either bacterial glycerol stock (section 2.3.2) or a single colony from a LB agar 
plate. Following inoculation, starter cultures were incubated at 37˚C with agitation (220 rpm) for 6-
16 hours in a Max-Q 4000 incubator shaker (Thermo Fisher Scientific Inc.). Large scale cultures were 
set up by inoculating 250ml LB media containing appropriate antibiotics with 500 µl starter culture 
and subsequently incubated at 37˚C with agitation (225 rpm) overnight in an InnovaTM 4300 
incubator shaker (Eppendorf). 
 
2.3.2 GLYCEROL STOCK PRODUCTION 
Glycerol stocks were prepared by adding 600 µl starter culture to 400 µl sterile glycerol (Sigma-
Aldrich). Stocks were stored at -80˚C and kept frozen on ice throughout use. 
 
2.3.3 HEAT SHOCK TRANSFORMATION 
For transformation of DNA into bacteria, competent cells were thawed on ice and incubated with 1-
5ng of DNA for 20 min. After incubation the bacteria cells were heat-shocked for 90 sec at 42oC in a 
water bath (Grant Scientific) and then quickly returned to ice for 10min before 1ml of LB media was 
added. Following on, the bacteria were incubated at 37˚C for one hour in a Max-Q 4000 incubator 
shaker with constant agitation at 220 rpm. The bacterial cultures were plated onto LB agar plates 
containing the appropriate antibiotic (reagents from Sigma-Aldrich; Appendix 1) and incubated at 
37˚C overnight in a Heraeus® T 5042 E gravity convection oven D 6450 Hanau (Thermo Fisher 
Scientific Inc.). Transformation efficiencies were routinely in the region of 1x107 colonies/µg DNA 
(data not shown). 
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2.3.4 ELECTROPORATION 
To electroporate DNA into bacteria, E.coli strain GS1783 competent cells carrying bacterial artificial 
chromosome (BAC) containing full-length, infectious DNA of HSV-1 strain 17 (BAC-HSV-1S17) were 
thawed on ice and 100ng-500ng DNA was added before transferring the mix to chilled 2mm 
cuvettes. The DNA was previously purified using QIAquick Gel Extraction Kit (Qiagen) kit. After 
addition of the DNA the cuvettes were briefly tapped to ensure cells sink to the bottom before 
electroporation with a single high voltage at V1500 for 5ms with a resistance of 200Ω and 
capacitance of 25µF was applied using a BioRAD electroporator (exact model unknown). Bacteria 
were then mixed into 1ml LB immediately after electroporation and were incubated at 30˚C for one 
hour in an incubator shaker (exact model unknown) with constant agitation at 220 rpm for 
regeneration. The bacterial cultures were pelleted using a Heraeus Biofuge Pico centrifuge (Thermo 
Fisher Scientific Inc.) and plated onto LB agar plates containing the 30 µg/ml kanamycin and 30 
µg/ml chloramphenicol (reagents from Sigma-Aldrich; Appendix 1) and incubated at 30˚C for 24 
hours in a convection oven (exact model unknown). Successful colonies were minipreped (section 
2.4.2) and further analysed by PCR and restriction fragment length polymorphism (RFLP) using 
appropriate restriction enzymes.  
 
2.3.5 RED RECOMBINATION 
For Red Recombination 100µl of overnight culture containing recombinant BAC was added to 2ml of 
LB broth containing 30 µg/ml chloramphenicol (reagent from Sigma-Aldrich; Appendix 1) and grown 
at 30°C for 4hrs in an incubator shaker (exact model unknown) with constant agitation at 220 rpm. 
After incubation 2ml of LB containing 34 µg/ml chloramphenicol and 1% arabinose (reagents from 
Sigma-Aldrich; Appendix 1) was added to each bacterial culture and grown for another hour at 30°C 
before transferring the cultures into a 42°C water bath shaker (exact model unknown) for 30 min to 
initiate Red recombination. Bacteria were then grown for another 2–4 h at 32°C, and serial dilutions 
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were spread onto agar plates containing chloramphenicol, and 1% arabinose. Replica plating was 
then used to detect kanamycin-sensitive colonies.  
Exact models of equipment are unknown as no note was taken when procedure was carried out in 
another laboratory at Cambridge University. 
 
2.3.6 β-GALACTOSIDASE STAINING 
Successful BAC excision of reconstituted recombinant BAC virus was detected by 5-Bromo-4-chloro-
3-indolyl -D-galactosidase (X-gal) staining. Vero cells grown to a 90-100% monolayer were infected 
with the recombinant virus as described in section 2.2.3. After visible plaque formation occurred 
cells were washed two times in 500 l PBS before being fixed in 500 l 4% w/v paraformaldehyde 
(PFA) (Sigma-Aldrich) for 15 mins at 4°C. Fixed cells were washed three times using ice-cold 2 mM 
MgCl2 (VWR) in PBS and then covered in the same solution for 10 min. After incubation in ice-cold 2 
mM MgCl2 (VWR) in PBS cell monolayers were covered with ice-cold detergent solution for 10 mins 
before removing and incubating in X-gal solution (see Appendix 1 for both solutions) at 37°C until 
blue staining was visible (around 4-8 hours). X-gal solution was removed, cells rinsed with PBS 
followed by water and counterstained with 0.1% Neutral red (Appendix 1) for 5min. 
 
2.4 PLASMIDS 
Plasmids used in this thesis are summarised in table 2.3.  
Plasmid maps of plasmids used for transfection in this thesis which were previously constructed in 
the Elliott lab are shown in Figure 2.1. 
Plasmid pCMV-SV5α was kindly provided by Colin Goding (Ludwig Institute for Cancer Research Ltd.). 
pPO85 and pcDNA-VP16 were kindly donated by Peter O’Hare (Imperial College London). Plasmids 
pEPkan-S and pgS403 were kindly provided by Klaus Osterrieder (Freie Universität, Berlin). 
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Table 2.3: Plasmids used in this study.  
Plasmids are named as they appear in the literature. pCMV-β-gal, pGE109, pGE169 and pGE204 were 
generated within our lab. pcDNA-VP16 was kindly provided by Peter O’Hare (Imperial College 
London). The β-galactosidase gene in pCMV-β-gal is from E. coli. pCMV-SV5α expresses an sv5 
epitope tag (a14 amino acid sequence) derived from the V protein of Simian Virus 5. VP16 and VP22 
expressed by pcDNA-VP16 and pGE109, respectively, are from HSV-1 wt strain 17. pGE169 consists 
of GFP open reading frame surrounded by the UL49 flanking sequences derived from HSV-1 wt strain 
17. pGE204 expresses wild-type vhs linked to the SV5 epitope tag. pPO85 expresses wild-type VP22 
linked to the SV5 epitope tag. pEPkan-S encodes kanamycin resistance gene aphAI flanked by 
homing endonuclease I-SceI restriction sites for excision. pgS403 expresses Cre-recombinase for 
excision by site-specific Cre/LoxP recombination. The Cre-encoding gene contained a synthetic 
intron which prevented expression of the functional protein in Escherichia coli but not in human 
cells. pEPkan-S encodes the kanamycin resistance gene; all other plasmids encode ampicillin 
resistance. IE, immediate-early; wt, wild-type; SV5, simian virus 5; TK, thymidine kinase. 
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Table 2.3 
Plasmid name Promoter Protein expressed Source 
pCMV-β-gal HCMV IE β-galactosidase Gill Elliott 
pCMV-SV5α HCMV IE SV5 epitope tag Colin Goding1 [141] 
pcDNA-VP16 HCMV IE wt VP16 Peter O’Hare2 
pGE109 HCMV IE wt VP22 Gill Elliott [93] 
pGE169 HCMV IE GFP open reading frame 
surrounded by the UL49 
flanking sequences 
Gill Elliott [94] 
pGE204 HCMV IE SV5 epitope tagged wt vhs Gill Elliott 
pPO85 HCMV IE SV5 epitope tagged wt VP22 Peter O’Hare2 
pEPkan-S HCMV IE I-SceI-aphAI cassette  Klaus Osterrieder 3 [398] 
pgS403 HCMV IE Cre-expression cassette Klaus Osterrieder 3 [355] 
phRL-TK HSV-1 TK Renilla luciferase Promega4 
pMKW6 HCMV IE  Maia Kavanagh Williamson1 
1 Colin Goding, Ludwig Institute for Cancer Research Ltd., University of Oxford, UK 
2 Peter O’Hare, Imperial College London 
3 Klaus Osterrieder, Freie Universität Berlin, De 
4 Madison, WI USA 
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Figure 2.1:  Plasmid maps of plasmids used for transfections.   
A) pcDNAVP16. B) pGE109. C) pGE204.   D) pPO85.  
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C)       D)   
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2.4.1 PLASMID PREPARATION 
Small scale plasmid preparations were carried out using the QIAprep® Spin Miniprep Kits (Qiagen) as 
per the manufacturer’s instructions, or by the boiling method as detailed below. Large scale DNA 
plasmid preparations were performed using the QIAGEN Plasmid Maxi kit (Qiagen) as per 
manufacturer’s instructions. All Qiagen buffers are detailed in Appendix 1. The total yield of DNA 
was determined using a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies) and 
diluted to 1mg/ml if required before storage at -20˚C.  
Briefly, for small scale plasmid preparations 2ml of overnight cultures grown in LB supplemented 
with 50 µg/ml ampicillin, 30 µg/ml kanamycin or 34 µg/ml chloramphenicol (all Sigma-Aldrich) as 
appropriate was pelleted at 4000rpm for 5min at 4˚C in a Sorvall Legend RT centrifuge (Thermo 
Fisher Scientific Inc.). All subsequent centrifugation steps were carried out at 13,000 rpm in a 
Heraeus Biofuge Pico microcentrifuge (Thermo Fisher Scientific Inc.), unless otherwise stated. The 
pellet was resuspended in 250 μl Buffer P1 with added RNase A (100µg/ml). To lyse the cells 250 μl 
Buffer P2 was added and cells were gently inverted five times before being incubated at room 
temperature for 5 min. After incubation 350 μl Buffer N3 was added, cells were gently inverted five 
times and centrifuged for 10 min at 13,000 rpm. The supernatant was applied to a QIAprep spin 
column and centrifuged for 30–60. The spin column was washed with 500 μl Buffer PB, followed by 
750 μl Buffer PE and centrifuged for 30–60. To remove residual wash buffer the spin column was 
centrifuged for an additional 1min before plasmid DNA was eluted in 50 μl Buffer EB (10 mM Tris·Cl, 
pH 8.5) by centrifugation for 1min.  
For the boiling method, 1ml of overnight cultures grown in LB supplemented with 50 µg/ml 
ampicillin, 30 µg/ml kanamycin or 34 µg/ml chloramphenicol (all Sigma-Aldrich) as appropriate were 
pelleted at 13,000rpm for 5min. The pellet was resuspended in 350µl STET buffer at pH 8 
(Appendix1) and 25 µl lysozyme (10 mg/ml) was added before samples were boiled at 100°C for 2 
minutes on a dri-block heater (Techne). After boiling samples were spun at 3000rpm for 5 minutes in 
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a Heraeus Biofuge Pico microcentrifuge (Thermo Fisher Scientific Inc.) to remove debris pellet. To 
precipitate DNA 350 µl of isopropanol (Thermo Fisher Scientific Inc.) was added to the supernatant 
and incubated for 5min at room temperature. Samples were then spun at 13,000pm for 2 minutes in 
a Heraeus Biofuge Pico microcentrifuge (Thermo Fisher Scientific Inc.) and DNA pellet was 
resuspended in nuclease free dH20. 
 
Briefly, for large scale DNA plasmid preparations 250ml of overnight cultures (section 2.3.1) in LB 
supplemented with 50 µg/ml ampicillin or 30 µg/ml kanamycin (both Sigma-Aldrich) as appropriate 
was pelleted at 6,000 rpm for 15 min at 4˚C in a SLA-3000 Super-Lite rotor for the Sorvall® RC5C 
centrifuge. The pellet was re-suspended in 10ml Buffer P1 with added RNase A (100µg/ml). To lyse 
the cells 10 ml Buffer P2 was added and cells were inverted five times before being incubated at 
room temperature for 5 min. After incubation 10 ml ice-cold Buffer P3 was added to neutralise the 
lysis reaction and cells were incubated on ice for 20 min. Cells were then centrifuged at 12,000 rpm 
for 30 min at 4˚C in a SLA-3000 Super-Lite rotor for the Sorvall® RC5C centrifuge to pellet genomic 
DNA, protein and cell debris. The supernatant was applied to a QIAGEN-tip 500 which had been 
equilibrated with 10 ml Buffer QBT. The QIAGEN-tip was washed twice with 30 ml Buffer QC and 
plasmid DNA was eluted in 15 ml Buffer QF. All liquids were allowed to pass through the QIAGEN-tip 
by gravity flow and solutions were used at room temperature unless otherwise stated. DNA was 
precipitated by adding 10.5 ml room temperature 100% isopropanol (Thermo Fisher Scientific Inc.) 
and centrifuging at 4,600 rpm for 30 min at 4˚C in an airtight swinging bucket rotor (7500 6445) for 
the Sorvall® Legend RT+ centrifuge. The pellet was washed in 5 ml 70% ethanol and re-pelleted at 
4,600 rpm for 10 min at 4˚C in an airtight swinging bucket rotor (7500 6445) for the Sorvall® Legend 
RT+ centrifuge. After air-drying the pellet, it was dissolved in a small volume of TE buffer (pH 8.0). 
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2.4.2 BACTERIAL ARTIFICIAL CHROMOSOME PREPARATION 
Bacterial artificial chromosome (BAC) small scale preparations were carried out using some of the 
reagents of the QIAGEN Plasmid Maxi kit (Qiagen) together with phenol-chloroform precipitation. All 
Qiagen buffers used are detailed in Appendix 1.  
 
For BAC small scale preparations 10ml of overnight cultures grown in LB supplemented with 30 
µg/ml kanamycin and 34 µg/ml chloramphenicol (Appendix 1) (all Sigma-Aldrich) was pelleted at 
3000rpm for 10min at 4˚C in a Sorvall Legend RT centrifuge (Thermo Fisher Scientific Inc.). All 
subsequent centrifugation steps were carried out at 13,000 rpm in a Heraeus Biofuge Pico 
microcentrifuge (Thermo Fisher Scientific Inc.), unless otherwise stated. The pellet was resuspended 
in 200 μl Buffer P1 with added RNase A (100µg/ml). To lyse the cells 300 μl Buffer P2 was added and 
cells were gently inverted five times before being incubated at room temperature for 5 min. After 
incubation 300 μl Buffer P3 was added, the cells were gently inverted several times and incubated 
on ice for 20 min before being centrifuged at 13,000 rpm for 10 min at 4˚C in a Heraeus Biofuge Pico 
centrifuge. The supernatant was added to Eppendorf tubes containing 300 μl phenol (Thermo Fisher 
Scientific Inc.) and 300 μl chloroform (Thermo Fisher Scientific Inc.) and centrifuged for 10 min. The 
upper aqueous phase was carefully removed and transferred into a fresh Eppendorf containing 800 
μl of isopropanol (Thermo Fisher Scientific Inc.). After gently inverting the tubes several times they 
were incubated for a minimum of 5 minutes at room temperature to precipitate out the DNA and 
centrifuged for 10 min. The resulting pellet was washed with 70% ethanol and air-dried for 5 min at 
room temperature. After air-drying the pellet, it was slowly dissolved in a small volume of EB buffer 
(Appendix 1) and left at RT for 1h 45min. The BAC preparations were stored at 4°C until further use. 
Phenol and phenol-chloroform waste were disposed of in Compliance University of Cambridge 
health and safety policy. 
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2.5 TRANSIENT TRANSFECTION 
Transient transfection of one-day-old cell monolayers grown to 70-80% confluency (unless stated) 
with plasmid DNA was achieved by the Calcium Phosphate method (Appendix 1) or the TransIT-LT1 
(Mirus Bio LLC) reagent method following manufacturer’s instructions. For each transfection cells 
were incubated at 37°C in the required CO2 environment until ready for harvesting. 
Briefly, for transfection using calcium phosphate method, cells were grown in antibiotic free tissue 
culture media which was changed 2 hours prior to transfection. DNA was diluted to the appropriate 
final concentration (unless stated otherwise) in sterile water and mixed with BES and Calcium 
Chloride (Appendix 1). The final transfection mix was incubated for 20min at room temperature 
before being added to the cell monolayer. 
Transfection using TransIT-LT1 (Mirus Bio LLC) required dilution of the transfection reagent with 
Opti-MEM® I reduced serum media (Appendix 1, Invitrogen) and incubation for 5min at room 
temperature before being combined with DNA at the required concentration (unless stated 
otherwise). The final solution mix was incubated for 30min at room temperature before media was 
removed from cells and mix was added to the cell monolayer. After two hours of incubation at 37°C, 
5% CO2 cells were topped-up with fresh media. 
 
2.6 DNA TECHNIQUES 
2.6.1 DNA EXTRACTION 
DNA extraction was carried out using phenol-chloroform precipitation of either existing virus 
working stock or virus infected Vero cells as described above in section 2.2.2 with advanced CPE. 
Briefly, cells were shaken or scraped into the medium and pelleted at 3000rpm for 5min at 4°C using 
a Sorvall Legend RT centrifuge (Thermo Fisher Scientific Inc.). After discarding supernatant, cells 
were washed in 1x PBS and pelleted again before resuspending them in 10ml lysis buffer (10mM 
Tris-HCl pH7.5, 2mM MgCl2, 10mM NaCl, 0.5% NP40, Appendix 1). Cells were vigorously vortexed, 
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incubated on ice for 5min and pelleted at 2000rpm for 5min at 4°C. Sodium dodecyl sulphate-
polyacrylamide (SDS) (Sigma-Aldrich) and Ethylenediaminetetraacetic acid (EDTA) (Appendix 1) were 
added to the supernatant at a final concentration of 1% and 1mM respectively. Alternatively, 500-
700µl virus stock was used in this step. Phenol-chloroform extraction was performed twice to 
remove protein and extract DNA by adding an equal volume of phenol-chloroform (Thermo Fisher 
Scientific Inc.) to the virus suspension, vortexing and spinning at 4000 rpm for 5min at 4°C using a 
Sorvall Legend RT centrifuge (Thermo Fisher Scientific Inc.). The DNA was then purified twice by 
adding chloroform (Thermo Fisher Scientific Inc.) to the aqueous supernatant, vortexing and 
spinning as above. To precipitate the DNA 2x the volume of 100% ethanol (VWR International Ltd.) 
was added to the final supernatant and incubated at -20°C overnight before being pelleted for 5min. 
After air-drying the pellet, it was dissolved in a small volume of EB buffer (Appendix 1). The total 
yield of DNA was determined using a Nanodrop ND-1000 spectrophotometer (NanoDrop 
Technologies) prior further use or storage at -20˚C. Phenol and phenol-chloroform waste were 
disposed of in compliance with Imperial College London health and safety policy. 
 
2.6.2 CONVENTIONAL PCR and SEQUENCING  
All primers used for conventional polymerase chain reaction (PCR) assays and sequencing reactions 
were obtained from Invitrogen and are detailed in table 2.4. Deoxynucleotides (dNTP’s) were used at 
a final concentration of 200µM for each dNTP (Promega) in each reaction. To facilitate amplification 
of HSV-1’s GC rich genome, autoclaved glycerol (Sigma Aldrich) was used at a final concentration of 
20% for all reactions with AmpliTaq Gold Polymerase Kit (Invitrogen); Q5 enhancer was used for all 
reactions with Q5 High Fidelity Polymerase (New England Biolabs); and Dimethyl sulfoxide (DMSO) 
was used at a final concentration of 5% for reactions with Phusion® High-Fidelity DNA Polymerase 
(Thermo Fisher Scientific Inc.). All PCR kits were used as detailed in the manufacturer’s instructions. 
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Table 2.4: Summary of primers used in this study 
All primers were used for PCR reactions apart from primers vhsFseq and vhsRseq which were used 
for sequencing reactions together with primers vhsF and vhsR.  
For primers BAC-VP22F and BAC-VP22R the lower case sequence is 50 bp upstream of UL49; the 
underlined sequence anneals to plasmid kan-S, while the sequence in capital letters is the duplicated 
reverse complementary sequence used for Red recombination. 
Primers vhsF and vhsR anneal to the flanking regions of the vhs gene, whilst primers vhsFseq and 
vhsRseq anneal to internal sequences within the vhs gene. 
.  
  
Chapter 2                                                                                                Materials & Methods 
89 
 
 
 
 
 
 
 
 
 
Table 2.4 
Primer Name Sense Sequence 
BAC-VP22F 5’- taattgtccg cgcatccgac cctagcgtgt tcgtggaacc aggatgacga cgataagtag gg -3‘ 
BAC-VP22R 
5’- gaacccctgt tggtgcttta ttgtctgggt acggaagttt GGTTCCACGA ACACGCTAGG  
    GTCGGATGCG CGGACAATTA caaccaatta accaattctg attag -3’ 
vhsF 5'- cagtaaccag gtccgtcca -3' 
vhsR 5'- tgtcctcttg tgtcggtgtt -3' 
vhsFseq 5'- tcctcgtcgt cttcgtatc -3’ 
vhsRseq 5'- ggtgtttacc caaaagtccc -3' 
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Briefly, Phusion® High-Fidelity DNA Polymerase kit (Thermo Fisher Scientific Inc.) was used for the 
amplification of plasmid pEPkan-S with primer pair BAC-VP22F and BAC-VP22R at a final 
concentration of 240µM and following cycling parameters 98°C for 30sec; 98°C for 30 sec, 60°C for 
30 sec, 72°C for 60sec (repeated 35 cycles); 72°C for 10min. AmpliTaq Gold Polymerase Kit 
(Invitrogen) and Q5 High Fidelity Polymerase kit (New England Biolabs) were used for the 
amplification of vhs with primer pair vhsF and vhsR at a final concentration of 200µM and following 
cycling parameters 97°C for 30sec; 97°C for 30sec, 58°C for 30sec, 70°C for 1min (repeated 5cycles); 
94°C for 30 sec, 58°C 30 sec, 72°C for 60sec (repeated 30 cycles), 72°C for 10min. All PCR reactions 
were carried out on a Veriti® Thermal Cycler (Applied Biosystems). 
To confirm the right size, amplified DNA was run on a 1% agarose gel (Sigma) containing SYBR®Safe 
stain (Life Technologies) and visualised under UV light. PCR products used for sequencing reactions 
with primers vhsF, vhsR, vhsFseq and vhsRseq were purified using QIAquick® PCR purification kit 
(Qiagen) as detailed in the manufacturer’s instructions. DNA concentration was determined using a 
Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies) and stored at -20˚C. 
 
2.6.3 RESTRICTION DIGEST and RESTRICTION FRAGMENT POLYMORPHISM (RFLP)  
Plasmid preparations were digested in a 37°C water bath (Grant Scientific) for 1-2 hours with 1 unit 
of the appropriate restriction enzyme (New England Biolabs). Digested plasmid preparations were 
separated on 1% agarose (Sigma) gels containing SYBR®Safe (Life Technologies) and visualised under 
UV light for analysis.  
For restriction fragment polymorphism analysis of BAC-HSV-1S17-derived recombinants, plasmid 
mini preparations were digested as above and run on a 0.8% gel which was stained with ethidium 
bromide (Sigma-Aldrich) prior visualisation under UV light. Colours were inverted for easier 
visualisation of restriction fragment polymorphism analysis against parental strain. Ethidium 
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bromide (Sigma-Aldrich) waste was disposed of in compliance with Cambridge University health and 
safety policy. 
 
 
2.7 ANTIBODIES 
All primary and secondary antibodies used for Western blotting (section 2.8.2) in these studies are 
detailed in tables 2.5 and table 2.6. 
 
2.8 PROTEIN ANALYSIS 
All protein samples were stored at -20˚C, or -80˚C for long-term storage. 
 
2.8.1 SDS-PAGE 
Cells were washed in ice-cold PBS and lysed in 100 µl (12-well plate) or 200 µl (6-well plate) 2X SDS-
PAGE sample buffer (Appendix 1). After lysis the cells were passed through a 23-gauge MicrolanceTM 
hypodermic needle (Becton Dickinson) to shear any DNA and boiled at 100°C for 3min. For analysis 
samples were diluted 1:1 using 2x SDS-PAGE loading dye (Appendix 1) and incubated at 100°C for 
3min prior loading onto a polyacrylamide gel cast (10, 12, or 14% polyacrylamide, depending on the 
molecular weight of the target protein) in prefabricated 10 cm x 10 cm mini-gel cassettes 
(Invitrogen); (resolving and stacking gel composition detailed in Appendix 1). For viral glycoprotein 
gM western blots, samples were denatured at 42°C for 20min to prevent aggregation of this 
transmembrane protein. Full range Novex® Sharp Pre-Stained Protein Standards (Invitrogen) were 
used to determine the size of the proteins. The lysates were separated using sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) run at 200V for one hour in SDS-PAGE 
running buffer (Appendix 1) using XCell SureLockTM Mini-Cell system (Invitrogen) as per 
manufacturer’s instructions. 
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2.8.2 WESTERN BLOTTING 
Proteins were transferred from SDS-PAGE gels to a Whatman® PROTRAN® nitrocellulose membrane 
(Whatman) at 25V for 2 hours or 7V overnight using transfer buffer (Appendix 1) and the  XCell 
SureLockTM Mini-Cell system (Invitrogen) as per manufacturer’s instructions. Membranes were 
rinsed briefly with reverse-osmosis water and stained with 0.1% w/v Ponceau S solution in 5% v/v 
acetic acid (Sigma-Aldrich) for 2min to confirm protein transfer. Ponceau S solution was removed by 
washing the membranes with reverse-osmosis water before blocking the membranes in 5% w/v 
skimmed milk powder and 0.1% v/v Tween® 20 (both Sigma-Aldrich) in PBS for at least one hour at 
room temperature or overnight at 4°C. Blocking buffer was removed by washing the membranes 
with 1xPBS. Membranes were then incubated with primary antibody for one hour, followed by three 
10 min washes in wash buffer consisting of  1% v/v Triton® X-100 (Sigma-Aldrich) in 1x PBS. 
Secondary antibody was added to the membrane for one hour and membranes were washed in 
wash buffer as after primary antibody incubation. All antibodies were diluted in 0.1% v/v Tween-
20®in PBS at concentrations listed in table 2.5 and table 2.6. All incubations and washes were 
performed at room temperature with agitation on a Stuart® Scientific gyro-rocker SSL3 (Sigma-
Aldrich) set at 30rpm. Membranes were incubated in SuperSignal® WestPico chemiluminescent 
substrate (1ml per membrane) for 1min before being exposed on to FujiFilm RX NIF X-ray film (both 
Thermo Fisher Scientific Inc.) and developed using a JP-33 automatic X-Ray film processor (Jungwon 
Precision Industries Co. Ltd) or later on manually . Blots were digitalised using an Epson Perfection 
V700 Photo scanner. Membranes were stored at 4°C in PBS for immediate use or at -20°C in 
chemiluminescent substrate for long term storage as membranes were routinely re-blocked and 
probed with additional antibodies as described above; membranes were not stripped. 
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Table 2.5: Primary antibodies for western blotting (WB). 
 All mouse antibodies are monoclonal, all rabbit antibodies polyclonal. Antibody names are as stated 
in the literature. Where no antibody name was available a catalogue order number (*) is given 
(accurate on 30/09/2014). Antibody FK2 recognises conjugated monoubiquitin and polyubiquitin 
[126]. The vhs antibody has no official name. WB, western blot. 
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Table 2.5 
Antigen Name Secondary 
Working 
Dilution  
Source 
   WB  
α-tubulin T-5168* mouse 1:10,000 Sigma-Aldrich
1
 
gC 3G9 Mouse 1:3200 Abcam
4
 
gB R69 mouse 1:10,000 Helena Browne
2
 
gD LP14 mouse 1:5,000 Tony Minson
2
 [251] 
gE 3114 mouse 1:10,000 David Johnson
3
 [46] 
gE ab6510* mouse  AbCam
4
 
GFP 632375* mouse 1:10,000 Clontech
5 
GFP 632460* rabbit 1:10,000 Clontech
5
 
gM Ab980 rabbit 1:1,000 Helena Browne
2
 [54] 
ICP0 11060 mouse 1:200 Santa Cruz
6
 [100] 
ubiquitin FK2 mouse 1:1000 
Enzo Life Sciences
7
 
[126] 
vhs  rabbit 1:2,000 Duncan Wilson
8
 [203] 
VP5 3B6 mouse 1:3,000 Virusys
9
 
VP13/14 5283 rabbit 1:5,000 In-house [76] 
VP16 LP1 mouse 1:5,000 Tony Minson
2
 [237] 
VP22 C-terminus AGV600 rabbit 1:20,000 In-house [95] 
VP22 N-terminus AGV031 rabbit 1:20,000 In-house [95] 
ICP27 H1113 Mouse 1:5000 Stephen Rice
10 
[4] 
ISG15 ISG15 rabbit 1:500 Santa Cruz
6
 
UL11 UL11 rabbit 1:3000 John Wills
11
[218] 
UL16 UL16 rabbit 1:3000 John Wills
11
[425] 
UL21 UL21 rabbit 1:3000 John Wills
11
[145] 
     
1
Dorset, England, 
2
 University of Cambridge, UK, 
3
 Oregon Health and Science University, Portland, OR USA 
4
 Cambridge, UK, 
5 
Saint-Germaine-Laye, France, 
6
 Santa Cruz, CA USA, 
7
 Farmingdale, NY USA 
8
 Albert Einstein College of Medicine, Bronx, NY-USA, 
9
 Taneytown, MD USA, 
10
 University of Minnesota, MN USA 
11
Penn State University PA USA
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Table 2.6: Secondary antibodies for western blotting (WB). 
 TrueBlot® anti-rabbit HRP-conjugate does not cross-react with denatured immunoglobulin and was 
used in combination with vhs antibody only. Catalogue numbers (*) given accurate on 27/07/2014. 
Goat anti-mouse HRP-antibody was used at 1:5,000 dilution for ICP0 (11060) antibodies. Goat anti-
rabbit HRP-antibody was used at 1:20,000 dilution for VP22 antibodies AGV031 and AGV600. IgG 
(H+L), immunoglobulin G (heavy and light chains); HRP, horseradish peroxidase; WB, western blot. 
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Table 2.6 
Reactivity Details Application 
Working 
dilution 
Source 
Catalogue 
number 
mouse IgG 
(H+L) 
goat HRP WB 1:10,000 Bio-Rad 
Laboratories1 
TI-2000 
rabbit IgG TrueBlot® 
HRP 
WB (gM) 1:1,000 eBioscience2 18-8816 
rabbit IgG 
(H+L) 
goat HRP WB 1:10,000 Bio-Rad 
Laboratories1 
170-6515 
1 Hercules, CA USA 
2 San Diego, CA USA 
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2.8.3 COOMASSIES BLUE GEL STAINING 
SDS-PAGE gels were washed in reverse-osmosis water for 10 min before adding 30 ml Pierce 
Imperial Protein Stain (Thermo Fisher Scientific Inc.) for one hour at room temperature. Gels were 
washed several times in water or overnight to de-stain until protein bands were clearly visible. All 
steps were performed on a Stuart® Scientific gyro-rocker SSL3 (Sigma-Aldrich) set at 30rpm. Gels 
were dried using DryEase Cellophane and digitalised using an Epson Perfection V700 Photo scanner. 
 
2.8.4 SILVER STAINING 
Pierce® Silver Stain Kit (Thermo Fisher Scientific Inc.) was used to stain the SDS-PAGE gels as per 
manufacturer’s instructions. The water used for all washes and staining procedures was reverse-
osmosis water. SDS-PAGE gels were washed in water twice for 5 min before being fixed in 30% 
ethanol: 10% acetic acid twice for 15min. After fixation, SDS-PAGE gels were washed in 10% ethanol 
twice for 5 min, followed by rinsing in water twice for 5 min. Fixed gels were incubated for 1 min in 
Sensitizer solution (50µl Sensitizer with 25ml water) and then rinsed clean with water twice for 1 
min. Gels were incubated with Stain Working Solution (0.5ml Enhancer with 25ml Stain) for 30 min 
and washed briefly twice for 20 sec with water. Immediately after, Developer Working Solution 
(0.5ml Enhancer with 25ml Developer) was added for 2-3min until the desired band density was 
reached. To stop development gels were incubated in Stop Solution (5% acetic acid) for 10min and 
then rinsed off with water. All steps were performed at room temperature on a Stuart® Scientific 
gyro-rocker SSL3 (Sigma-Aldrich) set at 30rpm. Gels were dried using DryEase Cellophane and 
digitalised using an Epson Perfection V700 Photo scanner. 
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2.8.5 IMMUNOPRECIPITATION 
One-day-old confluent Vero cells cultured in 60 mm tissue culture dishes were infected at a 
multiplicity of one as described in section 2.2.4 and incubated at 37˚C, 5%CO2 for 20 hours. GFP-
tagged VP22 expression was confirmed microscopically using an Olympus IX70 microscope with an 
Olympus U-RFL-T UV burner (Olympus). Other infections were confirmed by the appearance of 
rounded up adherent cells. To harvest the cells, the monolayers were washed twice in ice-cold 
sterile PBS and resuspended in 1.1 ml radioimmunoprecipitation assay (RIPA) buffer (Appendix 1). 
Samples were incubated on ice for 20min before cell debris was pelleted at 12,000 rpm for 30 min at 
4˚C in an airtight fixed angle F-45-18-11 rotor for the Eppendorf Centrifuge 5402 (both Eppendorf). 
Of the lysate 50 µl were taken and mixed 1:1 with 2x SDS-PAGE lysis buffer to form the input sample. 
For the remainder of the protocol samples were kept on ice or at 4˚C. For immunoprecipitation 400 
µl lysate was incubated with 10 µl polyclonal or 4 µl monoclonal antibody as detailed in figure 
legends at 4˚C overnight in a Stuart® Blood Tube rotator SB1 (Sigma-Aldrich) with top-over-tail 
rotation. Protein A sepharose beads (GE Healthcare) were washed twice and resuspended in ice-cold 
PBS at a 1:1 ratio. 40 µl of the protein A sepharose beads were added to the lysate and antibody mix 
and incubated for 1 hour at 4oC with top-over-tail rotation. Following immunoprecipitation beads 
were pelleted and washed three times in ice-cold PBS and resuspended in 40 µl 2X SDS-PAGE loading 
dye, followed by denaturation at 100oC for 3 minutes for western blot analysis. All GFP 
immunoprecipitations were performed with antibody 632460 (table 2.5). 
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2.8.6 GFP-TRAP ASSAY 
GFP-trap assays were performed using the Chromotek GFP-Trap®_A kit (ChromoTek GmbH) as per 
manufacturer’s instructions. All ChromoTek buffers are detailed in Appendix 1. One-day-old 
confluent Vero cells cultured in 225cm2 tissue culture flasks (CORNING®Inc.) were infected at a 
multiplicity of one as described in section 2.2.2. and incubated at 37˚C, 5%CO2 for 20 hours. GFP-
tagged VP22 expression was confirmed microscopically using an Olympus IX70 microscope with an 
Olympus U-RFL-T UV burner (Olympus) whereas other infections were confirmed by the appearance 
of rounded up adherent cells. Cell monolayers were washed twice in ice-cold sterile PBS before 
being harvested in 10 ml of ice-cold sterile PBS. Harvested cells were pelleted at 4000 rpm for 5 min 
at 4˚C in an airtight swinging bucket rotor (7500 6445) for the Sorvall® Legend RT centrifuge and 
resuspended in 800µl lysis buffer supplemented with protease inhibitors (cOmplete® Mini Protease 
Inhibitors Tablets; Roche Applied Science) (Appendix 1). Samples were incubated on ice for 5min 
before cell debris was pelleted at 12000 rpm for 10 min at 4˚C in an airtight fixed angle F-45-18-11 
rotor for the Eppendorf Centrifuge 5402 (both Eppendorf). The lysate was divided into two pre-
cooled eppendorf tubes and 500 µl dilution buffer (Appendix 1) was added. 100 µl of the diluted 
lysate were taken and mixed 1:1 with 2x SDS-PAGE sample buffer (Appendix 1) to form the input 
sample. GFP-Trap®_A beads were equilibriated by washing twice in ice-cold dilution buffer prior to 
use. For GFP-trap immunoprecipitation the lysate was incubated with 10 µl GFP-Trap®_A beads for 1 
hour at 4˚C in a Stuart® Blood Tube rotator SB1 (Sigma-Aldrich) with top-over-tail rotation. Following 
incubation beads were pelleted at 2000 rpm for 2 min and washed three times in ice-cold cold wash 
buffer containing 1% NP40 before resuspending beads in 150 µl 2X SDS-PAGE loading dye (Appendix 
1). Samples were denatured at 100oC for 3 minutes prior western blot analysis. 
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2.9 ASSAYS 
2.9.1 [35S]-METHIONINE RADIOACTIVE ASSAY 
Radioactive metabolic labelling assay using EasyTag™ L-[35S]-methionine, (Perkin Elmer) was carried 
out in the absence and presence of Actinomycin D (Sigma-Aldrich). Tissue culturing media free of 
methionine was prepared by adding 1% v/v L-Glutamine, 1% v/v Cysteine and 2% v/v FCS to amino 
acid-free DMEM (all Invitrogen). For assays in the presence of Actinomycin D cells were incubated in 
DMEM (2 % v/v NCS, 1%Pen-Strep) containing 5µg/ml Actinomycin D for 30 min at 37°C, 5% CO2 
prior infection. One-day old Hela cell monolayer grown to 100% confluency in 10cm2 dishes were 
used to carry out virus infections at a MOI 5 in the absence of Actinomycin D and a MOI 20 in the 
presence of Actinomycin D, as described in section 2.2.4. At chosen time points post virus infection 
cells were washed 2x using methionine-free media with or without  Actinomycin D (5µg/ml) before 
being incubated in 500 µl methionine-free media with or without  Actinomycin D (5µg/ml) at 37°C, 
5% CO2 for 15min or 30 min, respectively. After incubation, 50µCi of L-[
35S]-methionine, (Perkin 
Elmer) was added to the cells which were then incubated for 30min at MOI 5 or 60min at MOI 20 at 
37°C, 5% CO2. Following metabolic labelling, media containing L-[
35S]-methionine was removed and 
cells were washed 3x with 1xPBS before being harvested in 400µl 2x SDS-PAGE lysis buffer. After 
lysis the cells were passed through a 23-gauge MicrolanceTM hypodermic needle (Becton Dickinson) 
to shear any DNA and boiled at 100°C for 3min. Lysates were separated on two-dimensional SDS-
PAGE gel run at 200V for one hour in SDS-PAGE running buffer (Appendix 1) using XCell SureLockTM 
Mini-Cell system (Invitrogen) as per manufacturer’s instructions. Full range Novex® Sharp Pre-Stained 
Protein Standards (Invitrogen) were used to determine the size of the proteins. The protein gel was 
carefully rinsed with reverse-osmosis water before being incubated for 30min in Fix solution 
consisting of 50% v/v Ethanol and 10% v/v Acetic Acid (VWR). Fix solution was rinsed off with 
reverse-osmosis water and the gel was dried onto Whatman filter paper using a vacuum gel drying 
system with BioRAD 543 Gel Dryer (BioRAD). The dried gels were exposed on to FujiFilm RX NIF X-ray 
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film (Thermo Fisher Scientific Inc.) and developed using a JP-33 automatic X-Ray film processor 
(Jungwon Precision Industries Co. Ltd). Blots were digitalised using an Epson Perfection V700 Photo 
scanner. All radioactive work was carried out in compliance with Imperial College Health and Safety 
policy. 
 
2.9.2 LUCIFERASE QUANTIFICATION ASSAYS 
Hela cell monolayers grown to 80% confluency in 96-well tissue culture plates were transfected as 
described in figure legends and section 2.5. All transfection reactions were made up to a total of 0.7 
µg DNA per well using the empty vector pCMV-SV5α. At 24 hours posttransfection, monolayers were 
washed twice in 100 µl  ice-cold sterile PBS and lysed in 35 µl ice-cold passive lysis buffer (Promega) 
(Appendix 1) per well whilst incubating for 30 min at room temperature with agitation (30 rpm) on a 
Stuart® gyro-rocker SSL3. Plates were processed either straight away or stored at -80˚C until further 
use. The luciferase assay was performed in triplicate for each sample. To quantify luciferase activity, 
10 µl sample was combined with 100 µl Renilla substrate coelenterazine (Appendix 1) at 2 g/ml and 
Luciferase activity was immediately measured using an AutoLumat Plus LB953 luminometer 
(Berthold Technologies GmbH). Plates were read for light omission from Renilla Luciferase and 3 
reading were taken at 0.5 second intervals starting 2 seconds after the addition of coelenterazine. 
Mock-transfected samples were used as control values which were deducted from the 
measurements to account for background auto-luminescence activity in cells when the average light 
emission was calculated. 
 
2.9.3. MG132 STABILITY ASSAY 
One-day-old confluent Hela cells cultured in 6-well tissue culture dishes were infected at a 
multiplicity of 10 as described in section 2.2.4 and incubated at 37˚C, 5%CO2. Infected cells were 
treated with proteasome inhibitor MG132 at a final concentration of 10 M (from a 5mg/ml stock 
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solution dissolved in DMSO) 2 hours prior harvesting at 2, 4, 6 and 8 hours after infection. To harvest 
the cells, the monolayers were washed twice in ice-cold sterile PBS and resuspended in 400µl 2x 
SDS-PAGE lysis buffer. After lysis the cells were passed through a 23-gauge MicrolanceTM hypodermic 
needle (Becton Dickinson) to shear any DNA and boiled at 100°C for 3min before being subjected to 
8% SDS-PAGE followed by western blot analysis using antibody FK2 (Enzo Life Sciences). 
 
2.10 SOFTWARE AND IMAGE ADJUSTMENT 
All digital images were prepared using Adobe® PhotoShop® Elements 7 (Adobe Systems, San Jose, CA 
USA). Image manipulation was limited to adjustment of brightness and contrast. Graphs were 
prepared using Microsoft® Excel 2007 (Microsoft Corporation) and Diagrams were prepared using 
Microsoft® PowerPoint 2007 (Microsoft Corporation) or Inkscape (free downloadable software). The 
manuscript was written using Microsoft® Word 2007 (Microsoft Corporation). All software used was 
for PC. 
 
2.11 SOLUTIONS AND BUFFERS  
All solutions and buffers are listed in the Appendix 1. All solutions and buffer were made with ultra 
pure water from PURELAB OPTION-Q DV25 (ELGA Process water, UK) unless otherwise stated 
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3.1 CHAPTER INTRODUCTION 
The herpes simplex virus type 1 (HSV-1) structural protein VP22 is a major component of the virus 
tegument [147]. Despite numerous studies the precise role of VP22 in the virus replication cycle is 
unclear. Investigations into the role of VP22 have been carried out using V22 knockout viruses [81, 
82, 94, 225, 226, 230, 333, 377]. In the last few years bacterial artificial chromosome (BAC) 
recombination has become the favoured method for the construction of recombinant viruses 
including VP22 deletions in herpes simplex virus [81, 333]. The manipulation of herpesviruses has 
been difficult and time consuming due to their large DNA size. BAC vectors, however, have become a 
valuable tool due to their high capacity of up to 300kb for insert length, the maintenance of virus 
DNA without any selective pressure on the virus genome, bacterial antibiotic resistance cassettes for 
selection purposes, ease of manipulation, as well as the short time it takes to make virus 
recombinants. Within a few days, deletions, insertions, sequence replacements, single nucleotide 
mutations and reporter gene incorporation can in theory be readily achieved by homologues 
recombination techniques in E. coli and counter selection strategies. 
 BAC mutagenesis utilizes homologous recombination using both λ Red recombination and ET 
cloning in E. coli for accurate site-specific mutagenesis of viral genes and the generation of 
recombinant viruses. Red recombination or RecET cloning is an alternative method to RecA 
mediated mutagenesis in E. coli. It exploits DNA double strand breaks, directing homologous 
recombination to the ends of linear double stranded DNA [398]. PCR products containing a positive 
selection marker and sequences homologous to the target site in the BAC are used for 
recombination. Generated BAC clones are analyzed to ensure the integrity of the virus genome 
before being transfected into mammalian cells to allow recombinant virus rescue [reviewed in 10, 
18, 21, 24]. Using VP22 knockout virus to study its role has become complicated as it has been 
reported that  VP22 knockout viruses acquire secondary mutations within the vhs gene rendering 
the vhs protein inactive [230, 333]. Independent studies by Roizman et al. [333] and Duffy et al. 
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[230] using the BAC system to generate a Δ22 virus, reported isolates with mutations ranging from 
point mutations to gross deletions leading to frameshifts [230, 333]. Roizman et al. reported a Δ22 
virus expressing either a truncated or non-functional vhs protein, as the clones either lacked a 162bp 
segment close to the N-terminus resulting in an in-frame deletion of 54 amino acids, or contained a 
deletion of only 2 nucleotides towards the 3’-prime end resulting in a frameshift mutation [333]. 
Duffy et al. reported a frameshift at codon 248 that yields a non-functional vhs protein [230]. In light 
of the previous publications our group sequenced the vhs gene of our previously characterised VP22 
knockout virus (Δ22), that had been constructed by classical homologous replication, from DNA 
amplified by PCR [94] and found that, in contrast to other published VP22 knockout viruses, there 
were no mutations within the vhs gene. The sequence was identical to the wild-type strain 17 
(GenBank no. JN555585.1; S17REF) from which the Δ22 virus was derived. In an attempt to explain 
these different results we have considered a number of notable differences between the ∆22 virus 
constructed in our lab and those described by the groups of Roizman et al. [333] and Duffy et al. 
[230]. Firstly, our virus was generated in HSV-1 strain 17 compared to HSV-1 strain F [94]. The vhs 
protein of strain 17 has previously been shown to exhibit weak activity compared to those of other 
strains [111]. Secondly, our Δ22 virus was rescued in a complementing cell line, not Vero cells [94]. 
Lastly, our virus was generated by classical recombination using wild-type viral DNA [94], whereas 
the other two were constructed using BAC technology [230, 333]. This thesis focuses on investigating 
the possible relationship of VP22 and vhs during viral replication and the potential role VP22 plays in 
the regulation of a functional vhs protein in the HSV-1 life cycle. Our first step was to investigate if 
we can generate a Δ22 virus with a functional vhs using BAC recombination; and if our previously 
generated Δ22 virus contains any other possible mutations affecting vhs activity.  
 
Chapter 3                             BAC RECOMBINATION, BUT NOT CLASSICAL RECOMBINATION,                        
                                               RESULTS IN SECONDARY MUTATION WITHIN THE VIRION HOST            
                                            SHUTOFF PROTEIN IN A VP22-NEGATIVE HERPES SIMPLEX VIRUS-1 
 
106 
 
3.2 COMPARISON OF RELATIVE VIRION HOST SHUTOFF ACTIVITY IN HSV-1 STRAINS 
Publications investigating the vhs activity differ in the HSV-1 strain used [198, 230, 333]. HSV-1 strain 
17 was previously shown to have a weaker vhs activity compared to those of other strains [111].  
Differences observed when studying vhs activity might therefore be strain specific. The VP22 
deletion viruses containing a mutated vhs reported by Roizman et al. [333] and Duffy et al. [230] 
were generated in strain F, whereas our Δ22 virus was generated in strain 17 . To see if the wt vhs in 
our original VP22 deletion virus (Δ22) was maybe achieved due to a weaker vhs activity compared to 
strain F, we compared the vhs activity of those two HSV-1 strains together with other commonly 
used strains in research.  
To compare overall vhs activity in HSV-1 strains we carried out [35S]-methionine labelling assay as 
described in section 2.9.1. HeLa cells seeded into 6-well dishes were infected with strains S17, F, 
SC16, KOS and HFEM at an MOI of 5. After 8h and 16h incubation cells were washed and treated 
with methionine-free media before the cells were metabolically labelled with 50 µCi/mL [35S]-
methionine. The cells were harvested into SDS-lysis buffer and analysed by SDS-PAGE and 
autoradiography. Comparing the overall host shut off activity in the HSV-1 strains, all of the tested 
strains exhibited a functional vhs as host protein labelling intensity was reduced compared to the 
mock infected cells at 8h and 16h post infection, meaning fewer host proteins were made and 
therefore fewer host proteins were labelled (Figure 3.1). Comparing viral protein production of the 
strains at 8 hours, S17, F, Sc16, KOS and HFEM exhibited comparable viral protein production. 
However, comparing viral protein production of the strains at 16 hours post infection HFEM 
displayed a decreased viral protein expression compared to the other HSV-1 strains (Figure 3.1) 
indicating that the functional vhs in HFEM might be overactive or may not be regulated as tightly. 
Having established that the HSV-1 strains exhibit relative host shutoff activity in infection, we next 
examined the strains for tegument-associated vhs host shut off activity to determine if vhs is 
packaged into the virus particle and delivered in to the cell upon infection. This will establish if vhs is 
Chapter 3                             BAC RECOMBINATION, BUT NOT CLASSICAL RECOMBINATION,                        
                                               RESULTS IN SECONDARY MUTATION WITHIN THE VIRION HOST            
                                            SHUTOFF PROTEIN IN A VP22-NEGATIVE HERPES SIMPLEX VIRUS-1 
 
107 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Relative host shutoff function in HSV-1 strains early and late in infection.  
HeLa cells were infected with wt S17, F, Sc16, KOS and HFEM at an MOI of 5. Cells were treated with 
50 µCi/mL [35S]-methionine after 8 hours and 16 hours and subsequently harvested for analysis by 
SDS-PAGE and autoradiography. The values on the left are molecular weights in kDa. Arrows indicate 
expressed viral proteins. 
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active at the beginning of virus infection or if host shutoff activity is dependent on de novo 
synthesised vhs. HeLa cell monolayers were infected at an MOI of 20 in the presence of Actinomycin 
D, which is an inhibitor of mRNA transcription meaning no new host or viral proteins are produced. 
After 4 hours of infection the cells were treated with methionine-free media and labelled with 50 
µCi/mL [35S]-methionine for 1 hour before lysates were harvested in SDS lysis buffer and analysed by 
SDS-PAGE and autoradiography. The blots revealed that wild-type S17, F, Sc16 and HFEM contain a 
functional vhs associated with the tegument which is released into the cell upon infection, as they 
are able to shut off host cell protein synthesis in the absence of ongoing gene transcription (Figure 
3.2). This can be seen as the intensity of protein labelling is reduced compared to the mock. Strain 
Sc16 exhibited a slightly reduced tegument-associated vhs activity as host protein labelling intensity 
was slightly increased compared to S17, F and HFEM (Figure 3.2). Strain KOS did not exhibit 
tegument associated vhs activity, as its protein labelling intensity was similar to the mock indicating 
that cellular protein shut off was not exhibited. To ensure that strain KOS was infectious and used at 
the correct titre, plaque assays in HeLa cells were carried out (data not shown) and repeat assays 
performed. As host cell shut off activity of KOS was comparable to the other strains at 8 and 16 
hours post infection (Figure 3.2), it indicates that de novo synthesised vhs was efficiently expressed 
and active in this strain. However, for some unknown reason tegument-associated vhs activity was 
absent indicating a possible lack of vhs packaging or very low vhs activity of incoming virus particles 
which is then compensated by de novo synthesised vhs.  
To see if any of the differences in vhs activity observed could be attributed to any sequence changes 
in the vhs gene between the HSV-1 strains, the vhs gene was amplified by PCR. Sequencing analysis 
revealed that strains F, Sc16, KOS and HFEM contain nucleotide changes, with only very few leading 
to amino acid coding changes compared to S17 (Figure 3.3). The only strain not to contain any amino 
acid coding changes is Sc16. HFEM contains one amino acid change at position 113 expressing an 
isoleucine instead of serine. Strain F contains two amino acid changes at position 312 and 384, 
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Figure 3.2: Tegument-associated host shutoff function in HSV-1 strains. 
HeLa cells were infected with wt S17, F, Sc16, KOS and HFEM at an MOI 20 in the presence of 5 
μg/ml Actinomycin D (Act D). Cells were treated with 50 µCi/mL [35S]-methionine after 4 hours and 
subsequently harvested for analysis using autoradiography.  The values on the left are molecular 
weights in kDa. 
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Figure 3.3: Sequence Analysis of vhs in wt strain S17, F, Sc16, KOS and HFEM.   
(A) Line drawing of the HSV-1 S17 vhs gene open reading frame denoting the 4 conserved boxes (I to 
IV) and the VP16 binding domain. (B) Amino acid variations identified in wt Sc16, KOS, F and HFEM. 
Sequences have been compared to S17REF.  
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expressing threonine and serine instead of alanine and asparagine. Strain KOS contains three amino 
acid changes at position 19, 317 and 384 expressing glutamine, methionine and serine instead of 
arganine, threonine and serine (Figure 3.3).  It cannot be concluded if any of the amino acid changes 
lead to the differences in vhs activity observed between the HSV-1 strains. Additionally, as the 
relative host shutoff activity and the tegument associated vhs activity showed similar results for 
strain F and strain 17, it cannot be concluded that the observed secondary mutations of vhs in the 
absence of VP22 in strain 17 are due to a more active vhs. 
 
3.3 THE GENERATION OF A VP22-NEGATIVE HERPES SIMPLEX-1 VIRUS USING BACTERIAL 
ARTIFICIAL CHROMOSOME (BAC) RECOMBINATION 
As host shutoff activity of strain 17 and F seem to very similar, at least in our hands, we wanted to 
determine if we are able to generate a VP22 deletion virus in strain 17 with a wild-type vhs using 
BAC recombination. In order to generate a ∆22 virus using BAC recombination we utilised a bacterial 
artificial chromosome (BAC) containing full-length, infectious DNA of HSV-1 strain 17 (BAC-HSV-
1S17) and recombinant plasmid pEPkan-S [130]. BAC recombination has been successfully used for  
the manipulation of different alphaherpesviruses, including strain 17 [123, 164, 271, 279, 309, 381, 
395, 411]. The BAC-HSV-1S17 kindly provided by David Leib (Dartmouth Medical School, US) was 
previously generated by inserting in a LoxP site into the UL37/UL38 intergenic region of HSV-1 strain 
17 by standard homologous recombination (Figure 3.4). The inserted LoxP site facilitated the 
subsequent site-specific insertion of the BAC cassette into the UL37/UL38 intergenic locus by 
Cre/Lox recombination.  
Using Two-step Red-mediated recombination, which uses a combination of Red recombination and 
counter selection with the homing endonuclease I-SceI, we were aiming to generate a scarless VP22 
deletion. Red-mediated recombination was used as described by others [397]. In the first step of the 
mutagenesis, Red recombination was exploited to insert the linear construct of positive selection  
Chapter 3                             BAC RECOMBINATION, BUT NOT CLASSICAL RECOMBINATION,                        
                                               RESULTS IN SECONDARY MUTATION WITHIN THE VIRION HOST            
                                            SHUTOFF PROTEIN IN A VP22-NEGATIVE HERPES SIMPLEX VIRUS-1 
 
115 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Construction overview of the BAC-Herpes Simplex Virus-1 Strain 17  
[adapted from 8].  
A LoxP site was inserted into the UL37/UL38 intergenic region of HSV-1 strain 17 by standard 
homologous recombination. The inserted LoxP site facilitated the subsequent site-specific insertion 
of the BAC cassette into the UL37/UL38 intergenic locus by Cre/Lox recombination.  
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marker kanamycin into the VP22 gene target site of BAC-HSV-1S17, thereby generating a VP22 
deletion. For this, we utilized the recombinant plasmid pEPkan-S which contains a I-SceI-aphAI 
cassette encoding the kanamycin resistance gene aphAI flanked by homing endonuclease I-SceI 
restriction sites. The I-SceI-aphAI cassette was PCR –amplified using primers bearing 40bp extensions 
homologous to the VP22 flanking region in the BAC genome, which facilitate the first Red 
recombination. The second step of the recombination employed SceI counter selection, where 
endonuclease SceI cleaves at its recognition site adjoining the duplicated sequence, which was 
incorporated with the inserted PCR product, creating double-strand breaks (DBS). The duplicated 
sequence now serves as a new substrate for the second intramolecular Red recombination, which 
leads to subsequent deletion of the previously introduced positive marker kanamycin and the 
desired scarless gene manipulation (Figure 3.5). The first step of the experimental protocol was to 
amplify the I-SceI-aphAI cassette containing the positive selection marker kanamycin with primers 
BAC-VP22F and BAC-VP22R (Table 2.4) bearing 40bp extensions homologous to the VP22 flanking 
region in the BAC genome, which facilitate the first Red recombination. Both primers also contained 
approximately 40bp of the VP22 flanking region upstream of VP22, which were reverse comple-
mentary to each other. This produced short sequence duplications in the PCR product to facilitate 
scarless mutagenesis during the second Red recombination. 
The PCR product was checked for the correct size of 1.1kb (see appendix 2 for Figure 1) and 
subsequently inserted into the BAC-HSV-1S17 clone by classical Red recombination using E.coli strain 
GU1783, which contains a temperature-dependent promoter controlling the expression of the Red 
recombination proteins and an L-arabinose-inducible I-SceI endonuclease [396–398]. Electroporated 
BAC-containing bacterial cells were subsequently grown in the presence of kanamycin to screen for 
kanamycin-resistant colonies containing the successfully integrated PCR product in place of the VP22 
ORF.  Colonies in which successful integration of the PCR product into the BAC DNA had occurred 
were further analysed by restriction fragment length polymorphism (RFLP) using restriction enzymes  
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Figure 3.5: Construction overview of the generation of ∆ 22 mutant virus.  
A) The I-SceI-aphAI cassette was PCR-amplified to add approximately 40bp of target sequences (red 
and blue) and duplicated target sequences (red). B) The desired deletion mutation of the target 
sequence using the linear DNA fragment was obtained by homologues recombination. C) The I-SceI-
aphAI cassette was removed by inducing the expression of endonuclease I-SceI, allowing Red 
recombination between the duplicated sequences, which resulted in a markerless deletion. 
(Coloured lines symbolize identical sequences, whereas dotted lines indicate single homologous 
recombination events. aphAI, positive selection marker kanamycin; S, I-SceI restriction site.)  
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HindIII and AsiS1 as their restriction sites result in a fragment pattern that is easily comparable to 
the parental wild-type BAC for differences (Figure 3.6). Successful integration of the kanamycin 
cassette results in a fragment pattern with an additional 6.9kb band when digested with HindIII and 
a 4.7kb band when digested with AsiS1 compared to the parental HSV-1-S17-BAC (Figure 3.7). The 
next step involved the removal of the I-SceI-aphAI cassette. The bacteria containing the recombinant 
BAC were grown at 30°C for 2-4hrs in the presence of chloramphenicol to maintain the BAC; and in 
the presence of 1% arabinose to induce the expression of endonuclease I-SceI. The expression of 
endonuclease I-SceI results in the cleavage at the I-SceI site generating double-strand breaks. 
Cultures were then transferred into a 42°C water bath shaker for 30 min to initiate a second Red 
recombination event between duplicated sequences present within the modified BAC. Subsequently, 
bacteria were grown for another 2–4 h at 32°C, and serial dilutions were spread onto agar plates 
containing chloramphenicol, and 1% arabinose. Replica plating was then used to detect kanamycin-
sensitive colonies; however, despite several attempts we were unable to accomplish the second 
recombination step. We therefore decided to investigate the integrity of the I-SceI restriction site 
and duplication sequences required for the second recombination step using sequencing analysis. 
We sequenced two independently picked isolates and were able to confirm an intact cleavage site 
for endonuclease I-SceI (Figure 3.8A). However, we identified a missing nucleotide in the reverse 
complementary duplication primer sequence of one isolate, which results in reduced sequence 
homology of the duplication (Figure 3.8B). Subsequently, the recombination efficiency of the second 
Red recombination step was reduced. The second isolate contained the correct duplication 
sequence (Figure 3.8B), yet we were still unable to achieve recombination. Additionally, a point 
mutation was found in the sequence targeting the pEPkan-S plasmid (Figure 3.8A); however this 
should have no in impact on the recombination. Although we were unable to remove the I-SceI-
aphAI cassette from the BAC recombinant genome, we decided to reconstitute four independently 
isolated recombinant viruses (∆V22BAC4, ∆V22BAC6, ∆V22BAC7, ∆V22BAC17) by removing the BAC 
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Figure 3.6: Schematic diagram of expected fragment sizes of BAC -derived VP22 
deletion mutant.  Restriction sites of enzymes AsiS1 and HindIII in the HSV-1 genome containing 
the I-SceI-aphAI cassette in place of the VP22 gene locus. Underlined restriction site for AsiS1 and 
HindIII indicates the restriction site, which leads to a change of fragment size compared to the 
parental BAC strain. Expected band size of 4.6kb and 6.9kb for AsiS1 and HindIII, respectively, are 
shown. 
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Figure 3.7: Restriction Fragment Length Polymor phism (RFLP) of parental BAC clone 
and BAC-derived Δ22 mutants . DNA was extracted from bacterial cultures and digested with 
restriction enzymes HindIII and AsiSI before being visualised on an 0.8% agarose gel.  A) Restriction 
digest with HindIII; arrow pointing towards expected 6.9kb band compared to parental wt BAC 
strain. B) Computer generated picture of the expected fragment sizes of HindIII digest using software 
pDRAW.  C) Restriction digest with AsiSI; arrow pointing towards expected 4.6 kb band compared to 
parental wt BAC strain. D) Computer generated picture of the expected fragment sizes of AsiSI digest 
using software pDRAW. Colours were inverted. P, Parental wt BAC; 1-23, derived mutant with I-SceI-
aphAI cassette in place of VP22 gene locus, red box highlights fragment used for RFLP. 
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Figure 3.8: Sequencing analysis of PCR product from the I -SceI-aphAI  cassette.    
A) Integrity of the recognition site of endonuclease I-SceI (5‘…TAGGGATAACAGGGTAAT….3‘ ) and the 
reverse complementary sequence duplication in the reverse primer required for recombination. B) 
Integrity of the forward complementary sequence duplication in the forward primer required for 
recombination.  (blue, primer sequence homologues to the HSV-1 genome; green, primer sequence 
targeting I-SceI-aphAI cassette; underlined sequence, duplication sequence for Red recombination; 
boxed sequence,  recognition site of endonuclease I-SceI). 
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A) Reverse primer amplification 
 
 
 
 
 
 
 
 
 
B) Forward primer amplification 
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backbone, which was achieved by cotransfecting BHK cells with the recombinant BAC genome and a 
Cre-recombinase encoding plasmid. The Cre-mediated removal of the BAC sequence from the viral 
genome is essential, as its presence has been shown to impair virus growth and virulence [130]. The 
reconstituted ∆22 viruses (∆V22BAC4, ∆V22BAC6, ∆V22BAC7, ∆V22BAC17) were titrated and plaque 
assay was performed to confirm successful BAC excision employing x-gal staining. As a positive 
control the wt S17BAC virus containing the integrated BAC backbone was used (Figure 3.9A). 
Successful BAC excision of the reconstituted recombinant BAC viruses (∆V22BAC4, ∆V22BAC6, 
∆V22BAC7, ∆V22BAC17) was indicated by clear plaques, whilst the wt S17BAC virus containing the 
BAC backbone exhibited blue plaques, due to the expression of β- galactosidase encoded by the BAC 
genome (Figure 3.9B). The reconstituted recombinant viruses (∆V22BAC4, (∆V22BAC6, ∆V22BAC7, 
∆V22BAC17) were then plaque purified to ensure a pure population of the virus without the BAC 
backbone. 
 
3.4 ANALYSIS OF VP22 PROTEIN EXPRESSION IN THE BAC-GENERATED Δ22 VIRUSES 
Next, we aimed to confirm the lack of VP22 protein expression in our BAC-derived Δ22 viruses 
(Δ22BAC4, Δ22BAC6, Δ22BAC7, Δ22BAC17) using Western Blot analysis. Confluent Vero cell 
monolayers were either mock infected or infected with the BAC-derived ∆22 viruses at a MOI of 5. 
The cells were harvested 16 h after infection, resuspended in SDS-PAGE sample buffer and analysed 
by Western Blot for the expression of VP16 and VP22 (Figure 3.10A).  While VP16 was detected in all 
infected cell lysates (Figure 3.10A), confirming that all viruses had infected the Vero cells, no band 
for VP22 was detected in the BAC-derived Δ22 virus (Δ22BAC4, Δ22BAC6, Δ22BAC7, Δ22BAC17)   
infected cell lysate compared to the wt strain 17 and the wt BACS17  (Figure 3.10A), indicating the 
successful deletion of the VP22 gene. We have also investigated the expression in HeLa cells infected 
with the same viruses and found the result to be the same as for infection in Vero cells. Cell lysates 
of the HeLa cells were prepared the same way as cell lysates of Vero cells. VP16 was detected in all  
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Figure 3.9: Confirmation of BAC backbone excision of rescued ∆22BAC viruses using 
X-gal staining. Vero cells we infected with wt BAC and BAC-derived ∆22 viruses at an MOI of 5. 
After plaque formation cells were fixed, washed, treated with Y-gal and counterstained as described 
in section 2.2.6. A) X-gal staining of wt BAC containing the BAC backbone as confirmed by blue 
plaques which serve as a negative control (left), and wt BAC with excised BAC backbone as 
confirmed by clear plaques which serve as a positive control (right). B) X-gal staining of reconstituted 
∆22BAC4, ∆22BAC6, ∆22BAC7 and ∆22BAC17 virus. BAC backbone excision is confirmed by clear 
plaques.  
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Figure 3.10: Confirmation of VP22 deletion in ∆22BAC viruses.  
Vero or HeLa cells were infected with S17, wt BAC, BAC-derived ∆22 viruses at an MOI of 5. The cells 
were harvested at 16h and equal amounts of total cell lysates were analysed by SDS-PAGE and 
Western blotting for VP16 and VP22. A) Western Blot of S17, wt BAC, BAC-derived ∆22 viruses in 
Vero cells. B) Western Blot of S17, wt BAC, BAC-derived ∆22 viruses in HeLa cells. Presence of VP16 
expression is shown by a 60kDa band Presence of VP22 expression is shown by a 38kDa band. 
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cell lysates confirming that infection of all viruses took place. In the BAC-derived viruses no VP22 
band was detected confirming deletion of the VP22 gene compared to the wt strain S17 and wt 
BACS17  (Figure 3.10B). 
 
3.5 INVESTIGATING THE INTEGRITY OF VIRION HOST SHUTOFF PROTEIN IN VP22-NEGATIVE 
HERPES SIMPLEX-1 VIRUS  
Previous publications investigating VP22 deletion mutants reported acquired secondary mutations 
within the vhs gene [230, 333]. In light of these publications the integrity of the vhs gene in the 
recombinant BAC viruses was determined by sequencing analysis.  The vhs gene of the BAC-derived 
∆22 viruses was PCR-amplified with primers binding 80-100bp upstream and downstream of the vhs 
encoding region (Table 2.4). The PCR product suggested the presence of a full length vhs gene 
(Figure 3.11A) which was subsequently sequenced using the same PCR primers as well as primers 
targeting within the vhs gene. The initial sequence analysis of the BAC-derived Δ22 viruses revealed 
single nucleotide mutations in vhs leading to amino acid changes within two of the recombinant BAC 
virus isolates compared to the wild-type S17 (Figure 3.12). For Δ22BAC4 virus an amino acid change 
at position 196 from an Alanine to a Valine and an amino acid change at position 101 from an 
Arginine to a Histidine were observed. For Δ22BAC6 virus only one amino acid change was observed 
at position 175 from an Isoleucine to a Phenylalanine (Figure 3.12). For Δ22BAC7 and Δ22BAC17 
virus the sequencing analysis revealed multiple mutations and as the chromatogram of these viruses 
contained mixed peaks it suggested a possible mixed virus population (Figure 3.11B). To identify 
mutations acquired within vhs for Δ22BAC7 and Δ22BAC17, amplified DNA of the vhs gene was Topo 
cloned for sequencing. Sequencing analysis revealed multiple single nucleotide changes, deletions  
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Figure 3.11: Sequencing products of virion host shutoff protein of S17 BAC-derived 
Δ22 viruses.  
A) PCR product of vhs protein of S17 BAC-derived Δ22 viruses. Viral DNA was extracted as described 
in section 2.6.1 and amplified with primers vhsF and vhsR to yield a product of 1.7kb. The PCR 
products were purified and sent off for sequencing analysis using the above mentioned primers and 
primers vhsFseq and vhsRseq. B) Chromatogram traces of Δ22BAC7 and Δ22BAC17 showing low 
confidence in assigned nucleotides and mixed peaks indicating mixed population.  
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Figure 3.12: Sequence analysis of vhs in rescued Δ22BAC viruses derived from HSV -1 
S17 BAC.  
BAC-derived Δ22 viruses contain multiple coding changes affecting amino acids in conserved box III 
of vhs. (A) Line drawing of the HSV-1 vhs gene open reading frame denoting the 4 conserved boxes (I 
to IV) and the VP16 binding domain [20, 255]. (B) Amino acid variations identified in the original Δ22 
virus and its revertant, and Δ22 viruses derived from a S17 BAC. Sequences have been compared to 
S17REF.  
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and insertion in each of the chosen vhs Topo clones that lead to coding changes within vhs gene 
(Figure 3.12). The amino acid changes occurred at the following positions L178F, D195G, Y210H, and 
L216I. S247G, V256A, H263R, A312, L374, N384, A462T. Additionally, a nucleotide insertion at amino 
acid position 248, a nucleotide deletion at amino acid position 478 and a change to a stop codon at 
amino acid position 36 were observed (Figure 3.12). All our BAC-generated Δ22 viruses contain 
nucleotide changes leading to coding changes. The majority of the changes affected amino acids 
lying within domain III of vhs protein (Figure 3.12), which is a conserved region of vhs across the 
alphaherpesviruses and contains residues essential for vhs activity [20, 372].  
To confirm that the ∆22 mutant virus acquired the secondary mutation within the vhs gene during 
transfection of mammalian cells to rescue the virus, we sequenced the input BAC-HSV-1 DNA 
containing the VP22 gene deletion utilised to generate the ∆22 mutant viruses. The vhs gene was 
PCR amplified and sequenced with the same primers used for the Δ22BAC viruses. Sequencing 
analysis revealed no mutations within the input BAC DNA indicating a correct vhs open reading 
frame in the original constructs.    
 
3.6 FULL GENOME SEQUENCING ANALYSIS OF VP22-NEGATIVE HSV-1 VIRUS 
In light of previous publications reporting vhs mutations within VP22 deletion viruses [82, 333], our 
original Δ22 virus was also sequenced. Sequencing of our original Δ22 virus from DNA amplified by 
PCR revealed no mutations within the vhs gene. In order to exclude any other possible secondary 
mutations introduced into our VP22-negative virus we carried out full genome sequencing of our 
Δ22 virus and compared it to wild-type strain 17. The extracted genomic DNA was subjected to next 
generation sequencing at the University College London (UCL) and sequencing was carried out as 
previously described elsewhere [248]. The generated sequence data sets were analysed and aligned 
by QUASR [414] and BWA [210]; and SAMTools [211] was used to process the data into a consensus 
sequence. The consensus of the Δ22 virus was compared for single-nucleotide polymorphism (SNP) 
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and indel differences to the wild-type strain 17 using the software BaseByBase 
(http://athena.bioc.uvic.ca/). This process was carried out by Daniel Depledge at UCL who provided 
us with the established consensus sequence of the Δ22 virus. The consensus sequence revealed no 
major changes in the Δ22 genome compared to the wild-type strain 17 (GenBank no. JN555585.1; 
S17REF). Only 29 nucleotide changes in the entire genome (0.02%) were identified. Of those 
nucleotide changes only 14 led to coding changes in the amino acid sequence, while one was a 
nucleotide deletion (Table 3.1). Nucleotide changes occurred with no particular specificity for a 
group or type of proteins. Gene products affected range from DNase to glycoproteins. In contrast to 
our previous sequencing result from PCR-amplified DNA, full genome sequencing detected a single 
nucleotide change in the vhs gene of our Δ22 virus at position 271 with Valine changing to an 
Alanine (Figure 3.12). Population analysis revealed that about 50% of the genomic Δ22 virus 
population carried this mutation. No mutations within the vhs promoter were found. We also 
sequenced the full genome of our revertant Δ22 virus (Δ22R). Interestingly, analysis revealed that 
the revertant Δ22 virus (Δ22R) had also acquired a single nucleotide change leading to an amino acid 
change at position 257 changing it from an Arginine to a Cysteine (Figure 3.12). This mutation, 
however, was not found in our Δ22 virus. 
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Table 3.1: Coding changes in the genome of our Δ22 virus from wild-type strain 17. 
Coding changes with their location and associated amino acid change are given for the open reading 
frame and its gene product. (a Nucleotide numbers refer to the S17REF sequence (GenBank no. 
JN555585.1, deposited May 2012), bORF, open reading frame, cgL, glycoprotein L; TK, thymidine 
kinase; ssDNA, single-stranded DNA; pol, polymerase). 
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S17 Referencing location a ORF b Gene Product c Coding Changes(s) in the Δ22 
virus 
 
9984 
 
26671 
 
26863 
 
41209 
 
47095 
 
56878 
 
60783 
 
68223 
 
93835 
 
UL1/UL2 
 
UL12 
 
UL12 
 
UL20 
 
UL23 
 
UL28 
 
UL29 
 
UL32 
 
UL42 
 
gL/uracil DNA 
glycosylate 
 
DNase 
 
DNase 
 
Membrane protein 
 
TK 
 
DNA packaging 
 
ssDNA binding protein 
 
DNA packaging 
 
DNA pol subunit 
 
R216H/A34T 
 
R73H 
 
C9Y 
 
A94V 
 
R237C 
 
A428V 
 
E424D 
 
A314T 
 
A242T 
 
109553 
 
UL51 
 
Helicase/primase 
 
A169T 
 
115555 
 
UL55 
 
Nuclear matrix protein 
 
Deletion of 1 nt 
 
134619 
 
US2 
 
Unknown 
 
V105M 
 
140564 
 
US7 
 
Glycoprotein I 
 
T259M 
 
140771 
 
US7 
 
Glycoprotein I 
 
M328K 
 
143184 
 
US8A 
 
Nucleolar 
phosphoprotein 
 
C146Y 
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3.7 CHAPTER SUMMARY 
Bacterial artificial chromosome (BAC) recombination has become the favoured method for the 
construction of recombinant viruses including HSV-1 VP22 knockout viruses as it is supposed to save 
a lot of time and effort. However, having attempted to generate a VP22-deletion virus using BAC 
recombination it can be said that this is not always the case and one should be very careful in 
analyzing the recombinant virus as it is possible for secondary mutations to arise during gene 
manipulation, as shown in this chapter. Previous publications of VP22 knockout virus using a  
bacterial artificial chromosome (BAC) recombination system suggest that VP22 deletion viruses are 
only viable when the vhs gene acquires secondary mutations and abolishes vhs activity [230, 333]. 
We generated a number of VP22 deletion viruses in Vero cells using BAC recombination and 
sequencing analysis of the vhs gene of four isolates (Δ22BAC4, Δ22BAC6, Δ22BAC7 and Δ22BAC17) 
revealed several spontaneous secondary nucleotide mutations leading to amino acid coding changes 
(Figure 3.12). As the input HSV-1 BAC DNA containing the VP22 deletion had an intact vhs sequence 
capable of expressing a functional vhs protein, as confirmed by sequencing results, the mutations 
within vhs gene must have been acquired during virus rescue of the VP22 deletion virus in Vero cells. 
It should be noted that the mutations observed in the BAC-derived VP22-deletion viruses however, 
are only single point mutations and no gross deletions or frameshifts as observed by Roizman et al. 
[333] and Duffy et al. [230] , and therefore may not necessarily lead to an inactivation of the vhs 
protein activity. One difference in our Δ22 BAC recombinant is that the VP22-deletion virus 
generated in the Roizman lab was from strain F, whereas ours was in strain 17. It is possible that the 
severe attenuation seen in the VP22-deletion virus is strain dependent due to vhs having a possible 
stronger activity in strain F, however the assay looking at overall host protein shutoff activity and 
tegument-associates vhs activity  did not indicate that strain F vhs activity is stronger that strain 17 
in our hands (Figure 3.1).  
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In contrast to the BAC-derived VP22 deletion viruses our previously published VP22 knockout virus 
was generated using homologous recombination and rescued in a complementing cell line [94]. Full 
genome sequencing detected a wild-type vhs gene as well as a single nucleotide change at position 
271 with Valine changing to an Alanine (Figure 3.12). Population analysis revealed that about 50% of 
the genomic Δ22 virus population carry this mutation suggesting that both variants are coreplicating. 
These results suggest that the method of virus rescue used to produce a viable Δ22 virus from 
Bacterial Artificial Chromosome influences the acquisition of vhs mutations in a Δ22 virus. We 
hypothesize that direct transfection of HSV-1 DNA containing a VP22 deletion into non-
complementing cells may lead to pressure to mutate the vhs gene early during virus rescue which in 
turn may affect vhs expression and activity. This is supported by the fact that the generation of the 
Δ22 virus revertant (Δ22R) which involved transfection of genomic DNA lacking the VP22 gene 
proved highly problematic (personal communication, Gill Elliott) and sequencing results revealed a 
single amino acid change (R257C) that was not present in the originating Δ22 genome (Figure 3.12).  
These observations suggest that a VP22-deletion virus which maintains a wild-type vhs can be 
successfully generated providing the right conditions are used for virus rescue and propagation; but 
more importantly a wild-type vhs is not lethal in the absence of VP22 during virus replication. 
Taken together, these results imply a relationship between VP22 and vhs during virus replication 
whose investigation will be the focus in part of this thesis. As our previously generated VP22 deletion 
virus contains an intact vhs sequence, this virus will be used for future experiments to analyse the 
role of VP22 during virus infection. 
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4.1 CHAPTER INTRODUCTION 
In the previous chapter we have shown that the mode of rescue determines the acquisition of vhs 
mutations in VP22-negative herpes simplex virus 1 as BAC-derived Δ22 virus contain spontaneous 
secondary mutations within the vhs gene, whereas Δ22 virus rescued in a complementing cell line 
does not, indicating that HSV-1 is able to replicate with an intact vhs sequence in the absence of 
VP22 [83]. Previous publications investigating VP22 deletion viruses have reported acquired 
secondary mutations within the vhs gene rendering it inactive, indicating a relationship of VP22 with 
vhs [230, 333]. VP22 is thought to be involved in the regulation of vhs activity as has been suggested 
by Taddeo et al. [384]. So far, no exact mechanism has been established on how VP22 regulates vhs 
activity. Additionally to vhs mutations, reduced levels of vhs expression have been noted in the 
absence of VP22 expression [82, 230, 333]. It is possible that the reduce levels of vhs protein 
observed in the absence of VP22 are due to the mutations within vhs as the vhs mRNA might not be 
correctly transcribed, is inefficiently translated, or incorrectly localised due to the encoded 
mutations.  Alternatively, the vhs protein might be subjected to enhanced proteasomal degradation 
of the vhs protein. In the next chapter, it will be investigated if vhs expression in our Δ22 virus 
expressing a wild-type vhs is affected, and if so at what level vhs fails to be expressed efficiently.  
 
4.2 VP22-DELETION VIRUS CONTAINS NO TEGUMENT-ASSOCIATED SHUTOFF 
VP16 as well as VP22 have been suggested to be involved in regulating vhs activity and packaging the 
protein into the virus particle [182, 198, 230, 302, 303, 333]. Having established that our Δ22 virus 
contains a wt vhs gene, the next step was to investigate if tegument-associated vhs in our Δ22 virus 
particles is active upon release into the cell during virus infection, as vhs is delivered in the 
cytoplasm upon virus infection where it functions in host cell synthesis shutoff. 
For this we used [35S]-methionine labelling in the presence of Actinomycin D, which is an inhibitor of 
mRNA transcription meaning no new host or viral proteins are produced. HeLa cell monolayers were 
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infected with wild-type 17, Δvhs, Δ22 or Δ22 revertant virus at an MOI of 20 in the presence of 
Actinomycin D in 6-well dishes. After 4 hours of infection the cells were treated with methionine-
free media and labelled with [35S]-methionine for 1 hour before lysates were harvested in SDS lysis 
buffer and analysed by 10% SDS-PAGE gel exposed to film (autoradiography). The results revealed 
that, as expected, the wild-type is able to shut off host cell protein synthesis in the absence of viral 
gene expression as it contains a functional vhs associated with the tegument which is released into 
the cell upon infection. This is indicated by the reduced intensity of protein labelling in the wt S17 
infection compared to the mock, meaning fewer proteins are translated and therefore fewer 
proteins are labelled (Figure 4.1).  The vhs virus does not contain tegument-associated vhs, and 
therefore its protein labelling intensity is similar to the mock (Figure 4.1). According to the protein 
labelling intensity our 22 virus showed no tegument-associated vhs activity similar to the vhs 
virus (Figure 4.1). The revertant of the VP22 deletion virus, however, exhibited tegument-associated 
vhs activity as its protein labelling intensity is similar to the wild-type (Figure 4.1). These results 
suggest that either vhs in our 22 virions is inactive, or vhs is not packaged into the virus particle.  
 
4.3 VHS PACKAGING IS REDUCED IN THE ABSENCE OF VP22 IN THE HSV-1 VIRION 
Having investigated its vhs activity, it was discovered that our Δ22 virus does not contain tegument-
associated vhs activity compared to the wt S17 and the revertant of our VP22 deletion virus. 
Considering this observation packaging of vhs into the virion in the absence of VP22 was 
investigated. In order to do so, extracellular virions were ficoll-purified from Vero cells infected with 
wt S17, Δ22 or Δ22 revertant. The purified virions were then analysed by SDS-PAGE followed by 
coomassie blue staining and Western blotting. Coomassie blue staining was used to assess the 
general virion profile and to determine loading volume for Western blotting. Extracellular virions 
were blotted for major capsid protein VP5 for loading equalization, glycoproteins gE and gM and for 
the tegument proteins VP16, VP22 and vhs. The general virion profile of our Δ22 seems unaltered  
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Figure 4.1: Tegument-associated host shutoff function in our Δ22 virus. 
HeLa cells were infected with wt S17, Δvhs virus, our ∆22 virus and its revertant at an MOI 20 in the 
presence of 5 μg/ml Actinomycin D (Act D). Cells were treated with 50 µCi/mL [35S]-methionine after 
4 hours and subsequently harvested for analysis using autoradiography. The values on the left are 
molecular weights in kDa.  
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compared to the wt S17 and Δ22 revertant virus, apart for VP22 which is deleted as previously 
shown by Elliott et al. [94] (Figure 4.2A). Western blotting analysis revealed that, as expected, VP16 
was packaged into the virion for the wild-type as well as the ∆22 virus and the ∆22 revertant (Figure 
4.2B) with levels comparable to the wild-type. The packaging levels of glycoproteins gE and gM were 
also examined and showed that levels of both glycoproteins were similar in all virions confirming 
that the absence of VP22 has no effect on assembling gE and gM into the virion, as shown previously 
by Maringer et al. for HSV-1 [225], and Fuchs et al. for PRV [125] (Figure 4.2B). As expected, blotting 
for VP22 showed that the protein was absent in our Δ22 virus compared to the wild-type S17 and 
Δ22 revertant virus which packaged VP22 to wild-type levels (Figure 4.2B). Western blotting analysis 
for vhs showed that vhs was packaged into the wild-type S17 and Δ22 revertant virus which 
packaged vhs to wild-type levels. However, a greatly reduced packaging of vhs into the Δ22 virus was 
observed (Figure 4.2B). 
Our Δ22 revertant virus contains an amino acid change in vhs (R257C) (Figure 3.12). As the mutant 
vhs was packaged to wild-type levels into the Δ22 revertant virus the point mutation within vhs does 
not affect its packaging and the lack of vhs assembly in the VP22 deletion mutant is a direct 
consequence of the absence of VP22. Even though VP16 has been shown to interact with vhs [329, 
350] it cannot be concluded that VP16 is not sufficient to package vhs into our Δ22 virus as the low 
level of packaged vhs might be due to low expression levels of vhs in the absence of VP22. The 
reduced vhs packaging in our Δ22 virus correlated with our assay looking at tegument associated vhs 
activity as it confirms that the lack of tegument associated vhs activity in the VP22 deletion virus was 
due to the reduced packaging levels of vhs rather than inactive vhs.  
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Figure 4.2:  Packaging of vhs is reduced in our Δ22 virus.  
(A) Virions were Ficoll-purified from confluent Vero cells infected at an MOI of 0.02 with wt HSV-1 
strain S17, VP22 deletion virus (Δ22) and its revertant (Δ22R). Samples were analysed by Coomassie 
blue staining SDS-PAGE gel for virion quality and to equalise loading volume; the sizes of the 
molecular weight markers (kDa) are indicated on the left; identifiable virion components are 
annotated on the right. (B) Purified virions were analysed by Western blotting using antibodies 
directed against VP5, VP16, gE, gM, VP22 and vhs.   
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4.4. ANALYSIS OF VHS EXPRESSION IN THE ABSENCE OF VP22 
Investigating the tegument-associated vhs activity and vhs packaging in the absence of VP22 
expression, results indicated that vhs is not packaged efficiently into the virus particle in the absence 
of VP22. Previous publications investigating the effect of VP22 deletion on virus replication have 
documented not only a mutated vhs but also a reduced expression of vhs in their generated Δ22 
virus [82, 230, 333]. Therefore the reduced packaging and associated lack of tegument-associated 
vhs activity could be due to low level vhs expression. 
To examine vhs expression in the absence of VP22 confluent Vero cell monolayers were either mock 
infected or infected with wild-type strain 17, Δ22 virus or its revertant (Δ22R) at an MOI of 5. The 
cells were harvested 16 h after infection, resuspended in SDS-PAGE sample buffer and analysed by 
Western Blots targeting with antibodies against VP16, VP22 and vhs. Western Blot analyses 
confirmed that all viruses had infected the Vero cells as VP16 was detectable in all cell lysates; and 
that VP22 was absent in our Δ22 virus compared to the wild-type and Δ22 revertant virus (Figure 
4.3A). However, Western blot analysis for vhs expression showed a barely detectable band for vhs, 
suggesting that in the absence of VP22 expression, the expression of vhs is severely reduced (Figure 
4.3A). This suggests that the observations made, when investigating tegument-associated vhs 
activity and vhs packaging level, are due to reduced vhs expression rather than a defect in vhs 
packaging.  
While our original Δ22 virus encodes a wt vhs, the BAC-derived Δ22 viruses (Δ22BAC4, Δ22BAC6, 
Δ22BAC7, Δ22BAC17) encode vhs containing single amino acid mutations. It might be possible that 
our Δ22 virus expresses low levels of vhs because it maintains a wild-type vhs.  To examine if the 
reduced levels of vhs expression in the absence of VP22 are due to it being a wild-type vhs, 
expression levels of vhs in the BAC-derived Δ22 viruses (Δ22BAC4, Δ22BAC6, Δ22BAC7, Δ22BAC17) 
were examined. Confluent Vero cell monolayers were either mock infected or infected with wt S17, 
parental wt BACS17 or BAC-derived ∆22 viruses at a MOI of 5. The cells were harvested 16 h after  
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Figure 4.3: Western Blot analysis for the expression of protein VP22, vhs and VP16 in ∆22 viruses.  
Vero or HeLa cells were infected with either wt S17, wt BAC, BAC-derived ∆22 viruses or ∆22 virus 
and its revertant at an MOI of 5. The cells were harvested at 16h and equal amounts of total cell 
lysates were analysed by SDS-PAGE and Western blotting for VP16, vhs and VP22. A) Western Blot of 
S17, ∆22 virus and its revertant in Vero cells. B) Western Blot of S17, wt BAC and BAC-derived ∆22 
viruses in Vero cells. C) Western Blot of S17, wt BAC and BAC-derived ∆22 viruses in HeLa cells. 
Presence of VP16 expression is shown by a 60kDa band Presence of VP22 expression is shown by a 
38kDa band; presence of vhs expression is shown by a 55kDa band. 
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infection, and resuspended in SDS-PAGE sample buffer. Western Blots of VP16, VP22 and vhs were 
carried out with antibodies targeting against VP22, vhs and VP16. While VP16 was detected in all 
infected cell lysates (Figure 4.3B), confirming that all viruses had infected the Vero cells, no band for 
VP22 was detected in the BAC-derived Δ22 virus (Δ22BAC4, Δ22BAC6, Δ22BAC7, Δ22BAC17) infected 
cell lysate compared to the wt strain 17 and the wt BACS17 (Figure 4.3B), confirming the successful 
deletion of the VP22 gene which was shown in the previous chapter (Figure 3.10A/B). There was also 
no band detected for the vhs protein in the BAC-derived Δ22 viruses (Δ22BAC4, Δ22BAC6, Δ22BAC7, 
and Δ22BAC17) infected cell lysate (Figure 4.3B). While the Western blot for Δ22BAC4 and Δ22BAC7 
detected a faint band for the vhs protein (58kDa), for Δ22BAC6 and Δ22BAC17 no band of the 
correct size (58kDa) for vhs could be detected. We have also investigated the expression of vhs in 
HeLa cells and found the result to be the same as for infection in Vero cells. Cell lysates of the HeLa 
cells were prepared the same way as cell lysates of Vero cells. VP16 was detected in all cell lysates 
confirming that infection of all viruses took place. In the BAC-derived viruses, no VP22 band was 
detected confirming deletion of the VP22 gene compared to the wt strain S17 and wt BACS17  
(Figure 4.3C). Western blot for the detection of vhs in the Δ22BAC4 and Δ22BAC7 showed a faint 
band whereas no band for vhs was detected in the Δ22BAC6 and Δ22BAC17 virus. 
 
4.4.1 ANALYSIS OF VHS EXPRESSION IN THE ABSENCE OF VP22 IN DIFFERENT CELL TYPES  
Investigating the expression of vhs in the absence of VP22 during HSV-1 infection in our Δ22 virus                                                                                                                                                                                                                            
has shown that vhs expression is reduced in the absence of VP22 in Vero as well as in HeLa cells 
(Figure 4.3A-C). It was of interest to investigate the expression of vhs in the Δ22 virus in the different 
cell types routinely used in the lab for virus stock amplification and various experimental designs. 
The cell lines used were Vero, HeLa, BHK-21, HFFF2, HaCaT and a second African green monkey-
derived kidney fibroblast-like cell line (Cos). Confluent cell monolayers of the different cell lines were 
either mock infected or infected with the wild-type S17, Δ22 virus, and its revertant (Δ22R) at an 
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MOI of 5. The cells were harvested 16 h after infection, and Western Blot carried out with antibodies 
against VP16, VP22 and vhs. While VP16 was detected in all infected cell lysates, confirming that all 
viruses had infected the cells, no band for VP22 was detected in the Δ22 virus infected cell lysate 
compared to the wild-type S17 (Figure 4.4), confirming the lack of VP22 expression. Western blot 
analysis using an antibody targeting the vhs protein revealed that the expression of vhs was 
considerably reduced in cell lines Vero, HeLa, BHK-21 and Cos (Figure 4.4). This observation confirms 
previous publications on generated Δ22 virus by Duffy et al. Sciortino et al. and Mbong et al. [82, 
230, 333]. Western blot analysis in cell lines HFFF2 and HaCaT revealed that vhs expression seems to 
be completely lacking (Figure 4.4). While the Western blots for V22 and VP16 were exposed for a 
maximum of 10 seconds, the western blot for vhs was exposed for up to 20 min to ensure a low level 
of vhs expression could be detected. Longer exposure times, however, can result in the detection of 
background contamination as seen for the vhs blot in HFFF2, which makes detection of low level vhs 
expression difficult. The reduction or lack of vhs expression in the absence of VP22 during virus 
infection indicates that VP22 is required for the efficient expression of vhs. As vhs expression 
seemed to be even more affected in the absence of VP22 during virus infection in HFFF2 and HaCaT 
cells, it indicates that the relationship between VP22 and vhs might be more significant in 
physiologically relevant cell lines. The lack of vhs expression in physiologically relevant cell lines 
could be an indication for VP22 to be involved in the regulation of vhs expression as has been 
suggested by Taddeo et al. [384]. 
 
4.5 VHS TRANSLATION IS REPRESSED IN THE ABSENCE OF VP22 
The reduced expression of vhs in the absence of VP22 could be explained by several potential 
mechanisms – reduced transcription of the vhs mRNA; incorrectly localised vhs mRNA; inefficient 
translation of the mRNA; or enhanced proteasomal degradation of the vhs protein. To investigate if 
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Figure 4.4: Western Blot analysis for the expression of vhs in the absence of VP22 in different cell 
lines.  
Monolayers of HFFF2, HaCaT, COS, BHK, HeLa and Vero cells were infected with wild-type S17, Δ22 
virus and its revertant (Δ22R) at an MOI of 5. The cells were harvested at 16h and equal amounts of 
total cell lysates were analysed by SDS-PAGE and Western blotting for VP16, VP22 and vhs. Presence 
of VP16 expression is shown by a 60kDa band, presence of VP22 expression is shown by a 38kDa 
band, presence of vhs expression is shown by a 55kDa band. 
  
Chapter 4                     Efficient Translation of the Virion Host Shutoff Protein Requires VP22 
157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 4                     Efficient Translation of the Virion Host Shutoff Protein Requires VP22 
158 
 
the reduced vhs protein levels observed during infection with the Δ22 virus are due to reduced vhs 
mRNA levels and not inefficient mRNA translation, the relative mRNA levels for vhs were measured 
by qRT-PCR. For this, monolayers of HFFF2 and Vero cells were infected with wt S17 or Δ22 virus at 
an MOI of 2. The cells were harvested 16 h after infection, and cDNA was generated from total 
mRNA samples. Transcript levels for vhs and VP16 were measured using qRT-PCR and normalised to 
18S RNA. Protein levels were measured in total cell lysates using quantitative fluorescence imaging 
which is directly proportional to the amount of antigen used on Western blots (data kindly provided 
by Dr Juliet Jones). 
Analysis of mRNA levels in Vero cells showed that the amount of vhs mRNA was similar to wt levels 
at 16hrs post infection in the absence of VP22 expression, despite observed severely decreased 
protein levels (Figure 4.5). VP16 mRNA levels and protein levels were only slightly decreased 
compared to the wild-type, which enabled the detection of VP16 in the absence of VP22 using 
Western Blot. Analysis of mRNA levels in HFFF2 cells showed very similar results to Vero cells, with 
the vhs mRNA only slightly increased in comparison to wt levels (Figure 4.5). Protein levels of vhs 
were also drastically reduced in the absence of VP22. VP16 mRNA levels and protein levels were only 
slightly decreased in the absence of VP22. These results indicate that the lack of vhs expression 
observed in the Δ22 virus is not due to reduced vhs mRNA transcription, as mRNA levels comparable 
to the wt were detectable. It is possible that the reduced vhs levels detected by Western blotting are 
due to inefficient translation or that vhs is exposed to proteasomal degradation.   
To investigate if the reduced vhs expression in the absence of VP22 is due to proteasomal 
degradation of the vhs protein, virus infection was carried out in the presence of MG132 
(carbobenzoxy-Leu-Leu-leucinal), which is a commercially available proteasome inhibitor that 
reduces the degradation of ubiquitin-conjugated proteins in mammalian cells. Monolayers of HeLa 
cells were infected with wild-type S17, Δvhs or Δ22 virus at an MOI of 10. The cells were  
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Figure 4.5: Reduced vhs expression is not due to reduced mRNA transcription in the absence of 
VP22.  
Monolayers of Vero or HFFF2 cells were infected with Δ22 virus at an MOI of 2 and harvested at 16h 
post infection. Total lysates were analysed for relative mRNA and protein levels of VP16 and vhs in 
the absence of VP22 as measured by qRT-PCR and Western Blot Fluorescence. mRNA levels were 
normalised to 18sRNA and compared to wt S17. (The Figure was kindly provided by Prof Gill Elliott; 
the data was produced by Dr Juliet Jones for the preparation of a manuscript.) 
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harvested at 12h post infection after cells were treated with MG132 at various times (2h, 4h and 6h) 
prior to harvesting in SDS-PAGE sample buffer. Equal amounts of total cell lysates, as confirmed by 
blotting for α-tubulin, were analysed by SDS-PAGE and Western blotting using antibodies against 
proteins VP22, VP16, vhs and ubiquitin. Western blotting for VP16 indicated that all viruses had 
infected the HeLa cells, whereas Western blotting for VP22 confirmed the deletion of VP22 in the 
Δ22 virus compared to the wt S17 and Δvhs virus (Figure 4.6). Western blotting for ubiquitin was 
achieved with antibody FK2, which recognizes all types of conjugated, but not free, ubiquitin in 
mammalian cells (table 2.5) [127]. The results for ubiquitin blotting showed that MG132 inhibits the 
proteasomal degradation of ubiquitinated proteins during infection with wt S17 and Δ22 virus, as 
the level of ubiquitinated proteins increased with increasing time of MG132 treatment. Western 
blotting for vhs revealed no increase in vhs protein expression levels in the absence of VP22 despite 
the treatment with proteasomal degradation inhibitor MG132 for up to 6 hours (Figure 4.6). These 
results indicate that de novo synthesised vhs protein is not rapidly degraded by the proteasome 
after its expression in the absence of VP22. Instead, the vhs mRNA might not be efficiently 
translated during virus infection in the absence of VP22 expression. It has been reported that the 
absence of VP22 causes a defect in glycoprotein gD and gE translation that is independent of mRNA 
abundance [230], which may also be the case for vhs mRNA translation in the absence of VP22, 
leading to reduced vhs protein levels. 
 
4.6 CHAPTER SUMMARY 
This chapter focused on assessing the expression of vhs in the absence of VP22 as previous 
publications have reported reduced vhs expression levels in generated Δ22 viruses. However, in 
contrast to our Δ22 virus, the previously reported BAC generated VP22-deletion viruses contained 
mutated vhs protein [82, 230, 333]. As it was established that our Δ22 virus contains a wt vhs  
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Figure 4.6: vhs is not degraded in the absence of VP22. 
 Monolayers of HeLa cells were infected with wild-type S17, Δvhs or Δ22 virus at an MOI of 10. The 
cells were harvested at 12h post infection and treated with MG132 for the denoted times prior to 
harvesting. Equal amounts of total cell lysates were analysed by SDS-PAGE and Western blotting for 
proteins VP22, VP16, vhs and ubiquitin. Western blotting for ubiquitin indicates inhibited 
proteasomal degradation, and Western Blotting for α-tubulin indicates equal loading. 
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protein, subsequent investigation into tegument-associated vhs activity was carried out, as vhs is 
known to be delivered into the cytoplasm upon infection [354]. Even though our Δ22 virus contains a 
wt vhs, it was found not to exhibit tegument-associated vhs activity (Figure 4.1), indicating that vhs 
might not be packaged efficiently into the Δ22 virus. This could suggest a role for VP22 to be 
involved in packaging of vhs and not only in the regulation of vhs activity [82, 230, 333]. As our Δ22 
virus contained no tegument-associated vhs activity (Figure 4.1), packaging levels in the absence of 
VP22 were investigated and revealed reduced levels (Figure 4.2), which could be taken as an 
indicator for VP22-dependent packaging. However, using Western blot analysis it was shown that 
our Δ22 virus expressed substantially reduced levels of vhs compared to the wild-type (Figure 4.3A), 
which is in corroboration with the previous publications investigating Δ22 viruses [82, 230, 333]. 
Therefore, the lack of tegument-associated vhs activity and the reduced packaging levels observed in 
the absence of VP22 were essentially due to reduced expression of the vhs protein in the absence of 
VP22. Additionally the vhs expression levels of the BAC-derived VP22-deletion viruses (Δ22BAC4, 
Δ22BAC6, Δ22BAC7, Δ22BAC17) were measured and also revealed substantially reduced expression 
levels of vhs (Figure 4.3B). Therefore, it cannot be said that the reduced expression levels of vhs in 
the absence of VP22 observed in previous publications are due to the reported mutations within the 
vhs protein [82, 230, 333], as our Δ22 virus, which also expresses low levels of vhs, contains a wt vhs 
protein (Figure 3.12).   
The low levels of vhs expression were observed in a range of cell lines used for experimental 
investigation of HSV-1 and therefore vhs expression levels in the absence of VP22 are not cell type 
dependent (Figure 4.4). The reduced level of vhs expression in Δ22 viruses could be due to several 
possibilities, including transcription of the vhs gene or reduced translation of the vhs mRNA. 
Alternatively, de novo synthesised vhs might be degraded instantly and rapidly before it can achieve 
any detectable expression levels. Using our Δ22 virus it was shown that the observed reduced vhs 
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levels are most likely due to inefficient translation of vhs mRNA rather than reduced vhs mRNA 
transcription (Figure 4.5) or vhs protein degradation (Figure 4.6).  
The observation that VP22 is required for optimal expression of vhs in infection is in line with the 
previous suggestion that vhs only accumulated to detectable levels in the presence of VP16 and 
VP22 expression, observations that were made in transient transfection [384]. The next chapter will 
examine this relationship between VP22, VP16 and vhs. 
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5.1 CHAPTER INTRODUCTION 
In the previous chapter it was demonstrated that vhs is poorly expressed in the absence of VP22. 
The reduced levels of vhs expression are likely to be due to inefficient vhs translation as vhs mRNA 
levels have been shown to be efficiently transcribed (Figure 4.5) and de novo synthesized vhs is not 
subjected to proteasomal degradation (Figure 4.6). VP22 has been suggested to be involved in the 
regulation of vhs activity [230, 333, 384]. Vhs has been shown to interact with VP22 in infection, but 
only in the presence of VP16 [384]. Additionally, it has been shown that vhs protein levels only 
accumulate when expressed in the presence of VP22 and V16 in transfection, indicating a possible 
role of the VP22/VP16/vhs tripartite-complex in infection [384]. However, the interaction of VP22 
with vhs has not been defined in great detail yet, nor has its exact role in virus replication. The aim of 
this chapter is to investigate the relationship of VP22 with vhs in regards to vhs expression 
requirements and vhs packaging.  
 
5.2 FULL LENGTH VP22 IS NOT REQUIRED FOR EFFICIENT VHS EXPRESSION   
Having shown that VP22 is required for optimum expression of the vhs protein (Figure 4.3A), it was 
of interest to investigate if a full length VP22 protein is needed or if a particular region of VP22 is 
involved in the efficient expression of the vhs protein.  To examine the requirement of a full length 
VP22 protein for efficient vhs expression we utilised viruses expressing GFP-tagged N- and C-
terminal truncations of VP22 (Figure 5.1A). First, the level of vhs expression was assessed by 
infecting confluent Vero cell monolayers with wild-type S17,  GFP-tagged wild-type VP22 expressing 
virus (G22:1-301), and a set of viruses expressing the GFP-tagged N- and C-terminal truncations of 
VP22 (Figure 5.1A) at an MOI of 5. The cells were harvested 16 h after infection, resuspended in SDS-
PAGE sample buffer and analysed by Western blot analysis using antibodies against GFP to detect 
the expressed tagged N- and C-terminal VP22-truncations as well as VP16 and vhs. α-tubulin was 
used as a control. Blots for GFP confirmed the different sizes of the VP22 truncations (Figure 5.1B).  
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Figure 5.1: GFP-tagged VP22 truncation expressing viruses contain a single point mutation within 
the vhs gene.  
A) Line drawings of the N- and C-terminal VP22 truncation forms expressed as GFP-tagged proteins 
in VP22-expressing viruses used in this study. B) Western Blot analysis for the expression of vhs in 
VP22 truncation viruses in Vero cells. Vero cells were infected with wt S17 and viruses expressing 
each of the GFP-tagged mutant form of VP22 shown in panel A at an MOI of 5. After 16h equal 
amounts of total cell lysates were analysed by SDS-PAGE and Western blotting for GFP, VP16 and 
vhs. Presence of vhs expression is shown by a 55kDa band. Presence of VP16 expression is shown by 
a 60kDa band. Presence of truncated VP22 expression is shown by different sized bands blotted for 
GFP. C) Sequence Analysis of vhs in GFP-tagged VP22 expressing viruses. Line drawing of the HSV-1 
vhs gene open reading frame denoting the 4 conserved boxes (I to IV) and the VP16 binding domain 
[20, 255]. 
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VP16 was detected in all infected cell lysates expressed to the wild-type level (Figure 5.1B). Western 
blot analysis for vhs revealed that vhs was expressed in all VP22 truncation mutants; however, the 
expression levels of vhs differed between the different VP22 truncation viruses (Figure 5.1B). Viruses 
expressing C-terminal VP22 residues 108-301 and 160-301 showed vhs expression near wild-type 
levels as seen in wild-type S17 and G22:1-301, whereas viruses expressing N-terminal VP22 residues 
1-165 and 1-212 showed reduced vhs expression in the same way as the Δ22 virus (Figure 5.1B). 
These results indicate that VP22 residues 160-301 were sufficient for expression of vhs to levels of 
wild-type infection. Residues 160-301 also contain the VP16 binding domain [136, 277], which raises 
the question of whether the interaction of VP22 with VP16 may be involved in the efficient 
expression of vhs during virus infection. This is supported by the Western blot analysis of the VP22 
truncation viruses expressing residues 1-212 and 1-165 as they exhibited reduced vhs expression 
(Figure 5.1B). The sequence integrity of vhs was also examined in the set of viruses expressing N- 
and C-terminal truncations of VP22 to rule out any sequence changes that might influence the 
expression of vhs. The vhs gene of the set of viruses was PCR-amplified and sequencing analysis 
revealed that all viruses expressing GFP-tagged N- and C-terminal truncations of VP22 except for one 
(virus expressing G22:108-301) contained a vhs with the same point mutation (R257C) as the Δ22 
revertant virus (Figure 5.1C). Sequencing results of the virus expressing VP22 residues 108-301 
revealed a wild-type vhs. It cannot be said that the mutation within vhs affects its expression during 
infection as the virus expressing VP22 residues 160-301 and a mutant vhs showed similar vhs 
expression levels as the virus expressing VP22 residues 108-301 with a wild-type vhs. 
 
5.3 THE C-TERMINAL HALF OF VP22 IS SUFFICIENT FOR ASSOCIATION WITH VHS 
The expression of vhs seems to correlate with the expression of VP22 residues which contain the 
previously described VP16 binding domain (Figures 5.1B)  [136, 277]. It could be assumed that 
optimum vhs expression occurs in the presence of VP22 binding to VP16. In order to examine the 
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potential interaction of vhs with VP22 and identify the region of VP22 involved in VP22-vhs 
interaction in infected cells the aforementioned viruses expressing GFP-tagged N- and C-terminal 
truncations of VP22 (Figure 5.1A) were used in GFP-trap assays. These viruses were previously 
characterised for their ability to interact with VP16. Viruses expressing VP22 residues 108-301 and 
160-301 were able to interact with VP16 whereas virus expressing VP22 residues 1-165 were not 
[136]. Confluent Vero cell monolayers infected with our Δ22 virus, GFP-tagged full length VP22 
expressing virus (G22:1-301) or GFP-tagged truncated VP22 expressing viruses (G22:1-165, G22: 108-
301 and G22:160-301) at an MOI of 1, were harvested 20 hpi and subjected to GFP-trap 
immunoprecipitation using GFP-Trap_A beads, before analysing by Western blotting for the 
presence of VP16 and vhs. The cell lysates analysed by silverstaining showed that GFP-tagged full 
length VP22 and GFP-tagged truncated VP22 were precipitated with equal efficiency (Figure 5.2A). 
Western blotting analysis for VP22 binding showed that virus expressing full length VP22 bound 
VP16 as expected. Additionally, the analysis revealed that full length VP22 is able to bind vhs (Figure 
5.2B). Viruses expressing VP22 residues 108-301 and 165-301 also bound VP16 as well as vhs, 
whereas virus expressing residues 1-165 was unable to form a complex with VP16 or vhs (Figure 
5.2B). The Δ22 virus served as a negative control and showed no complex formation for either 
protein (Figure 5.2B). The results for VP16-VP22 complex formation in infection are in agreement 
with previous observations made by Hafezi et al. and O’Regan et al., that the VP16 binding domain is 
found at the C-terminal region of VP22 [136, 277].  Additionally, these immunoprecipitation studies 
indicate that amino acid region 160-301 previously identified to be sufficient in binding VP16 is also 
sufficient in pulling down vhs in infected cells.  
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Figure 5.2: aa160-301 of VP22 is sufficient for VP22/VP16/vhs complex formation as shown by 
GFP-trap.  
Vero cells were infected with full length GFP-tagged VP22 expressing virus (G22:1-301) and 
truncated GFP-tagged VP22 expressing viruses (G22:108-301, G22:160-301, G22:1-165) as well as a 
virus expressing GFP in place of VP22 (Δ22) at an MOI of 1. Whole cell lysates were harvested at 20 
hpi in lysis buffer containing RIPA and DNase and processed using the GFP trap® system. Samples 
were then subjected to A) silver staining and B) Western blot analysis using antibodies indicated. The 
values on the left are molecular weights in kDa. Arrows indicate the interacting partners of GFP-
tagged VP22 and its truncated forms identified by Western blotting.  
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5.4 VHS PACKAGING REFLECTS ITS EXPRESSION LEVELS  
Optimum vhs expression to wild-type levels required the expression of VP22 C-terminal residues 
160-301, whereas vhs expression levels were reduced when VP22 N-terminal residues 1-165 were 
expressed (Figure 5.1B). To examine if the vhs expression levels of the VP22 truncation viruses are  
reflected in the vhs packaging ficoll-purified extracellular virions from Vero cells infected with viruses 
expressing full length GFP-tagged VP22 or GFP-tagged N- and C-terminal truncations of VP22 were 
analysed by SDS-PAGE followed by coomassie blue staining and Western blotting. Coomassie blue 
staining revealed no changes in the general virion profile of the viruses other than the various sizes 
of VP22 (Figure 5.3A). Extracellular virions were blotted for major capsid protein VP5 for loading 
equalization, glycoproteins gE and gM and for the tegument proteins VP16, VP22 and vhs. Western 
blotting analysis revealed that VP16 is packaged into the virion at the same levels for the full length 
VP22 as well as the truncated VP22 proteins, including virus expressing VP22 residues 1-165 only 
(Figure 5.3B) as was shown previously by Hafezi et al. [136]. This was as expected as, even when 
VP22 and VP16 interaction is abolished as in virus G22:1-165 , VP16 is able to be packaged into the 
virus particle as the VP22-VP16 interaction is not required for its incorporation into virions [90, 275, 
277]. The VP22 truncation virus expressing residues 1-165, however did not package the truncated 
version of VP22 as it is lacking its gE interaction domain [276, 377]. Blotting analysis for vhs revealed 
that vhs is packaged into the virions at the same level in the presence of a full length VP22 protein as 
well as a truncated VP22 protein, providing residues 160-301 are expressed (Figure 5.3B). However, 
levels of vhs packaging were reduced when residues 1-165 of VP22 were expressed (Figure 5.3B). 
These results indicate that the packaging levels in the presence of truncated VP22 proteins (Figure 
5.3B) reflect the expression levels of vhs detected during virus infection (Figure 4.3A). For vhs to be 
expressed and subsequently packaged to wild-type levels into the HSV-1 virion, residues 160-301 of 
VP22 need to be expressed (Figure 5.3B). As already mentioned, this region of VP22 contains the  
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Figure 5.3: VP22 residues 160-301 are sufficient to package vhs into the virion.   
A) Virions were Ficoll-purified from confluent Vero cells infected at a Moi of 0.02 with full length 
GFP-tagged VP22 expressing virus (G22:1-301) and truncated GFP-tagged VP22 expressing viruses 
(G22:108-301, G22:160-301, G22:1-165). Samples were analysed by Coomassie blue staining SDS-
PAGE gel for virion quality and to equalise loading volume; molecular weight markers (kDa) are 
shown on the left; identifiable virion components are annotated on the right. (B) Purified virions 
were analysed by Western blotting using antibodies directed against VP5, VP16, gE, gM, GFP and 
vhs. 
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VP16 binding domain which indicates a possible involvement of both VP22 and VP16 in the efficient 
expression of vhs. 
 
5.5 EFFICIENT VHS EXPRESSION DOES NOT REQUIRE VP22-VP16 COMPLEX FORMATION 
It was shown that VP22 residues 160-301 were sufficient for expression of vhs to levels of wild-type 
infection (Figure 5.1B). These residues were also shown to be sufficient for forming a complex with 
VP16 and vhs (Figure 5.2B). The next step was to examine if VP22-VP16 complex formation is 
required for efficient vhs expression and for its incorporation into the HSV-1 virion. For this, we 
made use of a virus lacking the last 38 residues of the C-terminus (452-490aa) of the activation 
domain of VP16 (Δct) and its revertant virus (ΔctR) based on wild-type strain KOS, kindly provided by 
Professor S. Triezenberg (Michigan State University)[388]. The activation domain of VP16 contains 
the VP22-binding region required for VP16/VP22 complex formation. The deletion of these residues 
of the activation domain of VP16 result in an abolished VP22-VP16 interaction in the Δct virus. To 
examine the expression of vhs in the absence of VP22-VP16 complex formation, confluent Vero cell 
monolayers were infected with HSV-1 wild-type strain KOS, Δ22, ΔCt or revertant of ΔCt virus (ΔCtR) 
at a MOI of 5. Whole cell lysates were harvested and analysed by SDS-PAGE followed by Western 
blotting using antibodies targeting VP16, VP22, vhs and α-tubulin as a loading control. While full 
length VP16 was expressed in the wt KOS, Δ22, and ΔCt revertant viruses, the ΔCt virus expressed a 
truncated form of the VP16 protein due to the deletion of the C-terminal 38 residues (452-490aa) of 
its activation domain. VP22 was also present in all lysates apart from the Δ22 virus where VP22 
expression is absent. Interestingly, Western blot analysis for vhs revealed that, although vhs 
expression was substantially reduced in the absence of VP22 expression, in our Δ22 virus, vhs 
expression was not affected by the lack of VP22-VP16 complex formation (Figure 5.4B) in the ΔCt 
virus.  
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Figure 5.4: Vhs expression does not require a VP22-VP16 complex.  
A) Line drawing of VP16 in the Wt and Δct virus. The activation domain of VP16 is shown in the grey 
box. The interaction domain of VP16 with VP22 [90] is indicated by the yellow box. B) Vero cells 
were infected with Wt, Δ22, ΔCt or ΔCtR at an MOI of 5 and whole cell lysates were harvested at 16 
hpi. Whole cell lysates were analysed by Western blot analysis using antibodies raised against VP22, 
VP16 and vhs. α-tubulin served as a loading control. C) Western blot analysis using antibodies raised 
against VP22 and VP16 for VP22-Immunoprecipitation in Wt, ΔCt, ΔCtR or Δ22.  (Figure B was kindly 
provided by Prof Gill Elliott). 
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To confirm that VP22 and VP16 interaction was abolished in the Δct virus, the virus was subjected to 
immunoprecipitation with an anti-VP22 antibody and analysed by SDS-PAGE followed by Western 
blotting for the presence of VP22 and VP16 in comparison to wild-type KOS, Δ22 and Δct revertant 
virus. Confluent Vero cell monolayers were infected with HSV-1 wild-type strain KOS, Δ22, ΔCt virus 
or its revertant (ΔCtR) at an MOI of 5. Western blotting analysis of the input samples revealed that 
the VP16 C-terminal deletion mutant (ΔCt) expresses a truncated version of the VP16 protein as can 
be seen by the faster running of this band (Figure 5.4C). Using VP22-IP, analysis showed that VP22 
was equally precipitated in all samples and VP22 did not interact with VP16 containing the C-
terminal deletion (ΔCt) as only full length VP16 was co-precipitated as observed in wild-type KOS and 
revertant virus (ΔCtR) (Figure 5.4C). In regards to vhs expression in the ΔCt virus, these results 
indicate that it is not essential for vhs to be part of a VP22-VP16-vhs tripartite complex for efficient 
expression.  This result was unexpected, as Taddeo et al. [384] have demonstrated that VP22 is 
required together with VP16 to enable accumulation of vhs protein. Hence, it would be expected to 
see reduced levels of vhs expression in the Δct virus where the VP22-VP16 interaction is abolished, if 
VP22 binding to vhs was a requirement for vhs expression to wild-type levels. 
 
5.6 VHS PACKAGING DOES NOT REQUIRE VP22-VP16 COMPLEX FORMATION 
VP22-VP16 complex formation is not required for the efficient protein expression of vhs (Figure 
5.4B). To investigate if vhs packaging requires the complex formation of VP22 and VP16, 
extracellular virion particles were ficoll-purified from BHK cells infected with wild-type strain KOS or 
ΔCt virus. The purified virion samples were then analysed by SDS-PAGE followed by staining with 
coomassie blue or Western blotting. Virions were equalised against the major capsid protein VP5, 
which also served as a loading control. The coomassie stained gel of the extracellular virions of the 
wild-type KOS and VP16 C-terminal deletion mutant (Δct) confirmed that the general protein profile 
of ΔCt virions was unaltered compared to the wild-type KOS with only the truncated VP16 being 
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different (Figure 5.5A). Immunoblot analysis of the extracellular virions confirmed that the 
interaction of VP22 with VP16 was not required for the incorporation of VP22 into virions, as 
previously shown by O’Regan et al. [277]. Immunoblot analysis of vhs revealed that vhs was 
packaged into the virions of the wt KOS and Δct in similar levels, indicating that the C-terminus of 
VP16 and thus VP22-VP16 complex formation is not required for the efficient incorporation of vhs 
into the virus particle (Figure 5.5.B). As the interaction of VP22 with VP16 is not required for 
optimum vhs expression (Figure 5.4B), nor is it required for vhs packaging (Figure 5.5B), it is possible 
that the interaction of VP22 with VP16 and vhs is involved in the regulation of vhs activity. VP22 has 
previously been suggested to play a role in vhs regulation [230, 333], however the exact mechanism 
remains to be established. 
 
5.7 VHS EXPRESSION IS NOT ENHANCED BY VP22 AND VP16 IN TRANSFECTION 
In this thesis, optimal vhs expression has been shown to require VP22 in infected cells (Figure 4.3A). 
However, no role has been found for the VP22-VP16 interaction in this optimal vhs expression. In 
contrast, Taddeo et al. [384] have suggested that VP22 and VP16 enhance the accumulation of vhs 
protein in co-transfected cells, as vhs transfected by itself did not accumulate expressed proteins, 
compared to when coexpressed with VP22 and VP16. 
To validate this observation, transient transfection assays of VP22, VP16 and vhs in the absence of 
other viral proteins was carried out. In order to determine the effect of VP22 and VP16 on the 
expression of a functional vhs protein in the absence of other viral products, we needed to ensure 
that the vhs protein expressed in transfection was functioning in nuclease activity. Therefore, prior 
to the co-transfection assay, we determined the nuclease activity of the expressed vhs protein using 
a luciferase reporter assay. For this, subconfluent HeLa cells were transfected with three different 
concentrations of plasmid phRL-TK, which expressed a Renilla luciferase reporter protein together 
with increasing concentrations of vhs. At 24 hours posttransfection, cell lysates were harvested and  
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Figure 5.5: Vhs packaging does not require a VP22-VP16 complex.  
Virions were Ficoll-purified from confluent Vero cells infected at MOI of 0.02 with the wild-type HSV-
1 strain KOS or ΔCt viruses. A) Samples were analysed by Coomassie blue staining SDS-PAGE gel; 
molecular weight markers (kDa) are shown on the left; identifiable virion components are annotated 
on the right. B) Purified virions were subjected to Western blot analysis using antibodies directed 
against VP5, VP16, VP22 and vhs. (Figures were kindly provided by Dr Julianna Stylianou.).  
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luciferase activity was quantified. According to the results, the Renilla luciferase signal decreased 
with increasing concentration of vhs expressed in transfection (Figure 5.6) indicating that vhs is 
active in mRNA degradation and functions in the absence of other viral proteins. Having established 
a functional vhs protein when expressed in transfection, we carried out co-transfection assays by 
transfecting sub-confluent HeLa cells with plasmids expressing VP22, VP16 and SV5-tagged vhs 
either alone or in combination with VP22 and VP16. After 20 hours of incubation cells were 
harvested and analysed by Western blotting with antibodies targeting VP16, VP22 and SV5 for VP16, 
VP22 and SV5-tagged vhs, respectively. Western blot analysis for VP16 and VP22 showed that both 
proteins were efficiently expressed when transfected by themselves or cotransfected with vhs 
(Figure 5.7). Western blot analysis for vhs revealed detectable protein levels of vhs in the absence as 
well as in the presence of VP22 and VP16 expression. It is of importance to note that in order to 
detect vhs protein expression by ECL analysis exposure time of up to 20min was required, whereas 
for VP22 and VP16 a blot for expression was obtained within 5-20 seconds. This is an indication of 
how poorly expressed vhs is in transfection. Furthermore, Western blot analysis for vhs showed that 
vhs expression is not enhanced by VP22 or VP16 alone or in combination when coexpressed (Figure 
5.7) which is in contrast to observations previously reported by Taddeo et al. [384]. These results 
indicate that VP22 and VP16 or both in combination do not facilitate an increased expression of a 
functional vhs by regulating its activity.  
 
5.8 CHAPTER SUMMARY 
This chapter examined the role of VP22 and its interaction with vhs and VP16 in the expression and 
packaging of vhs in the HSV-1 virion. In the previous chapter it was demonstrated that our VP22 
deletion virus (Δ22) expresses low levels of vhs in the absence of VP22 expression (Figure 4.3A). As 
VP22 has been suggested to interact with vhs in the presence of VP16 and be involved in its 
regulation of vhs activity [384] we examined the relationship of VP22 and vhs by examining the 
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Figure 5.6: Activity of vhs of Δ22 virus in the absence of VP22 and VP16 
HeLa cells were transfected with 100ng, 300ng or 500ng of Renilla luciferase (phRL-TK) and 200ng of 
vhs (pGE204) using Calcium Phosphate; harvested 24h later and Renilla luciferase levels were 
measured. Data shown represents mean average of triplicate data, from which mock transfected 
control values have been deducted to account for background auto-luminescence.  
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Figure 5.7: VP16 and VP22 are not enhancing vhs expression HeLa cells.  
HeLa cells were transfected with plasmid pcDNA-VP16, pGE109 (VP22) and pGE204 (wild-type vhs) 
either alone or in combination with each other. DNA concentrations were standardised using the 
pCMV-SV5 vector. Cells were harvested 20 h later and analysed by SDS-PAGE and Western blotting 
with antibodies against VP16, VP22 and SV5. Blots for α-tubulin were used as a loading control. 
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region of VP22 required for vhs interaction and the possible role it plays in expressing and packaging 
vhs. In order to investigate the residues of VP22 required for vhs interaction, viruses expressing GFP-  
tagged N- and C-terminal truncations of VP22 previously used to show that VP22-VP16 complex 
formation requires the C-terminal 140 residues of VP22 [7] were utilised.  It was shown that the C-
terminal seemed to be sufficient in pulling down vhs, indicating that residues 160-301 are able to 
support vhs expression (Figure 5.1B) and complex formation of VP22 with vhs (Figure 5.2B). VP22 C-
terminal residues 160-301 were also sufficient in pulling down VP16 in infected cells, indicating that 
VP22 might form a tripartite-complex with VP16 and vhs. It was examined if the possible tripartite-
complex is required to efficiently express vhs and to package vhs into the virus particle. Using a VP16 
c-terminal deletion virus that has an abolished VP16-VP22 interaction, it was shown that vhs is 
efficiently expressed (Figure 5.4B) and packaged (Figure 5.5B) in the absence of VP16-VP22 binding, 
indicating that the tripartite complex is not involved in the efficient expression of vhs nor in the 
packaging of vhs into the virion. A possible reason for the tri-part complex to exist is the involvement 
of VP22 in the regulation of vhs activity, as has been suggested in previous publications [81, 230, 
333, 384].  
As VP22-VP16 complex formation was shown not to be required for efficient vhs expression, yet 
VP22 residues were sufficient to express vhs near wild-type levels, our results suggest that VP22-vhs 
complex formation might be mediated by a different viral protein, as Taddeo et al. have suggested 
that VP22 binds vhs only in the presence of VP16 [384]. It is a possibility that during infection other 
viral proteins are involved in regulating vhs expression and maybe activity, as recently has been 
suggested by Shu et al. who demonstrated tegument protein VP13/14 to interact with vhs in 
transfection [344].  
Furthermore, we were unable to validate the observations made by Taddeo et al. [384] as in our co-
transfection assay VP22 did not enhance the accumulation of vhs in transfection. A possible reason 
for Taddeo et al. observation being different to ours might be the use of a different cells line. Taddeo 
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et al. conducted their studies in HEK293 cells, whereas we carried out our studies in HeLa cells. Vhs 
accumulation in the presence of VP22 might therefore be cell-type specific. As this assay was carried 
out in transfection, it is difficult to conclude that VP22 and VP16 or both in combination do not 
facilitate an increased expression of vhs, as our transfection assay indicates. It might be possible 
that, as already mentioned, optimum vhs expression involves a complex of viral proteins, which 
include VP16 and VP22. In order to determine a possible involvement of VP22 in regulating the 
nuclease activity of vhs the luciferase reporter assay could be utilized. The effect of VP22 on the 
nuclease activity of vhs could be determined in cotransfection assays using luciferase luminescence 
as a quantitative measurement. Other known interaction partners of VP22 and VP16, such as 
VP13/14 could be included in these assays to identify a possible co-regulation.    
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6.1 CHAPTER INTRODUCTION 
Previous publications investigating the effect of VP22 deletion on virus growth have reported 
different results for VP22 homologues in alphaherpesviruses. In BHV-1, VP22 is dispensable in cell 
culture [213], however animal studies demonstrated slow replication and reduced virulence [214]. In 
pseudorabies virus VP22 is dispensable for virus growth in cell culture and in animal studies as no 
differences to the wild-type were observed [65]. In Marek’s disease virus (MDV) and Varicella Zoster 
virus (VZV), however, VP22 is essential for virus replication in vitro and in animal studies [38, 77]. 
Studies of HSV-1 and the effect of VP22 deletion on virus growth in the Elliott lab have shown that 
VP22 is not required for virus replication in cell culture using Vero cells and that the Δ22 virus 
replicates to wild-type levels and releases virus almost as efficiently as the wild-type S17; whereas it 
is required for efficient virus growth in epithelial MDBK cells [94], indicating a cell specific 
requirement for VP22 in HSV-1 replication. While VP22 was shown not to be required for virus 
replication in cell culture, several studies indicate that VP22 is important for replication and spread 
in animal models. Duffy et al. have shown that VP22 is important for viral spread in the mouse 
cornea as it was significantly reduced to the wild-type [81]. In the last few years VP22 has also been 
shown to promote neurovirulence as the replication and spread of a Δ22 virus in the brains of mice 
following intracerebral inoculation were significantly impaired compared to the wild-type [389]. 
While VP22 has been shown to play an important role in biological systems, using cell culture based 
assays VP22 has been shown to be to be involved in promoting late protein synthesis such as the 
accumulation of glycoprotein E and gD. Despite defects observed in late protein synthesis, Δ22 virus 
is able to replicate to wild-type levels in Vero cells [82]. Considering the previous observations of 
VP22 and its requirement for virus replication in cell culture vs animal models, it is of interest to 
investigate the effect of VP22 deletion on virus growth in biologically relevant cells lines and VP22’s 
associated function of optimal protein synthesis. The following chapter will investigate if the 
requirement of VP22 for virulence can be reflected in a more relevant cell type than Vero cells, 
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which subsequently could aid to investigate and define the role of VP22 in virus replication. 
Furthermore, the effect of VP22 deletion on viral protein synthesis will be examined to determine if 
its reported role in optimum late protein synthesis [230] is cell-type specific. 
 
6.2 PROTEIN SYNTHESIS IS SHUT OFF IN THE ABSENCE OF VP22 DURING HSV-1 INFECTION 
Having confirmed that our Δ22 virus expresses wild-type vhs at reduced levels in the absence of 
VP22 (Figure 4.3A) and does not contain tegument-associated vhs activity (Figure 4.1) it was of 
interest to examine if our Δ22 virus exhibits overall host protein shutoff activity. HeLa cells were 
seeded into 6-well dishes and infected the next day with wild-type S17, Δ22 virus, Δvhs virus and Δ22 
revertant virus at an MOI 5. After 8 hours incubation the cells were treated with methionine-free 
media and [35S]-labelled methionine as described previously (section 2.9.1). We examined the overall 
host shutoff activity of our ∆22 virus compared to the wt S17, ∆41 and ∆22 revertant virus. If the ∆22 
virus exhibits an overall host shutoff activity the background protein labelling intensity of host cell 
proteins will be less compared to the mock infected cells, where no overall protein synthesis shut off 
is occurring. If there is no shutoff activity the background protein labelling intensity of host cell 
proteins will be the same as in mock infected cells.  
Analysis of overall shutoff activity revealed that at 8h post infection the wild-type virus and the 
revertant of the VP22 deletion virus (Δ22R) exhibited host cell shutoff activity as background host 
protein labelling intensity was less compared to the mock infected cells (Figure 6.1). The ∆vhs virus 
exhibited a slightly reduced host shut off activity at 8hpi as host protein labelling intensity was 
comparable to mock (Figure 6.1). The overall host shutoff activity of the Δ22 virus was very slightly 
reduced compared to the wild-type, but not as much as it was observed for the Δvhs virus (Figure 
6.1). Additionally the level of viral protein production can be examined by analysing the labelling 
intensity of synthesized viral proteins. Viral protein production in the ∆22 virus seemed to be very  
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Figure 6.1: Relative host shutoff function in our Δ22 virus early and late in infection. 
HeLa cells were infected with wt S17, Δvhs virus, our ∆22 virus and its revertant at an MOI of 5. Cells 
were treated with 50 µCi/mL [35S]-methionine after 8 hours and 16 hours and subsequently 
harvested for analysis using autoradiography. The values on the left are molecular weights in kDa. 
Arrows indicate expressed viral proteins. 
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slightly decreased at 8 hour post infection compared to the wt S17 and the ∆22 revertant virus 
(Figure 6.1). We therefore wanted to investigate if viral protein production remains reduced later in 
infection in the presence of a functional vhs. The [35S]-methionine labelling assay was repeated and 
cells were harvested 16 hours post infection for comparison. Autoradiography analysis revealed that 
after 16hours post infection the wild-type strain 17 and the Δ22 revertant virus exhibited 
comparable overall host shutoff activity as can be seen by the background protein labelling intensity 
(figure 6.1). The ∆22 virus also contained host shutoff activity. Interestingly though, the background 
host protein labelling intensity of the Δ22 virus was even more reduced compared to the wild-type 
strain 17 and Δ22 revertant virus (Figure 6.1), indicating that the ∆22 virus exhibited an overall host 
shut off activity late in infection. Additionally, viral protein production in the ∆22 virus seems to be 
decreased even more significantly at 16 hours compared to 8 hours (Figure 6.1). The reduction in 
protein synthesis may be due to the lack of vhs regulation in the absence of VP22 or to a possible 
cellular response that shuts off protein expression in the absence of VP22, such as interferon 
signalling.  
 
6.3 VP22-DEPENDENT VIRUS PROTEIN SYNTHESIS IS MORE PRONOUNCED IN PRIMARY HUMAN 
FIBROBLASTS 
VP22 was shown above to be required for optimal protein synthesis at late times in infection (Figure 
6.1). This is in agreement with other studies where protein accumulation to wild-type levels at late 
time in infection required the expression of VP22 [81, 82, 94]. These results were reported in Vero 
cells;  but it was of interest to investigate if the absence of VP22 in virus infection in physiologically 
relevant cell types exhibits a more pronounced overall protein synthesis defect as previously 
observed in Vero cells [81, 82, 94]. To assess a possible difference in VP22-dependent protein 
accumulation in physiologically relevant cells, late protein expression in the absence of VP22 was 
compared in HeLa and HFFF2 cells. These cells were chosen as HeLa cells are human derived 
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epithelial cells; and HFFF2 cells are primary cells physiologically relevant to natural HSV-1 infection 
and fully competent in antiviral signalling.  
Monolayers of HeLa and HFFF2 cells were either mock infected or infected with the wild-type S17, 
Δvhs virus or Δ22 virus at an MOI of 5. The Δvhs virus was used in this assay for comparison, as it has 
been recently shown that vhs is required for enhancing the translation of viral late mRNA [62]. The 
cells were harvested 8h and 16 h after infection, resuspended in SDS-PAGE sample buffer and 
processed for Western Blot analysis blotting for immediate early proteins ICP0 and ICP27, tegument 
proteins VP22, VP16, VP13/14, vhs, UL11, UL16, UL21 and glycoproteins gB, gC, gD, gE and gM. 
Western blotting for α-tubulin was used as a loading control.  
The data analysis of the Western blots for viral protein expression in HeLa cells revealed that there is 
no global downregulation of protein expression in the absence of VP22 (Figure 6.2). A defect in 
optimal protein synthesis at late times in infection has been observed for ICP0, gE and gD (Figure 
6.2) as previously published by Duffy et al. [81, 82]. Additionally, reduced protein synthesis was 
observed in gC, gM, gB, VP16 and UL11 (Figure 6.2). The effect of VP22-dependent protein synthesis, 
however, is more pronounced in ICP0, gC and gM compared to gE, gD, gB, VP16 and UL11.  
The Western blot analysis of viral protein expression in the absence of VP22 in HFFF2 cells also 
showed no global downregulation of protein expression in the absence of VP22 (Figure 6.3). 
However, the defect in protein synthesis at late times in infection in HFFF2 cells in the absence of 
VP22 was more pronounced for a number of viral proteins. Strikingly, the defect in VP22-dependent 
protein synthesis can be observed early in infection (Figure 6.3). The expression of VP16, VP13/14 
and UL16 was only slightly reduced, whereas the defect in protein accumulation was more extensive 
in ICP0, UL11, UL21, gB, gC, gD and gE (Figure 6.3). Interestingly, all glycoproteins tested for were 
reduced in their protein synthesis in the absence of VP22 in HeLa cells as well as HFFF2 cells. 
Glycoprotein gB, gC, gD and gM are involved in virus entry [33, 178, 346] whereas glycoprotein gE  
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Figure 6.2: Protein expression in the absence of VP22 at early and late times of infection in HeLa 
cells.  
Monolayers of HeLa cells were infected with wild-type S17, Δvhs and Δ22 virus at an MOI of 5. The 
cells were harvested at 8h and 16h and equal amounts of total cell lysates were analysed by SDS-
PAGE and Western blotting with antibodies directed at tegument proteins VP22, VP16, VP13, ICP0, 
ICP27, vhs, UL11, UL16, UL21 as well as glycoproteins gB, gC, gD, gE and gM. Western blotting for α-
tubulin was used as a loading control.  
 
 
Chapter 6                                                    VP22 is Required for Optimal Protein Expression and  
                                                                          Plaque Formation in Primary Human Fibroblasts 
199 
 
  
 
 
 
 
 
 
 
  
Chapter 6                                                    VP22 is Required for Optimal Protein Expression and  
                                                                          Plaque Formation in Primary Human Fibroblasts 
200 
 
 
 
 
 
 
 
 
 
Figure 6.3: Protein expression in the absence of VP22 at early and late times of infection in HFFF2 
cells.  
Monolayers of HFFF cells were infected with wild-type S17, Δvhs and Δ22 virus at an MOI of 5. The 
cells were harvested at 8h and 16h and equal amounts of total cell lysates were analysed by SDS-
PAGE and Western blotting with antibodies directed at tegument proteins VP22, VP16, VP13, ICP0, 
ICP27, vhs, UL11, UL16, UL21 as well as glycoproteins gB, gC, gD and gE. Western blotting for α-
tubulin was used as a loading control. 
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has been shown to be required for cell-to-cell spread of the virus [69, 70, 140, 319]. UL11 has been 
shown to function in virus egress and is also thought to be required for efficient virus spread [9, 107, 
140, 178, 425]. Therefore, the reduced expression of glycoproteins in the absence of VP22 could 
have an effect on virus spread. It would be of interest to examine if a defect in virus spread is 
observed in physiologically relevant cell types in the absence of VP22. However, the greatly reduced 
expression of immediate-early protein ICP0 needs to be taken into consideration as it is a viral 
transactivator of early and late genes [31, 32, 99, 102, 169, 170], and it has been shown to enable 
the virus to efﬁciently evade the inhibitory effects of interferon [22, 85, 131, 199, 257]. The defect 
observed in protein accumulation could be attributed to the reduced expression of ICP0 and not just 
on the absence of VP22 alone, as ICP0-deletion virus display impaired expression of immediate-
early, early, and late genes during infection. Additionally, if a defect in virus spread in physiologically 
relevant cell types is observed, the reduced expression of ICP0 could be a contributing factor to 
interferon sensitivity as previously observed in ICP0-deletion virus [256, 317]. 
The effect of VP22 deletion on proteins synthesis in Vero and HFFF2 cells was quantified using 
radiometric detection which compared infrared fluorescent signals directly proportional to the 
amount of antigen used on Western blots. For this monolayers of Vero and HFFF2 cells were infected 
with Δ22 virus and Δvhs virus at an MOI of 2, harvested 8 and 16 hours later and protein levels of  
immediate early proteins ICP0 and ICP27, tegument proteins VP16, VP13/14, UL11, UL16, UL21 and 
glycoproteins gB, gC, gD, and gE were analysed. This data was kindly provided by Dr Juliet Jones. 
Analysis showed that protein synthesis in the Δ22 virus is substantially reduced in Vero as well as in 
HFFF2 cells late in infection, with a slightly more pronounced synthesis defect in HFFF2 cells (Figure 
6.4). However, in HFFF2 cells, the reduced protein levels were also more pronounced early in 
infection. The protein synthesis of ICP0, UL21 and gC were affected the most in HFFF2 cells. These 
results are in corroboration with the Western blots results shown in Figure 6.3. Protein synthesis in 
the Δvhs virus is slightly reduced in Vero cells early and late in infection, yet still near wild-type  
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Figure 6.4: Protein synthesis is repressed in the absence of VP22.  
Monolayers of Vero or HFFF2 cells were infected with Δ22 virus or Δvhs virus and harvested at 8h or 
16h post infection. Total lysates were analysed for relative protein levels of tegument and 
glycoproteins in the absence of VP22 or vhs using Western Blot Fluorescence. Protein levels were 
compared to wt S17. (This figure was kindly provided by Prof Gill Elliott; the data was produced by Dr 
Juliet Jones for the preparation of a manuscript.) 
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levels. Surprisingly, protein levels of Δvhs in HFFF2 cells are slightly increased early and late in 
infection, yet still close to wild-type levels (Figure 6.4). These results indicate that the role of VP22 is 
more profound in physiologically relevant cell type HFFF2 compared to vhs and therefore, HFFF2 
cells might serve as an excellent cell type to investigate the role of VP22 in virus infection. 
In summary, these results indicate that VP22 is required for optimum protein synthesis early as well 
as late times of infection. The defect in protein synthesis caused by the deletion of VP22 seems to 
affect additional proteins in HFFF2 cells compared to HeLa cells and Vero cells, with VP13/14, UL16 
and UL21 protein synthesis also affected (Figure 6.3). Moreover, the defect in protein synthesis in 
the absence of VP22 is more pronounced in HFFF2 cells (Figure 6.3) than in HeLa cells (Figure 6.2) 
and Vero cells (Figure 6.4). Therefore, it can be concluded that the requirement of VP22 for optimal 
protein synthesis is greater in physiologically relevant cell types, confirming that VP22 plays an 
important role in HSV-1 replication.  
 
6.4 VP22 IS REQUIRED FOR EFFICIENT PLAQUE FORMATION IN PRIMARY HUMAN FIBROBLASTS  
The first HSV-1 recombinant VP22 deletion virus was generated by Elliott and colleagues [94]. While 
this ∆22 virus was reported to replicate to wild-type levels in Vero cells, it displayed a cell specific 
replication defect in epithelial MDBK (Madin-Darby bovine kidney) cells compared to the wild-type 
virus. However, no plaque size comparison was published in this study. Others investigating the 
deletion of VP22 reported a significantly reduced plaque size in Vero cells compared to the wild-type 
due to defects in virus release in the absence of VP22 [81, 296, 333, 389]. In this chapter, it has been 
shown that VP22 deletion results in a protein synthesis defect, which is more pronounced in 
physiologically relevant cell types (Figure 6.3) and affects proteins involved in virus entry and spread. 
It was therefore of interest to examine if viral plaque formation is affected in physiologically relevant 
cells types in the absence of VP22 expression. We assessed the phenotype of the ∆22 virus in 
monkey kidney epithelial cells (Vero) and primary human foetal foreskin fibroblast (HFFF2) and 
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compared it to the wild-type S17, ∆41 virus and ∆22 revertant virus. The Δ41 virus was used for 
comparison as vhs is known to block antiviral responses by several means including reducing 
interferon- alpha and –beta activity [80, 188, 259, 288, 380][reviewed in 34]. Therefore plaque 
formation in physiologically relevant cell types might be affected in the absence of vhs expression. 
All viruses were titrated in a ten-fold dilution and plated onto a monolayer of Vero cells or HFFF2 
cells. Plaque development was assessed in the presence of neutralising serum (1%) which contains 
anti-HSV-1 neutralising antibodies inhibiting secondary plaque formation; and thus allows the 
analysis of cell-to-cell spread.  
Plaque analysis after 4 days indicated that the Δ22 virus formed plaques on Vero cells as expected, 
but the virus exhibited a reduced plaque size compared to wild-type. The most striking and notable 
difference was observed in HFFF2 cells, where infectious centres of the Δ22 virus were close to 
undetectable (Figure 6.5). These results indicate that VP22 is important for virus growth in specific 
cell-types. The plaque size of our Δ22 virus was also compared to the plaque size of the ∆vhs virus 
which was also reported to be reduced in Vero cells [302, 358]. Plaque formation of Δvhs virus might 
be affected in physiologically relevant cell types as vhs is known to block antiviral responses [80, 188, 
259, 288, 380][reviewed in 34]. The Δvhs plaque analysis revealed that its reduced plaque size is 
comparable to the Δ22 virus in Vero cells. Surprisingly though, in HFFF2 cells the Δ41 virus produced 
plaques, whereas the Δ22 virus showed no cytopathic effect compared to the wild-type (Figure 6.5). 
This observation of a more profound phenotype of Δ22 virus in HFFF2 compared to the Δvhs virus, 
which has reduced ability to counteract antiviral responses activity, suggests that the phenotype of 
the Δ22 virus is not necessarily a consequence of an indirect effect on vhs itself. As the ∆22 revertant 
virus has regained the plaque size of wild-type S17 in all cell types, the phenotype of Δ22 virus can 
be attributed to the deletion of VP22 only and not any other coding changes in the viral genome 
(Figure 6.5).  
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Figure 6.5: Comparison of plaque morphology of Δ22 virus, Δvhs virus and Δ22 revertant virus with 
parental wild-type virus S17.   
Confluent monolayers of Vero and HFFF2 cells were infected with wild-type S17, Δ22 virus, Δvhs 
virus or Δ22 revertant virus, after 1 hour of infection the inoculum was replaced with media 
containing human serum and cells were fixed and stained after three days.  
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Having generated BAC-derived ∆22 viruses and discovered that they have obtained spontaneous 
secondary mutations within the vhs gene, it was of interest to analyse their phenotype in Vero cells 
and HFFF2 cells to see if the acquired vhs mutation has an additional effect on virus spread. The 
BAC- derived ∆22 viruses (∆22BAC4, Δ22BAC6, Δ22BAC7 and Δ22BAC17) were titrated together with 
the parental wild-type BAC strain as well as the wild-type strain S17 in a ten-fold dilution and plated 
onto a monolayer of Vero cells or HFFF2 cells. Plaque development was assessed by adding virus-
neutralising serum in to the media, thereby blocking virus spread. Plaque comparison of wild-type  
S17 with the parental BAC S17 showed that their plaque size is comparable in all cell types, which 
allows a direct plaque size comparison of the BAC-derived ∆22 viruses with our own ∆22 virus 
(Figure 6.6A). Plaque analysis of the BAC-derived ∆22 viruses (∆22BAC4, Δ22BAC6, Δ22BAC7 and 
Δ22BAC17) indicated that all VP22 deletion viruses formed plaques on Vero cells, but as expected 
the viruses exhibited a reduced plaque size compared to wild-type (Figure 6.6B). Most striking 
however, were the results in HFFF2 cells, where it was found that two of the four BAC-derived Δ22 
viruses were able to form plaques. Δ22BAC6 and Δ22BAC7 produced a small plaque size, while 
∆22BAC4 and Δ22BAC17 showed only a slight indication of cytopathic effect with infectious centres 
barely detectable (Figure 6.6B).  
Comparing the plaque size of our Δ22 virus in HFFF2 cells (Figure 6.5) with the plaque development 
of the BAC-derived Δ22 viruses (∆22BAC4, Δ22BAC6, Δ22BAC7 and Δ22BAC17) (Figure 6.6B) the 
plaque sizes of our Δ22 virus is comparable with ∆22BAC4 and ∆22BAC17 only, as Δ22BAC6 and 
Δ22BAC7 exhibited a slightly larger plaque size. The differences seen between our Δ22 virus and the 
BAC-derived Δ22 viruses could be due to the additional mutations found within the vhs gene or any 
other additional viral gene mutation acquired during virus rescue. As vhs mutations have been 
suggested to rescue VP22 dependent translation [230], it is possible that the discovered vhs 
mutations within the BAC-derived Δ22 viruses also enables slight recovery of plaque formation. 
However, it is not possible to attribute this effect in virus spread to a particular vhs mutation.  
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Figure 6.6: Comparison of plaque morphology of BAC-derived Δ22 viruses with parental HSV-1 
virus.  
A) Confluent monolayers of Vero and HFFF2 cells were infected with wild-type S17 and wtBAC, after 
1 hour of infection the inoculum was replaced with media containing human serum and cells were 
fixed and stained after three days for Vero cells and five days for HFFF2 cells. B) Confluent Vero and 
HFFF2 cells were infected with wild-type BAC S17 (wtBAC) or BAC-derived Δ22 viruses (Δ22BAC4, 
Δ22BAC6, Δ22BAC7 and Δ22BAC17). After 1 hour of infection the inoculum was replaced with media 
containing human serum. Cells were fixed and stained after three days for Vero and HFFF2 cells. 
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The different results of the plaque sizes of the BAC-derived Δ22 viruses on HFFF make it difficult to 
draw any clear conclusion, as it is possible that mutations other than vhs have occurred during the 
rescue of these viruses which might affect virus growth; and they need to be ruled out before 
making conclusions. Nonetheless, these results emphasize the importance of choosing a cell line for 
function-defining studies as results can differ between different cell types. 
 
6.5 VP22 HAS A POSSIBLE ROLE IN INTERFERING ANTIVIRAL RESPONSES  
It has been shown that the absence of VP22 expression severely affects the virus spread in HFFF2 
cells (Figure 6.3) which are physiologically relevant to natural HSV-1 infection and are fully 
competent in antiviral signalling. It can be hypothesized that one possible reason for the lack of viral 
spread in HFFF2 cells in the absence of VP22 is the possible involvement of VP22 in interfering with 
antiviral responses. In order to investigate if VP22 plays a role in blocking antiviral responses and if 
the interferon system plays a role in the restricted growth of the ∆22 virus in HFFF cells, monolayers 
of the cell line were either mock infected or infected with the wild-type S17, Δvhs virus and Δ22 virus 
at an MOI of 1. The cells were harvested 24h after infection, resuspended in SDS-PAGE sample 
buffer and processed for Western Blot analysis. To confirm that interferon stimulated genes are 
activated by interferon in response to virus infection mock cells were treated with interferon beta 
(IFN-) as a positive control and incubated alongside infected cells. Western blots of the viral 
proteins were carried out with antibodies against VP22, VP16, ICP0, gC and interferon stimulating 
gene 15 (ISG15).  
Western Blot analysis revealed a band for ISG15 detection in the interferon beta (IFN-) treated cells 
which confirm that the positive control has worked (Figure 6.7) and that HFFF2 cells induce ISG15 in 
response to interferon. Western Blot analysis of the infected cell lysates revealed that after 24h of 
infection no induction of ISG15 can be detected for wild-type S17, whereas in the Δ22 virus and Δvhs 
virus infections there is a clear increase in the level of ISG15 (Figure 6.7). This indicates that while  
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Figure 6.7: Expression of interferon stimulated genes in the absence of VP22.  
Monolayers of HFFF2 cells were infected with wild-type S17, Δvhs, Δ22 virus at an MOI of 1. Cells 
were harvested at 24h post infection and equal amounts of total cell lysates were analysed by SDS-
PAGE and Western blotting for viral proteins VP22, VP16, ICP0 and gC as well as interferon 
stimulating gene 15 (ISG15). As a positive control cells treated with 500IU/ml interferon beta (IFN-) 
were incubated alongside. Western Blotting for α-tubulin was used as a positive loading control. 
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the wild-type virus is able to block ISG15 activation, this ability is greatly reduced in both the Δ22 
and the Δvhs viruses. The Δvhs virus was chosen for comparison as it has been shown that vhs is 
involved in evading host immunity by several means including reducing interferon- alpha and –beta 
activity [80, 188, 259, 288, 380][reviewed in 34]. The lack of vhs expression, therefore potentially 
should lead to the activation of ISG15 as interferon signalling is not blocked.  The observation that 
VP22 possibly functions in blocking anti-viral response is exciting as it provides a new insight into the 
role of VP22 in infection and presents new opportunities for research. 
 
6.6 CHAPTER SUMMARY 
This chapter looked at the possible role VP22 may play during HSV-1 infection in physiologically 
relevant cell type HFFF2. VP22 has been extensively studied in the last two decades, but no precise 
role has been established for this tegument protein during HSV-1 infection. VP22 interacts with 
several other viral proteins, including tegument and glycoproteins [41, 94, 107, 225, 226, 277, 377]. 
Historically, HSV-1 replication has been studied in Vero cells and the majority of functions or roles 
established for viral components have been made in this cell line. The drawback of using Vero cells 
however, is that they are highly permissive, are not of human origin and lack cellular antiviral 
responses [40, 254]. Therefore, data obtained might not fully reflect natural HSV-1 infection and 
some determined functions might be of more importance than thought.  
For VP22, it has been reported that plaque formation is reduced in size in its absence but only by 
40% in Vero cells compared to plaques produced by the wild-type virus [81]. In order to investigate 
and confirm the requirement of VP22 in virus spread, the more relevant cell line HFFF2 was utilised. 
Strikingly, plaque formation was severely restricted in HFFF2 cells in the Δ22 virus compared to the 
wild-type, as it exhibited no cytopathic effect at all after 3 days (Figure 6.5), confirming that VP22 
plays a significant role in virus replication and/or plaque formation in physiologically relevant cells; 
much more than thought when observed in Vero cells. Even though the Δ22 virus contains some 
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coding changes compared to the wild-type S17 (Table 3.1) the phenotype of the Δ22 virus observed 
in HFFF2 can be attributed to the deletion of VP22 as the ∆22 revertant virus had regained the 
plaque size of wild-type S17 (Figure 6.5).  
The lack of plaque formation in HFFF2 cells could be due to reduced replication, reduced cell-to-cell 
spread or a combination of both.  This data emphasises the importance of using investigation tools 
as close to the natural system as possible in order to establish viral replication processes and viral 
component functions during natural HSV-1 infection. HFFF2 cells appear to be a highly suitable cell 
line to investigate VP22 in virus infection as the lack of VP22 showed such a severe defect in virus 
spread.  
Another function attributed to VP22 during virus infection is the optimum protein synthesis late in 
infection [82]. In this study it was confirmed that VP22 plays a role in protein production late in 
infection using HeLa and HFFF2 cells. However, it was also shown that VP22 functions in protein 
synthesis early in infection, in particular in HFFF2 cells. This suggests that VP22 plays an important 
role in optimum protein synthesis throughout the virus life cycle. As already shown in Chapter 4, vhs 
is one of the proteins affected in its synthesis in the absence of VP22 in (Figure 4.3A). Previous 
publications investigating the effect of VP22 deletion also reported reduced expression of vhs during 
virus infection in Vero cells [82, 230, 333].  
This relationship of VP22 and vhs was confirmed in HFFF2 cells, where vhs expression was shown not 
to be detectable. The other proteins severely affected in synthesis in the absence of VP22 in HFFF2 
cells are ICP0, UL11 and glycoprotein C, gD and gE. These might only be a small subset of protein 
affected, as they were the only ones tested for. ICP0, gC and vhs are involved in fighting antiviral 
responses by blocking interferon signalling [86, 144, 222, 259]. As their levels are severely reduced in 
the absence of VP22, it is possible that the lack of plaque formation in HFFF cells is the result of 
reduced inhibition of antiviral signalling and that the defect in virus spread is due to the reduced 
levels of a combination of viral proteins and their function. Figure 6.7 shows that in the absence of 
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VP22 interferon-stimulating-gene 15 (ISG15) is activated by interferon in HFFF2 cells in response to 
virus infection. This supports a possible role of VP22 in immune evasion, directly or indirectly. 
Furthermore, previous publications reporting reduced pathogenesis in the absence of VP22 in 
mouse models support the idea [81]. However, as shown in Figure 6.7 the expression of ICP0 is 
reduced during Δ22 infection in HFFF2 cells. ICP0 has been shown to play an important role in 
blocking antiviral responses by blocking the activation of interferon regulatory factor 3 (IRF3), a key 
transcription factor of the innate antiviral response [391].  As the synthesis of ICP0 is reduced in the 
absence of VP22, it could be argued that the activation of ISG15 is an effect seen due to the 
decreased ICP0 expression, rather than VP22 deletion. Nevertheless, if not direct, VP22 might play 
an indirect role in blocking antiviral responses via its interaction with ICP0. 
 
Considering the data, it is very likely that VP22 is important for virus growth throughout the entire 
life cycle and is involved in many aspects of it, as reflected in the lack of plaque formation and 
reduced optimum protein synthesis in HFFF2 cells.  
 
In conclusion, it is very important to study HSV-1 infection in physiologically relevant cell types in 
order to examine and define functions of viral proteins and their interaction. Primary human 
fibroblasts are shown here to be a good model for studying VP22 and its many associated functions 
in HSV-1 infection as we have shown here that the importance of VP22 is more pronounced in HFFF2 
cells. 
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This thesis characterised the relationship of tegument proteins VP22 and vhs during virus infection. 
It is demonstrated that, contrary to previous publications [82, 230, 333], wild-type vhs functional in 
overall host shutoff activity can be expressed in the absence of VP22 expression. Therefore, a 
functional vhs is not lethal for virus replication in the absence of VP22 as previously reported [333]. 
Despite the ability to express a functional wild-type vhs in the absence of VP22 during infection, a 
relationship of these two proteins is existent in that VP22 is required for optimum vhs expression. 
Furthermore, this study showed that VP22 is required for optimum protein synthesis early and late 
in infection as well as for plaque formation in primary human foetal foreskin fibroblasts (HFFF2) 
which are physiologically relevant to HSV-1 infection as they are able to generate antiviral responses. 
It is demonstrated that it is important to use an appropriate cell type which resembles as close as 
possible the natural environment of HSV-1 infection in order to study and define protein functions, 
as in the case of VP22 the requirement for plaque formation was not observed in non-physiologically 
relevant cells [81, 82, 333], nor was the effect of VP22 deletion on protein synthesis early in 
infection [82, 230]. 
 
7.1 MODE OF VIRUS RESCUE AS A CONSIDERATION IN VIRUS RECOMBINATION  
Over the last few years BAC recombination has become an invaluable tool for studying herpesviruses 
and has contributed to the understanding of the viral replication cycle. As they are able to maintain 
large genomic DNA inserts without any selective pressure on the virus genome, and provide ease in 
manipulating genes they have become the primary choice in creating recombinants for functional 
studies [reviewed in 16], including the generation of VP22 deletion viruses [81, 230, 333].  
It was reported by two individual groups that the deletion of VP22 using BAC recombination resulted 
in multiple spontaneous secondary mutations within a conserved region of vhs rendering it inactive 
[230, 333] indicating that viruses with VP22 deleted require secondary mutation of vhs in order to be 
viable. However, we have found, using sequencing analysis, that our VP22 deletion virus which was 
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generated by classical homologous recombination expressed a wild-type vhs and was replication-
competent (Figure 3.12). Additional full genome sequencing ruled out any other secondary 
mutations which may have conferred viability to our VP22 deletion virus, such as mutations in the 
vhs promoter or the UL13 kinase that previously have been shown to result in a vhs-negative virus 
[283].  
It is possible that the different observations in vhs integrity in the absence of VP22 were due to the 
different strains used as our Δ22 deletion virus was generated in wild-type strain 17 instead of strain 
F. While it has been shown that vhs activity is type-specific between HSV-1 and HSV-2 with HSV-2 
displaying a more rapid and complete shutoff [103, 104], no strain specificity has been shown 
between strain F and S17. According to the published sequence (GenBank no. GU734771.1) and our 
own sequencing data (Figure 3.12) strain F vhs has amino acid changes compared to s17, which may 
lead to different vhs activities. However, we have shown that overall vhs activity between strain 17 
and F is equivalent (Figure 3.2) and exhibited similar protein synthesis profiles during virus infection 
(Figure 3.1). As we found that both strains seemed to exhibit similar strength in vhs activity at least 
in our hands, it did not provide a possible explanation why differences in vhs integrity were observed 
in the absence of VP22.  
Another obvious difference between our VP22 deletion virus and the other published VP22 deletion 
viruses was the method used for HSV-1 gene manipulation as well as the mode of virus rescue used. 
The VP22 deletion viruses containing an inactive mutant vhs were generated using the popular BAC 
recombination method, whereas our VP22 deletion virus (Δ22) was generated using classical 
homologous recombination. In order to test the hypothesis that the use of BAC recombination for 
VP22 deletion in HSV-1 results in spontaneously acquired secondary mutations within vhs, BAC 
recombination was used to create a VP22 deletion in our lab strain 17. Subsequent sequence 
analysis revealed that a total of nine individual isolates contained multiple secondary mutations with 
the vhs gene. These mutations were identified as single nucleotide mutations. While these 
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mutations led to amino acid coding changes within vhs , they did not lead to gross deletions or 
mutations of vhs as was observed in the VP22 deletion viruses in strain F published by other groups 
[230, 333]. While it could still be argued that the more severe mutations of vhs observed in strain F 
in the absence of VP22 are due to strain specificity, the clear observation remains that vhs acquires 
secondary mutation during VP22 deletion when BAC recombination was used. However, as already 
mentioned, the mode of virus rescue also differed in the generation of our VP22 deletion virus and 
viruses generated by other groups [230, 333]. Therefore, the mode of virus rescue needs to be 
considered as a possible factor leading to vhs mutations in the absence of VP22.  
Our VP22 deletion virus was rescued in a VP22-complementing cell line whereas the VP22 deletion 
virus generated by other groups were rescued in Vero cells [230, 333]. Comparing the mode of virus 
rescue used for the generation of VP22 deletion viruses and considering that the vhs sequence of 
the input BAC was confirmed to be wild-type for our VP22 deletion virus as well as for the other 
published VP22 deletion viruses, leads to the hypothesis that virus rescue in cells where no VP22 is 
present creates pressure to mutate vhs rendering it inactive in order to propagate a VP22-deficient 
virus. Duffy et al. previously generated a VP22 deletion virus using BAC recombination; however, it 
was reported that this virus did not contain mutations within the vhs gene. The likely reason for this 
observation is the fact that virus rescue of the generated BAC recombinant was carried out in VP22 
expressing cells [82] which supports our conclusion.  
Seeing that direct transfection of infectious DNA lacking the VP22 gene into cells where no VP22 is 
present leads to pressure to inactivate vhs, it might explain why the revertant virus of our VP22 
deletion virus contains a single amino acid change (R257C) that was not present in the originating 
Δ22 genome (Figure 3.12). It is possible to generate a VP22 deletion virus with an intact vhs gene, as 
we have shown in this thesis, as long as the right environment for virus rescue and propagation is 
created. Nevertheless, while it was shown in this study that a functional vhs is not inherently lethal 
for virus replication in the absence of VP22 in contrast to previous publications [230, 333], it does 
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not imply that no relationship between VP22 and vhs exist in virus replication, as vhs expression is 
reduced in the absence of VP22 during virus infection. Additionally, it is striking that the majority of 
nucleotide changes leading to amino acid coding changes identified in nine individual VP22 deletion 
virus isolates generated by BAC recombination clustered in domain III of the vhs gene (Figure 3.12), 
which has been shown to be conserved amongst alphaherpesviruses [20]. 
 
7.2 UNDERSTANDING THE RELATIONSHIP OF VP22 AND VHS IN HSV-1 INFECTION 
An indication that a relationship between VP22 and vhs exist in virus replication was first suggested 
during the generation of a VP22 deletion virus which accumulated deletion and frameshift mutations 
in vhs when propagated on non-complementing cells, suggesting the presence of vhs was 
detrimental in the absence of VP22 [333]. While it was shown in the preparation of this thesis that 
an intact vhs is not lethal for virus replication in the absence of VP22 expression, it cannot be denied 
that a possible relationship between VP22 and vhs exist during virus replication, probably involving 
the regulation of vhs expression.  
VP22 has been suggested by Taddeo and colleagues [333] to play a role in regulating vhs activity as 
vhs protein levels but not mRNA levels were increased in transient transfection assays when 
coexpressing both VP16 and VP22. An indication for a relationship of VP22 and vhs in virus infection 
is the observation that vhs expression is greatly reduced in the absence of VP22 in every cell type 
analysed (Figure 4.4). Similar low level of cellular vhs has been reported in other Δ22 virus infections 
[82, 104] indicating a relationship of VP22 with vhs. Additionally, a further possible indication of a 
relationship between VP22 and vhs in regards to vhs activity regulation is the observation in this 
thesis that the majority of nucleotide changes leading to amino acid coding changes identified in 
nine individual VP22 deletion virus isolates generated by BAC recombination clustered in domain III 
of the vhs gene (Figure 3.12). Domain III, as already mentioned, has been shown to be a conserved 
region containing residues essential for vhs activity [168, 194, 372]. Additionally, mutational analysis 
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of domain III indicated that this region is required for virulence [372]. It could be hypothesized that 
vhs acquires mutations in the absence of VP22 favourably in domain III in order to reduce or even 
abolish its activity of host cell protein shutoff, due to the possibility that unregulated vhs activity is 
detrimental to efficient virus replication, as it creates an unfavourable environment by degrading 
viral as well as host cell mRNA uncontrollably.  In support of this hypothesis is the observation by 
Lam et al. who reported that in the absence of VP16 expression, viral protein synthesis and mRNA 
levels undergo a severe decline during infection with a VP16 null mutant, culminating in virtually 
complete translational arrest. Therefore, any host infected cell might be unable to facilitate efficient 
virus replication, if viral proteins required in viral replication processes cannot be synthesized to an 
optimum level early in infection in order to facilitate efficient and productive viral replication late in 
infection.  
Mutational analysis into vhs has been carried out to identify particular amino acids that are required 
for vhs activity. Everly et al. identified possible amino acid differences likely to be responsible for 
type-specific differences in vhs activity [103]. Strand et al. [371] have identified the VP16 binding 
domain of vhs to be required for tegument derived RNA degradation activity as well as wild-type 
replication and virulence, but not for VP16 binding and packaging, as originally demonstrated [302, 
329, 350]. Even though nucleotide regions comprising the VP16 binding domain of vhs have been 
identified to be required for vhs activity, these do not correlate with any mutations observed in our 
BAC-derived VP22 deletion viruses (Figure 3.12).  Strelow et al. however, have identified that 29- and 
31 amino acids deletions in domain III and IV, but outside the VP16-binding domain abolished RNA 
degradation activity as well as virulence [372]. Despite Strelow’s observation, it cannot be concluded 
that the reason they cluster in domain III is because it is purely required to inactivate vhs activity as 
other nucleotides, including within the VP16 binding domain, have been demonstrated as a 
requirement for the degradation activity of vhs [371].  
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We did not establish if our BAC generated VP22 deletion viruses expressing mutant vhs exhibited 
overall host shutoff activity, as the mere fact that several individual isolates lacking VP22 expression 
had acquired several point mutations within vhs indicated that the cause for the acquired vhs 
mutations was the requirement to mutate vhs in the absence of VP22. However, as we have 
subsequently demonstrated that the revertant of our VP22 deletion virus exhibits overall host cell 
shutoff activity likely to be conferred by the expressed vhs which has an amino acid change (Figure 
6.1), it would be of interest to see if the BAC-derived VP22 deletion viruses express a functional vhs 
despite present mutations (Figure 3.12). Furthermore, it was shown that our Δ22 virus contains 
overall vhs activity during virus replication (Figure 6.1) unlike other generated Δ22 virus viruses [230, 
333] confirming that our Δ22 expresses a functional vhs in the absence of VP22. Nevertheless, a 
relationship between VP22 and vhs is thought to exist in virus replication as vhs expression is 
reduced in the absence of VP22 [82, 104].  
VP16 has been shown to directly interact with vhs [329, 350]. Furthermore, VP16 has been 
demonstrated to regulate vhs activity late in infection [182, 198, 302, 303]. Lam and colleagues have 
shown that VP16-null mutants exhibited enhanced degradation of host and viral mRNA leading to 
almost complete arrest of viral protein synthesis [198]. Knez et al. confirmed that VP16-vhs binding 
is required to downregulate the RNase activity of vhs [182]. In addition to VP16, tegument protein 
VP22 was also suggested to regulate vhs activity by Taddeo and colleagues [384]. Rather than block 
RNase activity, VP22 is thought to rescue viral mRNA in conjunction with VP16, and makes it 
available to the machinery of the cell for translation [384].  
VP22 is thought to carry out vhs regulation via its interaction with VP16 as it does not directly bind 
to vhs [384]. We have shown that the same C-terminal residues 160-301 that are sufficient to bind 
VP16 [136], are also sufficient to interact with vhs (Figure 5.2B). Additionally, it was shown that the 
C-terminal residues 160-301 of VP22 are required for assembly of vhs to wild-type levels [136]. This 
observation led us to investigate if the interaction of VP22 and vhs is involved in recruiting vhs into 
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the virus particle. While vhs packaging is reduced in the absence of VP22 (Figure 4.2B), it is more a 
reflection of the levels of vhs expressed in the absence of VP22, rather than a reflection of absent 
VP22 packaging. Using a virus containing a 38 residue C-terminal deletion (452-490aa) in the 
activation domain of tegument protein V16, thereby abolishing VP16-VP22 binding, we have shown 
that vhs packaging to wild-type levels occurs independent of VP22 (Figure 5.5B), as vhs has been 
shown to only to bind VP22 in the presence of VP22-VP16 binding [384]. These results indicate that 
the interaction between VP22 and vhs is more likely to be involved in regulating vhs expression 
during virus infection. vhs has previously been shown to be packaged by VP16 as a large deletion in 
the vhs protein that included the VP16-binding domain failed to package vhs [302]. Therefore, vhs 
might be part of the VP1/2-VP16 complex that has been shown to be important for viral assembly of 
VP16 into the virion capsid [381].  
We have shown that optimum vhs expression required the expression of VP22 in infection (Figure 
4.3A). Taddeo et al. reported that vhs only accumulated to detectable levels in the presence of VP16 
and VP22 expression in transfection [384]. We aimed to validate these results using transient 
transfection assay. While vhs was poorly expressed and Western blotting required long exposure 
times to detect protein levels, our results were in stark contrast to Taddeo’s results [384]. In our 
hands vhs expression levels did not increase in the presence of VP22 and VP16 (Figure 5.7). A 
possible reason for Taddeo et al. observation being different to ours is the use of a different cells 
line. Taddeo conducted his studies in HEK293 cells, whereas we carried out our studies in Hela cells. 
Whilst in infection VP22 seems to be required for vhs expression, as has been shown by others [82, 
104], VP22 does not seem to improve expression of vhs in transfection when coexpressed (Figure 
5.7). It seems that VP22 alone does not seem to be sufficient for vhs to accumulate, therefore vhs 
might not actually require the presence of VP22 alone during active virus replication as previously 
suggested [384]. It is possible that VP22 does not function alone to increase expression levels of vhs; 
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and that other viral factors are involved in optimum expression of vhs via their association with 
VP22.  
Recently VP13/14, in addition to ICP27, has been demonstrated to interact with vhs and regulate its 
activity [344, 387]. Additionally, research in our lab by Dr Julianna Stylianou has shown that VP13/14 
is able to complex with VP22 in infection. It could by hypothesised that VP22 is enhancing vhs 
expression and possibly regulate vhs activity in combination with VP13/14 and VP16 via its 
interaction with these proteins. Additionally, VP22 might be responsible for enabling optimum vhs 
expression together with ICP27; however an interaction of VP22 with ICP27 remains to be 
established. It is likely that the regulation as well as the packaging of vhs includes a much larger 
protein complex than previously thought (Figure 7.1) as VP13/14 and ICP27 have also been shown to 
interact [72].  
As it was shown that VP22 does not enhance vhs expression by itself or in combination with VP16 in 
transfections assays (Figure 5.7), it would be of interest to investigate if they nonetheless regulate its 
activity. Attempts were made to establish if VP22 is involved in regulating vhs activity using a 
luciferase reporter assay. However attempts so far have remained unsuccessful (data not shown). 
Even though a trend of vhs activity regulation by VP22 was observed, no certain conclusions could 
made as measurements of luciferase luminescence could vary considerably during coexpression 
studies and  might not be the true reflection of vhs activity and its possible regulation by VP22. The 
inconsistency seen in the luciferase assay could be due to operator errors in pipetting small volumes. 
If the luciferase reporter assay is able to be optimised, it would be advisable to include VP13/14 and 
maybe ICP27 in the transfection studies looking at vhs expression levels and activity to examine if 
VP22 is regulating expression and activity of vhs in conjunction with either, VP16, VP13/14 or ICP27 
or any other protein combination.  
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Figure 7.1: Protein-protein interactions identified around tegument protein vhs. 
A small network of protein interactions identified for vhs in HSV-1 which are involved in efficient 
protein expression, virion packaging and regulating vhs activity. [72, 329, 344, 350, 381, 384, 387]. 
Solid lines indicate direct interactions and broken lines indicate indirect interactions identified. Red 
lines indicate interactions identified by Dr Julianna Stylianou in the studies for her thesis.  
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VP22 has also been shown to bind RNA, and with even higher affinity ssDNA in transfection and 
infection [76, 334]. It is suggested that VP22 binds RNA and transports it to adjacent uninfected cells 
where it is subsequently expressed, thereby creating an environment necessary for efficient viral 
replication in advance of the infection itself [334]. We have shown that in the absence of VP22 
expression, vhs protein levels are substantially reduce despite the fact that vhs mRNA is transcribed 
to wild-type levels (Figure 4.5). Having also shown that vhs is not subjected to proteasomal 
degradation in the absence of VP22 (Figure 4.6), vhs protein levels are potentially reduced due to 
inefficient translation. Additionally, we were able to generate a VP22 deletion virus with a functional 
vhs (Figure 6.1). Considering these results, it could be hypothesized that VP22 enables efficient vhs 
expression by binding to its transcribed mRNA. Taking into account Sciortino et al. observation [334], 
VP22 may also transport vhs mRNA into neighbouring cells in order to ensure subsequent efficient 
viral replication of incoming virus particles.  
 
7.3 VP22 IS IMPORTANT FOR HSV-1 PATHOGENESIS  
VP22 is not an essential tegument protein for viral replication at a high multiplicity as VP22-deletion 
virus are able to replicate to wild-type levels in Vero cells [81, 82, 94, 230, 333]. Despite being non-
essential in cell culture, animal models have shown a requirement of VP22 for pathogenesis [81]. 
VP22 has been associated with a number of functions, including the regulation of the virion host 
shut off (vhs) activity [230, 384], the transport of viral mRNA to uninfected cells for initiation of 
infection [334], and the accumulation of late protein in virus infection [82, 94]. It is of importance to 
point out that all the functions assigned to VP22 have been mainly studied in non-physiological cell 
types or cell types void of antiviral responses. Therefore, the importance of these functions might be 
undervalued, especially as it has been shown that in animal models the lack of VP22 expression 
results in reduced pathogenesis [81]. 
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Duffy et al. reported that VP22 deletion results in reduced optimum protein synthesis at late times in 
infection and reduced accumulation of viral mRNAs at early times in infection, at least for gE, gD, and 
vhs [82]. Later in infection the reduced levels of mRNA had recovered [82]. Our VP22-deletion virus 
also exhibits reduced protein accumulation late in infection in Vero and HFFF2 cells (Figure 6.4). 
While this is in agreement with Duffy’s observation [82], we have also shown that our VP22 deletion 
virus exhibits reduced viral protein accumulation early in infection, particularly in HFFF2 cells (Figure 
6.4) differences may be due to the different parental HSV-1 strains used, as Duffy et al. use strain F 
and our lab uses strain 17. Additionally, we have identified additional viral proteins whose 
expression is negatively affected in the absence of VP22. As well as ICP0, gE and gD we have also 
identified glycoproteins gC, gM, gB, and tegument proteins UL11, UL16, UL21 to be reduced in 
protein accumulation. The effect of VP22 deletion on viral protein accumulation early and late in 
infection was more profound in HFFF2 cells, which is of high interest as these cells are physiologically 
relevant to HSV-1 infection and are able to express antiviral responses. These results suggest that 
VP22 plays an important role in optimum protein synthesis throughout the virus life cycle. When 
analysing the effect of VP22 deletion on viral protein synthesis and virus life cycle, the reduced 
protein levels of ICP0 need to be taken into consideration, as the reduced levels of ICP0 might 
contribute to the observed phenotype of the Δ22 virus. Previous studies using ICP0-deletion virus 
have shown that early and late gene expression require ICP0 for efficient progression [31, 32, 169, 
256]. Therefore, the observed reduced expression of viral early genes (gD, gE) and late genes (gC, gB, 
UL21) in HFFF2 cells (Figure 6.3) might be a contribution of reduced ICP0 expression and not solely 
down to VP22-deletion.  
Duffy et al. have also reported that the protein translation defect observed in the absence of VP22 is 
complemented by mutations within vhs rendering it inactive [230]. This observation supports the 
idea that VP22 is involved in regulating vhs nuclease activity [230]. It is therefore, possible that the 
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reduced protein levels in our VP22 deletion virus are due to the active vhs, which has reduced 
regulation in the absence of VP22. 
 
It has been shown that vhs enhances the translation of late viral mRNA during infection, by 
preventing mRNA overload in a cell type-dependent manner as the accumulation of true late-gene 
proteins gC and US11 were strongly reduced in the absence of vhs in HeLa cells and several other 
restrictive cell lines, but not in Vero cells and other permissive cell lines [61, 62]. While our results 
agree with the observation that viral protein production is reduced in the absence of vhs expression 
in Vero cells (Figure 6.4), our data does not agree with the observations made for non-permissive 
cell lines, as overall protein accumulation is slightly increased in our HFFF2 cells early and late in 
infection (Figure 6.4). And any reduction in protein levels observed early in infection had increased 
above wild-type levels late in infection, apart for VP13/14. Additionally, the reduction in protein 
accumulation levels observed for our vhs deletion virus do not seem as severe, as the measured 
protein levels are close to wild-type levels in contrast to the reduced protein levels observed in our 
VP22 deletion virus (Figure 6.4).  
Comparing our data with Dauber’s et al. observation [61, 62] we cannot conclude that vhs enhances 
late viral translation in restrictive cell lines. Our data on late protein production in the absence of 
VP22 seems more convincing in the role of VP22 in protein accumulation, especially in restrictive 
cells lines. The observation that vhs expression in the absence of VP22 was detectable in non-human 
cell lines, however non-detectable in physiologically relevant cell lines (Figure 4.4) indicates that the 
relationship of VP22 and vhs may seems to be more relevant in physiologically relevant cell lines; 
and therefore supports the use of appropriate cell types to study the function of viral proteins. This 
conclusion is supported by the preliminary results showing increased expression levels of interferon-
stimulating gene 15 in the absence of VP22, indicating a possible role of VP22 in interfering with host 
cell responses. VP22-deletion viruses have been reported to be exhibit a slightly reduced plaque size 
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in Vero cells compared to plaques produced by the wild-type virus [81, 333], suggesting a role for 
VP22 is virus spread. Having observed that VP22 deletion has a more profound effect on protein 
accumulation in restrictive cell line HFFF2, we were interested if that also translates into virus 
spread. Expecting a reduced plaque size in HFFF2 cells, it was still very striking to see that our VP22 
deletion virus exhibited no plaque formation at all after 3 days (Figure 6.5). This observation 
confirmed that VP22 plays a significant role in virus replication and/or plaque formation in 
physiologically relevant cells; much more than thought when originally observed in Vero cells. As our 
∆22 revertant virus has regained the plaque size of wt S17 (Figure 6.5) we can be assured that the 
lack of plaque formation is not due to any other secondary mutations. Full genome sequencing has 
also confirmed that no other cross mutations are present in our VP22 deletion virus (Table3.1). The 
lack of plaque formation indicates that virus growth/spread is severely affected.  
Considering our data looking at protein synthesis in the absence of VP22, the lack of plaque 
formation could possibly be attributed to the reduced expression of the glycoproteins as well as 
UL11 in the absence of VP22 (Figure 6.2). Glycoprotein gB, gC, gD and gM are involved in virus entry 
[33, 178, 346] whereas glycoprotein gE has been shown to be required for cell-to-cell spread of the 
virus [69, 70, 140, 319]. UL11 has been shown to function in virus egress and is also thought to be 
required for efficient virus spread [9, 107, 140, 178, 425]. Therefore, the reduced expression of this 
small set of proteins might contribute to the lack of plaque formation observed in the HFFF2 cells in 
the absence of VP22 (Figure 6.3). However, it is important to point out that HFFF2 cells are able to 
generate an antiviral response and that the restricted spread in HFFF2 cells in the absence of VP22 
may not be just due to the reduced expression of viral proteins involved in viral spread, but could be 
caused by immune pathways interfering with plaque formation. Furthermore, considering that 
HFFF2 cells express antiviral responses and plaque formation is inhibited in the VP22 deletion virus, 
these suggest that VP22 might be a virulence factor in HSV-1 replication. Preliminary data presented 
here (Figure 6.7) suggest that VP22 is required for blocking expression of interferon stimulated 
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genes, indicating that VP22 might function in blocking interferon. Previous publications reporting 
reduced pathogenesis in the absence of VP22 in mouse models support the role of VP22 as a 
virulence factor in HSV-1 infection [81]. However, as ICP0 expression levels are reduced in the 
absence of VP22 in HFFF2 cells (Figure 6.3) the reduced efficiency in blocking antiviral responses 
could partly be attributed to low levels of ICP0. This is due to its ubiquitin ligase activity, which 
directs proteasome-dependent degradation of nuclear ND10 components inducible by interferon, 
being reduced [22, 56, 199], as well as the reduced expression of other viral proteins downstream of 
the temporal gene expression cascade which are involved in antiviral response evasion [31, 32, 169, 
256]. Nevertheless, the data presented here has shown the importance of using a cell type as close 
to the natural system as possible in order to investigate viral replication. Furthermore, we have 
identified HFFF2 cells an appropriate cell line to investigate VP22 and its role in viral infection in 
regards to interfering with antiviral responses. 
 
7.4 FUTURE DIRECTIONS 
From the results presented here, it has become apparent that our Δ22 virus expresses a wt vhs 
protein. Additionally, it was determined that the revertant (Δ22R) expresses a mutant vhs. Having 
determined that both viruses contain overall host shutoff activity conferred by their vhs activity it 
would be of interest to determine if any of our BAC-derived Δ22 viruses which have been shown to 
express mutant vhs exhibit host cell shut off activity and thus a functional vhs protein. If it is found 
that functional as well as non-functional vhs is expressed, the previous sequencing analysis of vhs for 
the BAC-derived VP22-deletion viruses might be able to point towards a possible region important 
for vhs activity, or even specific nucleotide mutations that abolish vhs activity. Furthermore, full 
genome sequencing of the BAC-derived VP22-deletion viruses is important if they are used for any 
further experimental studies to investigate the effect of VP22 deletion as other secondary mutation 
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within additional viral proteins may have occurred which would distort any conclusion made on the 
function of VP22, including plaque formation. 
Deletion of VP22 has demonstrated to have a negative effect on the expression of a vhs. 
Furthermore, VP22 has been suggested to be involved in down regulating vhs activity as it has been 
shown that VP22 interacts with vhs only in the present of VP16, yet this complex formation is not 
required for packaging vhs into the virus particle. An obvious next step to further define the role of 
this complex formation is to investigate if VP22 regulates vhs activity alone or together with VP16 
using cotransfections combined with a luciferase reporter assay. Tegument protein VP13/14 has 
been suggested to also regulate vhs activity [344]. Recent data generated by Dr Julianna Stylianou 
for her thesis established that VP13/14 binds directly to VP16 and is part of the VP22-VP16-vhs 
complex.  
Therefore, it would be prudent to also include VP13/14 in the luciferase reporter assay to investigate 
if VP22 requires coexpression of VP16 and/or VP13/14 in order to regulate vhs activity. 
Having shown that vhs mRNA is efficiently transcribed, but not translated in the absence of VP22, it 
might be worth investigating if vhs mRNA contains a region that inhibits its translation when VP22 is 
not expressed. VP22 has been shown to bind mRNA [334]. It is possible that VP22 enables the 
translation of vhs by binding to its mRNA. By defining the region that possibly inhibit vhs translation, 
coexpression studies with VP22 might be able to establish if VP22 bind vhs mRNA and enables its 
translation. Furthermore, having shown that VP22 is necessary for efficient vhs expression in 
infection, but not sufficient to enhance vhs expression in transfection, it would be of interest to 
investigate if VP22 has any co-factors that enable the translation of vhs mRNA. VP22 has been 
shown to be an interaction partner for many viral proteins and to be part of protein complexes. 
Therefore it is possible that the low level of vhs expression observed in the absence of VP22 is 
enabled by one of VP22’s interaction partners, and only the additional interaction of VP22 enables 
efficient translation. 
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Finally, it would be important to characterise the function of tegument VP22 in virus infection using 
primary human foetal foreskin fibroblast. Preliminary results presented here indicate that VP22 
interferes with antiviral responses. Even though ICP0, known to be involved in combating antiviral 
response, is not efficiently expressed and assembled in the absence of VP22, its absence does not 
result in complete inability to form plaques in HFFF2 cells as seen for VP22. Therefore, it would be 
highly interesting to investigate the role VP22 plays as a virulence factor. To establish if VP22 
interferes with immune responses, the expression of additional interferon-stimulating genes other 
than ISG 15 in the absence of VP22 could be investigated as a starting point. If VP22 functions in 
blocking antiviral gene expression, the Δ22 virus could be investigated for its sensitivity to interferon 
production. For this Vero cells could be utilised which are known not to produce interferon, yet they 
respond to added interferon. In order to fully assess the effect of VP22 on global protein 
accumulation, viral replication and combating immune responses, a ΔICP0 virus should be included 
for comparison.  
 
7.5 CONCLUDING REMARKS  
This work has characterized the relationship of tegument proteins VP22 and vhs in virus infection; 
and has provided valuable insight into VP22 and its role it might play in HSV-1 infection. A novel 
finding of this thesis is that, contrary to previous observations, vhs is not inherently lethal for virus 
replication in the absence of VP22. Furthermore, primary human foetal foreskin fibroblasts (HFFF2) 
have been identified as an appropriate cell type to study the function of VP22 in virus infection. 
Ongoing research into VP22 and its role in virus infection as a possible virulence factor using primary 
human foetal foreskin fibroblast (HFFF2) is carried out by Prof Gill Elliott and lab members. 
Importantly, this work demonstrates that the mode of virus rescue can influence secondary 
mutations; and more importantly the requirement of studying viral protein function in a 
physiologically relevant cell type.
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APPENDIX 1: SOLUTIONS AND BUFFERS 
 
All reagents from Invitrogen; details as stated at www.invitrogen.com (accessed 09/5/2015). 
All reagents from Sigma-Aldrich; details as stated at www.sigmaaldrich.com (accessed 
09/5/2015). 
All reagents from VWR; details as stated at www.vwr.com (accessed 09/05/2015). 
 
A1.1 CELLS AND TISSUE CULTURE 
A1.1.1 DMEM 
Glycine (0.4 mM), L-arginine hydrochloride (0.398 mM), L-cystine 2HCl (0.201 mM), L-
glutamine (4 mM), L-histidine hydrochloride-H2O (0.2 mM), L-isoleucine (0.802 mM), L-
leucine (0.802 mM), L-lysine hydrochloride (0.798 mM), L-methionine (0.201 mM), L-
phenylalanine (0.4 mM), L-serine (0.4 mM), L-threonine (0.798 mM), L-tryptophan (0.0784 
mM), L-tyrosine disodium salt dihydrate (0.398 mM), L-valine (0.803 mM), choline chloride 
(0.0286 mM), D-calcium pantothenate (0.00839 mM), folic acid (0.00907 mM), niacinamide 
(0.0328 mM), pyridoxine hydrochloride (0.0194 mM), riboflavin (0.00106 mM), thiamine 
hydrochloride (0.0119 mM), i-inositol (0.04 mM), anhydrous calcium chloride (CaCl2) (1.8 
mM), ferric nitrate (Fe(NO3)3•9H2O) (0.000248 mM), anhydrous magnesium sulphate 
(MgSO4) (0.814 mM), potassium chloride (KCl) (5.33 mM), sodium bicarbonate (NaHCO3) 
(44.05 mM), sodium chloride (NaCl) (110 mM), sodium phosphate monobasic 
(NaH2PO4•H2O) (0.906 mM), D-glucose (dextrose) (25 mM), sodium pyruvate (1 mM), 
phenol red (0.0399 mM) (Invitrogen).
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A1.1.2 TRYPSIN-EDTA IN HANKS’ BALANCED SALT SOLUTION WITHOUT CaCl2, 
MgCl2•6H2O and MgSO4•7H2O 
Potassium chloride (KCl) (5.33 mM), potassium phosphate monobasic (KH2PO4) (0.441 mM), 
sodium bicarbonate (NaHCO3) (4.17 mM), sodium chloride (NaCl) (137.93 mM), sodium 
phosphate dibasic (Na2HPO4•7H2O) (0.336 mM), D-glucose (dextrose) (5.56 mM), phenol 
red (0.0251 mM), sodium EDTA (Na2•EDTA) (0.481 mM), trypsin (0.021 mM) (Invitrogen). 
A1.1.3 Opti-MEM® I Reduced Serum Medium 
Opti-MEM® I Reduced-Serum Medium is a unique medium which contains insulin, 
transferrin, hypoxanthine, thymidine, and trace elements. The exact composition of Opti-
MEM® I Reduced Serum Medium is confidential Invitrogen. (www.lifetechnologies.com, 
accessed 09/05/2015) 
 
A1.2 VIRUS TECHNIQUES 
A1.2.1 2X FORMAL SALINE SOLUTION 
Formaldehyde (8% v/v) (Sigma-Aldrich), NaCl (0.291 M) (Sigma-Aldrich). 
A1.2.2 0.1% CRYSTAL VIOLET SOLUTION 
Crystal violet (2.45 mM) (Sigma-Aldrich), ethanol (15% v/v) (VWR). 
A1.2.3 X-GAL DETERGENT SOLUTION 
MgCl2 (2 mM), PBS, sodium deoxycholate (240 mM) (Sigma-Aldrich), Nonidet P40 (NP40) 
substitute (0.01% v/v) (Amresco Inc. OH, USA). 
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A1.2.4 X-GAL SOLUTION  
Potassium ferrocyanide (5 mM) (Sigma-Aldrich), Potassium ferricyanide (5 mM) (Sigma-
Aldrich), X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) (1 mg/ml) (Sigma-Aldrich) in X-
Gal detergent solution. 
A1.2.5 NEUTRAL RED SOLUTION 
3-amino-7-dimethylamino-2-methylphenazine hydrochloride (10mg/ml) (Sigma-Aldrich). 
A1.3 BACTERIOLOGICAL TECHNIQUES 
A1.3.1 LB AGAR 
Tryptone (10 g/L), yeast extract (5 g/L), NaCl (5 g/L), agar (15 g/L) (OXOID). 
A1.3.2 LB MEDIA 
Tryptone (10 g/L), yeast extract (5 g/L), NaCl (5 g/L) (OXOID). 
A1.3.3 KANAMYCIN 
Kanamycin sulphate from Streptomyces kanamyceticus (≥750 μg per mg (dry basis) (Sigma-
Aldrich). 
A1.3.4 CHLORAMPHENICOL 
D-(−)-threo-2,2-Dichloro-N-[β-hydroxy-α-(hydroxymethyl)-β-(4-
nitrophenyl)ethyl]acetamide (≥98% HPLC) (Sigma-Aldrich). 
A1.3.5 ARABINOSE  
C5H10O5 (20-40% w/v) (Sigma-Aldrich). 
 
A1.4 PLASMIDS 
A1.4.1 QIAGEN PLASMID MAXI KIT REAGENTS (QIAGEN) 
Buffer compositions as outlined in manufacturer protocol (04/2012). 
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A1.4.1.1 BUFFER P1 (RESUSPENSION BUFFER) 
Tris-HCl (50 mM) (pH8.0), EDTA (10 mM), RNase A (100 µg/ml). 
A1.4.1.2 BUFFER P2 (LYSIS BUFFER) 
NaOH (200 mM), sodium dodecyl sulphate (SDS) (1% w/v). 
A1.4.1.3 BUFFER P3 (NEUTRALISATION BUFFER) 
Potassium acetate (3.0 M) (pH5.5). 
A1.4.1.4 BUFFER QBT (EQUILIBRATION BUFFER) 
NaCl (750 mM), MOPS (50 mM) (pH 7.0), isopropanol (15% v/v), Triton® X-100 (0.15% v/v). 
A1.4.1.5 BUFFER QC (WASH BUFFER) 
NaCl (1 M), MOPS (50 mM) (pH 7.0), isopropanol (15% v/v). 
A1.4.1.6 BUFFER QF (ELUTION BUFFER) 
NaCl (1.25 M), Tris-HCl (50 mM) (pH 8.5), isopropanol (15% v/v). 
A1.4.1.7 BUFFER TE  
Tris-HCl (10 mM) (pH 8.0), EDTA (1 mM). 
A1.4.2 QIAprep® SPIN MINIPREP KIT REAGENTS (QIAGEN) 
Buffer compositions as outlined in manufacturer protocol (04/2012). 
A1.4.2.1 BUFFER P1 (RESUSPENSION BUFFER) 
Tris-HCl (50 mM) (pH8), EDTA (10 mM), RNase A (100 µg/ml). 
A1.4.2.2 BUFFER P2 (LYSIS BUFFER) 
NaOH (200 mM), sodium dodecyl sulphate (SDS) (1% w/v). 
A1.4.2.3 BUFFER N3 (NEUTRALISATION BUFFER) 
Potassium acetate (3.0 M) (pH5.5) 
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A1.4.2.4 BUFFER PB (BINDING BUFFER) 
Contains a high concentration of guanidine hydrochloride and isopropanol. The exact 
composition of Buffer PB is confidential to Qiagen. (www.qiagen.com, accessed 19/12/2014) 
A1.4.2.5 BUFFER PE (WASH BUFFER) 
Buffer PE is confidential to Qiagen. (www.qiagen.com, accessed 19/12/2014) 
A1.4.2.6 BUFFER EB  
Tris·Cl (10mM) (pH 8.5) 
A1.4.3 STET LYSIS BUFFER 
sucrose (8% w/v), Triton X-100 (0.5%v/v), EDTA (50mM) and Tris-HCL (10mM) (all reagents 
Sigma-Aldrich). 
 
A1.5 TRANSIENT TRANSFECTION 
A.1.5.1 CALCIUM PHOSPHATE BUFFER 
N,N-bis[2-hydroxyethyl] 2-aminoethanesulfonic acid (BES) (50mM), NaCl (280mM), Na2HPO4 
(1.5mM) (pH 7.06) (VWR). 
A1.6 DNA TECHNIQUES 
A1.6.1 LYSIS BUFFER 
Tris-HCl (10mM) (pH7.5), MgCl2 (2mM), NaCl (10mM) (VWR), NP40 substitute (0.5% v/v) 
(Amresco Inc. OH, USA). 
A.1.6.2 ETHYLENEDIAMINETETRAACETIC ACID (EDTA) (pH 8.0) 
Ethylenediaminetetraacetic acid (EDTA) (0.5mM) (pH 8.0) (VWR). 
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A1.7 PROTEIN ANALYSIS 
A1.7.1 2X SDS-PAGE SAMPLE BUFFER/LOADING DYE 
Tris-HCl (100 mM) (pH 7.0), SDS (4% w/v), beta-mercaptoethanol (10% v/v), glycerol (20% 
w/v), bromophenol blue (0.2% w/v) (all reagents Sigma-Aldrich). 
A1.7.2 POLYACRYLAMIDE RESOLVING GEL 
Acrylamide/bis-acrylamide (37.5:1) (10% / 12% / 15% w/v) (Bio-Rad Laboratories), Tris-HCl 
(0.375 M) (pH 8.8) (Bio-Rad Laboratories), SDS (0.1% w/v), N,N,N’,N’-
tetramethylethylenediamine (0.05% v/v) (Sigma-Aldrich), ammonium persulphate (0.1% 
w/v) (Sigma-Aldrich). 
A1.7.3 SDS-PAGE STACKING GEL 
Acrylamide/bis-acrylamide (37.5:1) (4% w/v), Tris-HCl (0.13 M) (pH 6.8) (Bio-Rad 
Laboratories), SDS (0.1% w/v), N,N,N’,N’-tetramethylethylenediamine (0.1% v/v), 
ammonium persulphate (0.1% w/v) (Sigma-Aldrich). 
A1.7.4 SDS-PAGE RUNNING BUFFER 
Glycine (192 mM), Tris base (25 mM), SDS (1% w/v) (all reagents Sigma-Aldrich). 
A1.7.5 SDS-PAGE GEL TRANSFER BUFFER 
Glycine (192 mM), Tris base (25 mM), methanol (20% v/v) (VWR). 
A1.7.6 RIPA BUFFER (pH 7.5) 
Tris-HCl (50 mM), NaCl (150 mM), SDS (0.1% w/v), sodium deoxycholate (1% w/v) (Sigma-
Aldrich), Triton® X-100 (0.2% v/v) (Sigma-Aldrich), 1X complete ULTRA Mini protease 
inhibitors (Roche Applied Science, Penzberg, Germany). 
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 A1.7.7 CELL LYSIS BUFFER 
Tris (50 mM) (pH 7.5), NaCl (200 mM), MgCl2  (2 mM), NP40 substitute (1% v/v), 1X 
Complete® Mini Protease Inhibitors (Roche, Penzberg, Germany). 
A1.7.8 CHROMOTEK DILUTION/WASH BUFFER 
Tris-Cl (10mM) (pH 7.5), NaCl (150mM), EDTA (0.5mM) (Chromotek). 
 
1.8 ASSAYS 
A1.8.1 5x PASSIVE LYSIS BUFFER  
5x Passive Lysis Buffer is confidential to Promega. (www.promega.com, accessed 
5/05/2015) 
A1.8.2 RENILLA LUCIFERASE SUBSTRATE 
Coelenterazine (LUX Innovate, Edinburgh, UK) stock was dissolved at 1 mg/ml concentration 
in 100% ethanol and stored at -20˚C. Coelenterazine stock was diluted to 1 µg/ml in room 
temperature PBS before use. 
 
A1.9 GENERAL LABORATORY SOLUTIONS 
A1.9.1 PBS (pH 7.2) 
NaCl (8.77 g/L), Na2HPO4•12H2O (19.2 g/L), NaH2PO4•2H2O (6.55 g/L) (VWR). 
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APPENDIX 2: EXPERIMENTAL RESULTS 
 
Results for Chapter 3. 
 
 
 
Figure 1: PCR product of I-SceI-aphAI cassette.  
Gel Electrophoresis of the PCR product amplified from the I-SceI-aphAI cassette with 
primers BAC-VP22F and BAC-VP22R listed in Table 2.4. The PCR product includes VP22 
flanking sequences and duplication sequence, yielding a 1.1kb band (arrow pointing towards 
PCR product). NB: the band in this picture was excised for gel extraction of the PCR product 
of the SceI-aphAI cassette.  
